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ABSTRACT 
 
INTRODUCTION: The “vulnerable plaque” is defined as the “precursor lesion” that ultimately ends in 
acute coronary thrombi (clots) that create a heart attack.  Macrophages and inflammatory cells, found 
preferentially in vulnerable plaque, sustain their activity in the plaque through anaerobic metabolism and 
lactate production. The ultimate goal is to assess anaerobic metabolism in-vivo by measuring tissue pH and 
lactate concentration in atherosclerotic plaques using optical spectroscopy. The proposed in-vitro optical 
probe design, experimental method, and spectroscopic data analysis methodology are established in this 
research.  
 
 METHODS: A fiber optic probe was designed and built based on both Monte Carlo simulations and bench 
testing with the goal to collect light from a small volume of tissue. A simulation of the depth penetration of 
the proposed probe was performed on normal and atherosclerotic aortic tissue, and the final probe was 
bench tested using normal aorta. A method was developed to preserve plaque metabolic status of tissue 
harvested from patients. Human atherosclerotic tissue obtained immediately after carotid endarterectomy 
was placed in Minimum Essential Medium (MEM) with non-essential amino acids supplement, bubbled 
with 75%O2/20%N2/5%CO2 at 37°C. Tissue pH, pCO2, pO2 and temperature with (n=7) and without (n=2) 
the media preparation over time were reviewed to assess plaque viability and maintenance of physiological 
conditions. Additional plaques placed in media were used for development of chemometric methods to 
measure pH and lactate. Areas of each plaque were randomly chosen for analysis.  Reflectance spectra 
were collected with a dispersive spectrometer (400-1100 nm) and a Fourier-transform near-infrared 
spectrometer (1100–2400 nm) using the fiber optic probe. Reference measurements for tissue pH and 
lactate were made with glass microelectrodes and micro-enzymatic assay, respectively. Partial least-squares 
(PLS) data analysis was used to develop multivariate calibration models on an initial set of 5-6 plaques 
relating the optical spectra to the reference tissue pH (n=20) or the lactate concentration (n=21) to assess 
data quality. The coefficient of multiple determination (R2), the standard error of cross-validation (SECV), 
and the number of factors were used to assess the model performance. Additional points were collected 
from ~14 plaques and added to preliminary data. Pre-processing techniques were then used to see if 
preliminary data results could be improved by reducing different sources of variability with the 
introduction of more points. 
 
RESULTS: Monte Carlo simulations and depth penetration tests with the final probe design showed light is 
collected from ~1 mm3 volume of tissue using a 50 micron source-receiver separation. Tissue pH, pCO2, 
pO2 and temperature values demonstrated that the plaques were viable and stable in the media preparation 
for a maximum of 4 hours. Data from the first six plaques collected for lactate analysis showed that for 
seventeen points, a six-factor model produced adequate results (R2=0.83 SECV=1.4 micromoles 
lactate/gram tissue). Data from the first five plaques collected for tissue pH analysis, showed for seventeen 
different points, a three-factor model produced adequate results (R2=0.75 SECV=0.09 pH units). When 
additional points were added to either data set, model results were degraded.  
 
CONCLUSIONS: The in-vitro optical probe design and experimental procedures was established and the 
feasibility of the optical method demonstrated with preliminary data. However, with the addition of more 
data points, different sources of tissue and spectral variability were observed to affect calibration. The gross 
pathology type and mismatched optical volume to reference measurement volume limited the tissue pH 
determination. The reference measurement precision, the spatial resolution of the reference lactate 
measurement, and unmodeled tissue variability (water and proteins) limited the lactate determination. 
Large variability in all optical measurements was observed. Additional in-vitro data collection would be 
required such that the variability due to the tissue is reduced and any spectrometer variability adequately 
compensated to be able to use the optical calibration in-vivo. 
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1. INTRODUCTION – PROBLEM IDENTIFICATION 
 
Cardiovascular disease is the number one cause of death in the United States.  Each year 
in the U.S., approximately 1.5 million people experience heart attacks, one of the many 
possible consequences of cardiovascular disease.  Approximately 250,000 are sudden 
cardiac deaths. Atherosclerosis, a form of cardiovascular disease, is an arterial disease 
primarily found in medium or large sized arteries, such as the aortic, carotid, coronary, 
and cerebral arteries. In the over forty age group, most sudden cardiac deaths are 
attributed to atherosclerotic cardiovascular disease. Due to the critical nature of sudden 
cardiac arrest, more than half of these individuals die before reaching the hospital. The 
direct and indirect cost of coronary heart disease is estimated at $111.8 billion dollars in 
the United States alone. [1] The World Heart Federation reports that atherosclerotic 
cardiovascular disease account for 6.3 million deaths per year world wide, and occurs in 
both developing and industrialized nations, with the poor being affected the most.  
 
The prevention of heart attacks in genetically predisposed individuals is geared toward 
the modification of many environmental and lifestyle factors.  Atherosclerotic disease is 
common in the middle-age population; however, the lesions (or plaques) may not 
manifest themselves on a typical angiogram, an invasive diagnostic test performed by 
physicians in a cardiac catheterization laboratory. Angiography involves injecting radio-
opaque dyes through a catheter and viewing the dye distribution through the coronary 
vessels using x-ray fluoroscopy. Atherosclerotic disease is verified through the 
angioscopic identification of severely reduced lumen size or reduced intensity of the dye 
in the vessels. However, approximately a third of all sudden cardiac deaths occur in 
otherwise healthy individuals, with little to no risk factors, who did not have an 
angiogram performed. Current medical knowledge cannot predict those individuals that 
may be at risk due to this clinically silent, asymptomatic disease. This lack of information 
prevents the clinician from using more aggressive, prophylactic measures to prevent a 
first, and often fatal, heart attack.  If this at-risk patient subtype could be identified, the 
at-risk or vulnerable atherosclerotic plaque(s) that would cause a fatal heart attack could 
be potentially reversed, or at the very least, the threat significantly reduced [2]. In the 
long run, this knowledge will improve the quality of life and productivity among the 
affected populations. 
 
Several invasive and non-invasive technologies have been proposed. Some modalities are 
being implemented to address the problem of identification of the smaller atherosclerotic 
lesions by finding structural differences that the atherosclerotic process causes in the 
vessel walls [3-19]. The elusiveness lies in predicting those plaques that are prone to 
rupture and/or cause large clots to form, blocking the blood flow in the artery and causing 
severe damage to the heart muscle or tissue downstream. A more accurate method to 
diagnose the vulnerable atherosclerotic plaque(s) would be required to ensure that the 
individual would receive the most appropriate therapy.  This method must be easily 
adapted into the cardiac catheterization laboratory or, if possible, be completely non-
invasive. The information provided by the new diagnostic method should be clinically 
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acceptable and relevant to current research trends in atherosclerosis diagnosis and 
treatment in order to succeed in saving lives.  
 
Optical spectroscopy, a minimally invasive technique that could be adapted into the 
cardiac catheterization laboratory, is such a technique that could meet this medical need. 
Chemical information and/or metabolism of the atherosclerotic plaques could potentially 
be studied in-vivo with optical spectroscopy. However, this method requires a calibration 
between the optical spectra and destructive reference chemical measurements with 
accepted techniques. The establishment of an in-vitro optical calibration is the first in a 
series of steps that would be required in bringing this technique to the clinic.  
 
The precise mechanisms of atherosclerosis are unknown. It is a disease state under heavy 
research from several different fields including, among others, immunology, pathology, 
epidemiology, cardiology, pharmacology and hematology, all in an effort to improve the 
diagnosis, treatment, and outcomes.  The challenge in providing this new metric or 
diagnostic tool is further complicated by not being able to fully appreciate how that 
information fits into the current understanding of the underlying mechanisms of 
atherosclerotic cardiovascular disease.  
 
1.1. Atherosclerotic Process 
 
It has been well known since the 1950’s that high blood cholesterol levels leads to 
deposit formation in the human arterial system. At the affected site(s), known as the 
plaque, the vessel wall will thicken and/or the vessel diameter will decrease, reducing the 
amount of blood that can pass through. This is known in layman’s terms as “hardening of 
the arteries” or atherosclerosis, a process in which the artery’s function is compromised. 
The decreased function over time can lead to the development of several types of 
cardiovascular disease states. For sudden death, it is believed that it should be possible to 
identify the specific atherosclerotic process(es) that create plaques that suddenly erode, 
erupt, or block a critical coronary artery, i.e. to identify the “vulnerable plaque”. 
Lowering blood cholesterol alone has not been sufficient to prevent sudden cardiac death.  
 
There are several important factors beyond cholesterol that have been implicated as part 
of the atherosclerotic process. It has been suggested by several researchers [20, 21] that 
atherosclerosis may be thought of as a chronic inflammatory response of the arterial wall, 
initiated by some injury to the lining of the vessel wall (also called the endothelium). 
How or why the chronic response sometimes forms a stable plaque versus an unstable, 
potentially life-threatening plaque is unknown [22]. The plausible injury could be either 
physical (e.g., high shear, turbulent blood flow due to a branching of arteries) or other 
chemical factors [23]. Similar to a wound healing response on the skin, the 
atherosclerotic process seems to initiate repair through recruiting blood components such 
as platelets and clotting factors and creating fibrous, necrotic scar tissue. Since the 
“wound” never seems to heal (or the source of injury isn’t reduced), local and systemic 
signaling occurs to recruit inflammatory cells to attack the site(s).  
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Different molecular and cellular responses of the endothelium, smooth muscle cells, 
and/or extracellular matrix chemical influx/efflux, have been studied on their effects in 
alleviating vessel dysfunction with both positive and negative feedback cascades. Smooth 
muscle cells, present normally in the medial portion of the vessel wall, have been shown 
to migrate towards the luminal surface in some cases.  Additional chemical factors have 
been identified, secreted into the extracellular matrix by either the infiltrating, activated 
inflammatory cells from the lumen or by the migrating smooth muscle cells from the 
medial portion of the vessel. New vessel development, or angiogenesis (a naturally 
occurring phenomenon throughout the body), can occur within the thickening diseased 
vessel wall, but, at the atherosclerotic site, these new vessels are erratically formed and 
are often “leaky”, i.e. they do not hold the blood plasma components like a normal artery. 
These “leaky” vessels could contribute to blood clots (known as thrombi) inside the 
plaque and destabilize the plaque. Again, how or why this process may form the 
vulnerable plaque has not been elucidated.  
 
1.2. The Unknown Diagnosis – Vulnerable Plaque 
 
The “gold standard” in vulnerable plaque identification is histological classification. 
Current medical knowledge has not been able to explain all the observed vulnerable 
plaque characteristics such as fibrous cap erosions, ruptures, and clot inducing factors, as 
seen by microscopic examination of a heart’s coronary arteries post-mortem.  Histology 
is useful as a retrospective view of atherosclerotic disease, not as a diagnostic tool. The 
histology can significantly differ from coronary plaques, to carotid plaques, to aortic 
plaques.  The individual plaques are very heterogeneous as to the cell types, amount of 
fatty deposits, and their make-up of structural components such as collagen, fibrin and 
elastin. Pathologists struggle with classification schemes and gradation of lesions that are 
not or were not angiographically apparent, as these are the typical culprits of sudden 
cardiac death. Current research is focusing on the chemical composition of the plaque to 
pinpoint the sources of vulnerability before they can cause an acute event [2, 24, 25]. 
 
A new metric or diagnostic tool must therefore be able to access the chemical information 
of the atherosclerotic plaque without losing sight of the importance of structural 
information in the living patient. First, the feasibility of the new metric must be shown in-
vitro, and ultimately in-vivo with animal models. The technique should be accurate with 
respect to its own range of determination. The sensitivity and specificity of the new 
metric must ultimately be equal to or greater than the histological classification or 
another proven clinical method. However, only by looking at clinical outcomes over time 
for the affected populations, can one validate the final diagnostic accuracy of the new 
diagnostic tool. 
 
1.3. Summary 
 
The lack of an accurate technique to diagnose vulnerable plaque that is intuitive, 
clinically relevant, and inexpensive, presents a significant medical challenge. Vulnerable 
plaque diagnosis may require a novel, invasive approach that can deliver useful 
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information about the plaque to the physician.  The active metabolism of the 
atherosclerotic plaques could potentially be studied in-vivo with optical spectroscopy and 
be used in the future as an indicator of vulnerability. Determining the feasibility of the 
optical method would require a better understanding of the atherosclerotic tissue 
energetics, tissue optics, and any factors that could affect the accuracy and range of an 
optical determination. In this research, feasibility is studied for a specific in-vitro optical 
probe design, experimental method, and spectroscopic data analysis methodology. The 
knowledge gained in this research is hoped to aid in the development of a clinical 
instrument for the detection of vulnerable plaque.  
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2. THE SPECIFIC AIMS OF THE RESEARCH 
2.1. Project Statement  
 
The intent of this research is to demonstrate the feasibility of using optical spectroscopy 
to accurately determine the metabolic status (tissue pH and lactate concentration) of 
living human atherosclerotic plaques. This goal is to be accomplished through the design 
of a small, fiber optic-based, reflectance-mode spectroscopic probe to collect continuous 
optical spectra (400-2400 nm) from an approximately 1-mm3 volume of tissue.  This 
probe will then be used in an in-vitro study in order to develop equations that calculate 
pH and lactate from these spectra. The in-vitro study is performed on freshly excised 
human carotid artery atherosclerotic plaques maintained for a prolonged period using 
tissue culture techniques.  The spatial performance of the optical probe will be assessed 
by an actual measurement of the tissue depth interrogated. The optical spectra collected 
with this probe will be matched with the standard destructive reference measurements of 
tissue pH and lactate concentration of the living plaque. Multivariate mathematical 
models will be developed by analyzing the optical spectra for the most relevant factors 
that correlate with the individual reference measurements. These models will serve as a 
calibration of the optical system. Each calibration model will be tested for its capability 
to predict the desired parameter(s) from unknown optical spectra using accepted 
techniques for small sample sizes (N<100, e.g. cross-validation). Target acceptance 
criteria for model accuracy, predictive ability, and complexity are drawn to determine if 
feasibility has been met.  
 
For the purposes of this research, the optically determined tissue pH and lactate 
calibration that provides the best accuracy and predictive ability after multivariate 
calibration will only be reviewed as to its possible correlation to the current destructive 
method of classifying atherosclerotic plaques (i.e. histology). At the conclusion of this 
phase of research, it is hoped that the model developed on in-vitro data can be translated 
to an appropriate in-vivo animal model for validation, with at the very most, minor 
additional destructive experimentation for improving model accuracy and prediction.  It 
is not the intent of this research to definitively answer whether optically determined 
metabolic status based on tissue pH and/or tissue lactate is sensitive and/or specific 
enough to differentiate different atherosclerotic lesion types or identify vulnerability. 
Limitations will be discussed for the feasibility of using optical spectroscopy and for the 
long-term objective of making a clinical optical spectroscopy catheter that can predict 
plaques that are vulnerable to rupture. An additional contribution of this research is 
gaining a better understanding of the gross metabolic properties of atherosclerotic lesions, 
which could help future researchers develop better diagnostic and therapeutic agents to 
reduce the number of sudden cardiac deaths, and possibly aid in the prevention of heart 
attacks. 
 
Short-term goals must first be achieved to realize the potential benefit to society. The 
following specific aims outline how these research goals will be met: 
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1) Design a reflectance-based optical fiber probe that uses visible to near-infrared light 
optimally to interrogate a small volume of tissue. The target of a 1 mm3 tissue volume 
is based on the normal wall thickness of a coronary artery, the average thickness of 
atherosclerotic plaques with less than 70% blockage of the artery, and a plausible x-y 
plane of heterogeneity with respect to the atherosclerotic plaque.  
 
a) Perform Monte Carlo simulations of the probability of diffuse radial reflectance 
for several theoretical source-receiver separations as a function of depth. Optical 
properties of vessel wall and atherosclerotic lesions described in the literature are 
to be used. Infer possible source-receiver fiber separations that meet target 
volume based on the simulation depth penetration. 
b) Design and build fiber optic probe(s) using the simulation results as a starting 
point (first design iteration).   
c) Collect and analyze 400-2400 nm optical spectra using the fiber probe(s) and their 
different source-receiver separations on normal vessel walls. Estimate signal-to-
noise ratio at different key wavelengths and implement design improvements 
(second design iteration). 
 
2) Using the optimized custom-manufactured optical probe built after the second design 
iteration, estimate the depth penetration.  Measure the depth penetration at key 
wavelengths by successively stacking thin sections of non-diseased tissue on to the 
end of optical probe and collecting the reflectance spectra. Compare to theoretical 
calculations and estimate resulting tissue volume over the wavelength region studied. 
 
3) Identify major interferents to the optical spectra and reference measurements. 
Determine which may prove to be significant to the calibration accuracy. Propose or 
develop methodology to reduce their effects. Show that the stability of metabolic 
parameters over the time course of data collection can be achieved using tissue 
culture techniques. The stability is required to mimic in-vivo situations and decrease 
time-correlated effects on the measurements.  
 
4) Using the optimized fiber optic probe, collect and analyze a large calibration set of 
human carotid endarterectomy specimens (~100 data points) while maintaining 
physiological state in-vitro. 
a) Perform multivariate calibration using wavelength selection and/or signal 
conditioning for optical tissue pH and tissue lactate determinations.  
b) Compare the optically-predicted values from the multivariate calibration to the 
reference measurements using calibration metrics of correlation coefficient (R2), 
standard error of cross-validation (SECV), and the number of factors needed to 
describe the correlation for model accuracy.  Review acceptance criteria and make 
recommendations. 
 
2.2. General Requirements 
 
Table 2.2.1 summarizes the general performance requirements for this feasibility study. 
There is no consensus as to what the exact requirements are to find the vulnerable plaque 
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based on metabolic status.  However, to ensure the applicability of the methods and 
apparatus described within, performance specifications must be outlined, and it must be 
shown that the apparatus meets these specifications. The expected range of measurement 
and estimated accuracy required for each parameter is needed. Frequency of 
measurements (time dependence issues), and experimental stability also need to be 
addressed. The experiments are conducted in a controlled environment, so it is important 
to understand how the multivariate calibration model will respond to the presence of 
other unmodeled inputs such as experimental conditions or compounds. The maximum 
number of factors allowed is based on the current multivariate calibration literature for 
small data sets [26].  The performance of the final optical prototype shall be discussed in 
terms of the feasibility to optically determine the metabolic status of atherosclerotic 
plaques.   
 
Table 2.2.1: General Performance Requirements 
Specification Tissue pH Tissue Lactate Concentration 
[micromoles lactate / gram tissue] 
in-vitro 
Temperature 
(°C) 
in-vitro Experimental 
Stability 
< 0.03 
change/hr 
- <0.4°C change/hr 
Optical Calibration 
Range 
6.80 – 7.60 2 – 20 32.0 – 38.0 
Optical Calibration 
Coefficient of Multiple 
Determination (R2 ) / 
Estimated Accuracy 
(SECV) 
≥0.75 / 0.08 
pH units 
≥0.75 / 1.0 umoles/ gram tissue - 
Maximum # of Factors in 
Optical Calibration 
Model [26] 
5 to 6 
independent 
samples per 
factor 
5 to 6 independent samples per 
factor 
- 
 
In review, the optical spectroscopy techniques described here are investigated to 
determine feasibility and the potential use in identifying the metabolic status of 
atherosclerotic plaques in a cardiac catheterization setting.  In 1997, an estimated 2 
million inpatient cardiac catheterizations were performed [1]. Technological 
improvements in other modalities for vulnerable plaque detection such as intravascular 
ultrasound (IVUS) and magnetic resonance coronary catheters are still on the horizon.  
Optical fiber technology is currently used in different intravascular applications, and can 
be rapidly adapted to include spectroscopic techniques.  The interventional cardiologist’s 
interest drives the industry to produce sterile, disposable coronary catheters within the 
$200-400 price range.  An accurate spectroscopic optical catheter system for determining 
the metabolic status of atherosclerotic plaque should meet this need. The research here 
aims to establish feasibility of a spectroscopic-based catheter for vulnerable plaque 
identification. As the optical method gains acceptance, so will the interest to outfit 
cardiac catheterization labs with new, inexpensive technology, in order to improve the 
health and well being of patients. 
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3. HYPOTHESES AND RESEARCH METHODS 
3.1. Hypotheses 
 
The long-term objective is to develop an optical spectroscopy catheter system to 
determine the metabolic status of atherosclerotic vessels without the need for exogenous 
dyes, ionizing radiation or a high capital medical unit setting. To date, there have not 
been any reports of using this technique to determine metabolic parameters such as the 
tissue pH or lactate concentration of atherosclerotic plaques. The feasibility of using 
optical spectroscopy to accurately determine metabolic derangements (namely, tissue pH 
and lactate concentration) in living human atherosclerotic lesions is under investigation. 
The overall hypothesis is that reflectance-mode optical spectroscopy, using visible to near 
infrared light energy, can be used in-vitro to develop calibration equations that provide an 
optical determination of the atherosclerotic tissue pH and lactate concentration.  The 
performance of the optical probe will be reviewed in light of the calibration accuracy that 
can be achieved.  
 
Three specific hypotheses will be tested in this research: 
 
1) A small fiber optic prototype (< 3 mm optical working diameter) can make optical 
measurements in-vitro for the assessment of metabolically active plaque in a 
defined region of tissue (< 1mm3 volume).  Both theoretical and practical 
considerations are allowed for in the design and implementation.  
 
2) The in-vitro experimental factors, identified a priori as the tissue temperature, 
experiment time, and the gross constituent information of the plaque (i.e. gross 
pathology), can be assessed to their importance in affecting the optical calibration.  
It is hypothesized that the acceptance criteria for in-vitro experimental stability as 
defined in Section 2.2 can be met. 
 
3) Mathematical models can be developed which relate the corresponding optical 
spectra to the individual metabolic parameters (pH and lactate), measured with 
accepted reference methods, in the presence of inherent pathological variability.  
By collecting the optical spectra in a controlled, stable in-vitro environment and 
by using partial least-squares (PLS) multivariate calibration, accurate 
determinations can be achieved for the individual metabolic parameters of plaque 
tissue pH and plaque lactate concentration. The correlation coefficient of the 
determination and standard error of cross-validation will be used to determine 
calibration performance. The number of factors will be used to determine the 
appropriateness (e.g., overfit/underfit) of the optical calibration. 
 
3.2. Research Methods 
 
Methods and apparatus based on reflectance-mode spectroscopy of visible and near-
infrared light were chosen to solve the main research problem (Chapter 1) for the 
following reasons: 
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• Standard medical-grade optical fibers can provide inexpensive, remote, vascular 
access to the atherosclerotic lesion or known diseased areas. Optical spectroscopy 
can provide specific biochemical information, unlike intravascular ultrasound 
(IVUS), or magnetic resonance (MR) catheters that currently provide only 
structural information. 
• The potential for Catheterization Laboratory research and clinical use is 
enormous. 
• Preliminary results in Dr. Soller’s laboratory show tissue pH can be feasibly 
determined by optical reflectance spectroscopy in several different tissue beds. 
[27-29] Other researchers have used optical methods to determine lactate and 
other metabolites in cell culture [30], and blood plasma [31]. 
• No other researchers have reported results on using this method for determining 
the metabolic status of atherosclerotic lesions. This is a novel approach based on 
the idea that vulnerable plaques are more metabolically active than the stable 
plaque or background vessel wall. This research will contribute significantly to 
the existing knowledge in the field of vulnerable plaque research.  
Optical spectroscopy is one of many techniques available for non-destructive analysis of 
tissues. However, it is relatively inexpensive compared to other modalities such as NMR, 
B-mode ultrasound, and nuclear (x-ray) radiography.  Optical spectroscopy has been 
proposed by several researchers (Lodder [12], Muller [32], Feld [33], Jaross [34], Wang 
[35]) to characterize the properties of vulnerable atherosclerotic plaques, such as thin cap 
and large lipid core.  However, in this previous body of work they were not able to 
resolve the issue of the inherent tissue heterogeneity with respect to these histological 
variables and their optical measurement.  The apparent mismatch is identified as a key 
reason why the optical methods accuracy is less than desired. 
 
There is also considerable metabolic heterogeneity in human atherosclerotic lesions [25], 
[36]. It is precisely because of the structural and metabolic heterogeneities observed that 
an accurate optical tissue pH or lactate determination can only be made in the 
atherosclerotic plaque when the light is collected from a known volume of tissue, and the 
reference measurements are equally well resolved. Therefore, the primary requirement 
for the reflectance-mode optical probe design in this research is to have a well-defined 
region of interrogation, such that the optical measurement is matched to the reference 
measurement, within the limits of the size of a typical intravascular catheter. This is 
achieved by examining both the theoretical and experimental depth penetration for 
different source-receiver separations. This distance between the source light optical 
fibers, interacting with the tissue, and the light receiving optical fibers is critical to the 
ultimate performance of the prototype.  First, Monte Carlo simulations are performed, 
using optical property data of the vessel wall and atherosclerotic plaque available in the 
literature.  The resulting output of the probabilities of diffuse reflectance as a function of 
radius, and the probabilities of absorption as a function of depth are interpreted.  The 
simulations aid in the practical design of the probe by providing a starting point for the 
testing of different source-receiver separations. Since optical property data is available 
only at certain wavelengths, some extrapolation is necessary. A final depth penetration 
test shall confirm the design. 
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The experimental optical setup will include the building and testing of source-receiver 
separations of 50 and 500 um, different fiber sizes, with and without an optical window. 
The probe(s) signal-to-noise ratios on a specified spectrometer are analyzed to aid in 
decision-making of optical components and configurations. The depth penetration of the 
optimal configuration is measured at several key wavelengths and assessed to see if the 
target volume criterion has been met.  
 
The potentially confounding and unmodeled experimental variables are identified a 
priori. These variables are the in-vitro tissue temperature, the experiment time, and the 
gross pathology of the atherosclerotic plaque.  The thickness and the co-registration of 
optical spectra to the reference measurements are documented.  The existence of other 
systematic errors that affect the optical determination or the multivariate calibration 
model development, if any, shall be evaluated. Large-scale in-vitro experimentation on 
freshly excised human carotid plaques are conducted in oxygenated tissue culture media 
with temperature control.  The stability of this methodology is validated over time by 
using a pCO2, pO2, and tissue pH multi-parameter sensor for several different plaques.  
The maximum data collection time is fixed at four (4) hours to ensure tissue stability for 
all plaque types and thickness.  
 
The optical calibration model development process will begin with a multivariate data 
analysis technique called partial least squares regression. It is the technique known to 
work for tissue pH in other applications in Dr. Soller’s lab [29]. Different wavelength 
regions for the tissue pH and lactate determination will be used and selection criteria 
developed based on model improvements. The calibration model statistics will be 
reviewed and standard calibration set acceptance criteria (such as the F-ratio for outlier 
detection and minimum PRESS for optimal number of factors) will be used.   
 
Figure 3.2.1 shows a flowchart for this research approach.  The major components are the 
optical design, the in-vitro carotid plaque experiments, and finally the multivariate 
calibration model development. The design and experiment process is usually iterative, 
however, for the purposes of this study, only the performance through the second 
iteration was evaluated.   
 
The optical design process involved several steps, including: 
• Definition of optical probe requirements; 
• Theoretical considerations of tissue optical properties; 
• Monte Carlo simulations and interpretation;  
• Building and testing several optical probes; 
• Depth penetration assessment  
 
Preliminary experimentation with intermediate design optical probes provided insight 
into the methodology and execution of the in-vitro experiments for the desired optical 
determinations. Once the optical probe has been designed and built to address as many of 
the issues as possible, the large-scale in-vitro testing program will provide the data for the 
optical calibration models. Preliminary data analysis will be performed after 
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approximately 20 points to assess data quality.  Factors that may influence the results will 
be documented. Additional data collection and points will be added to see if model 
results may be improved. The calibration model development is a complex, statistically 
based empirical process involving, but not limited to, data compression, factor analysis, 
and outlier selection. The performance of the final optical prototype will be evaluated 
using standard metrics in the multivariate calibration literature.  The feasibility of the 
optical determination of plaque tissue pH and lactate concentration in the context of any 
unmodeled variables will be assessed. Finally, the applicability of the prototype’s 
performance towards detection of the vulnerable plaque via metabolic status and 
recommendations for future modifications to either the optical design or calibration 
method will be addressed. 
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Figure 3.2.1: Flowchart for research approach. 
 
Previous Work 
Considerations 
Experimental 
Probe(s) Tests 
Theoretical 
Calculations 
Optical Probe and 
Experimental Setup 
Validation 
in-vitro experiments 
n≈100 points 
Preliminary analysis at n≈20 pts 
Determination of significance of 
major experimental factors on the 
desired measurements  
Development of a calibration model for 
plaque tissue pH and lactate 
concentration 
Assess if Acceptance Criteria are met, 
make recommendations 
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4. BACKGROUND 
 
This research endeavors to establish the feasibility of the determination of metabolic 
status in atherosclerotic plaque by using optical spectroscopy.  Specifically, the plaque 
tissue pH and tissue lactate concentration are used as the primary indicators of metabolic 
status. The key concepts for the research performed are discussed in this chapter. It is 
expected that the reader will grasp the nature and complexity of the proposed research 
aims, and how each concept is important to the outcome of the studies reported. The 
following sections outline the basis for the research methodology: 
 
1) Vasculature – structure, function, and mechanisms of disease; 
2) Natural history of atherosclerosis and the concept of the vulnerable plaque; 
3) Available technology; 
4) Reflectance spectroscopy and tissue optics; 
5) Multivariate calibration methods; 
6) Absorbance characteristics of the vessel wall and atherosclerotic plaques; and 
7) Experimental factors 
 
The vasculature and concept of the vulnerable plaque is thoroughly reviewed to gain 
understanding of changes that can affect vessel wall structure and metabolism. Next, the 
current technology to diagnose cardiovascular disease and vulnerable plaque are 
reviewed. Basic optical terminology and tissue optics are described to appreciate the 
complexity of the optical probe design requirements. Multivariate calibration methods 
and their necessity are introduced. Finally, the absorbance characteristics and the 
experimental factors associated with making optical measurements in living 
atherosclerotic plaques are presented. Challenges in establishing the metabolic status 
independent of optical or pathophysiological interferents is briefly discussed as it relates 
to the overall research goals. 
4.1. Vasculature – Structure, Function, and Mechanisms of Disease 
 
The structure and function of the different types of arteries found in the cardiovascular 
system play a major role in maintaining systemic balance and health. In this section, the 
normal cardiovascular system is described in the context of arterial structure and 
function.  Possible mechanisms of atherosclerotic disease are briefly discussed with 
clinical correlation. Finally, the importance of environmental and genetic factors that 
imply that atherosclerotic cardiovascular disease is a world epidemic that requires more 
accurate diagnostic methods is discussed. 
4.1.1. The Cardiovascular System 
 
The arteries and veins form a comprehensive network to maintain homeostasis by 
carrying blood throughout the human body. The purpose of the cardiovascular system is 
to deliver blood to the various organs and tissue beds such that the following basic, life-
supporting functions are adequately maintained: gas exchange, nutrient exchange, blood 
flow/pressure and circulation, and systemic hormones exchange. A schematic view of the 
human cardiovascular system is depicted in Figure 4.1.1. The heart (H) functions as the 
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pump that drives oxygenated blood through the arteries (A) to the head and body and 
deoxygenated blood returns to the lungs via the veins (V) for gas exchange. Ventricular 
contraction of the heart (or systole) propels the blood through the aorta, which in turn, 
through muscular recoil, gives the appropriate pressure head such that blood can reach 
the lower part of the body and steady blood flow is achieved in capillary beds. 
Ventricular relaxation (or diastole) both allows the heart to refill to its oxygenated (left 
ventricle) and deoxygenated (right ventricle) blood capacity as well as letting blood flow 
into the coronary tree. The heart itself has its own network of arteries, the coronary 
system, which branches directly from the aorta and experiences flow only in diastole 
[37].  
Figure 4.1.1: Overview of Cardiovascular System 
  
 
Arteries are divided into three basic types: 1) large or elastic, 2) medium-sized or 
muscular, and 3) small (< 2mm in diameter). All arteries -- the aorta, to the coronary, 
carotid, femoral, and brachial arteries -- to the smaller arterioles -- are composed of three 
distinct layers, the intima, media, and adventitia (Figure 4.1.2). 
 
Figure 4.1.2: Schematic representation of the principal structural components of a medium-sized 
artery. [38] 
 
 
The intimal layer is characterized by a single cell layer of endothelial cells, which line the 
interior of the vessel wall (the endothelium). It is in direct contact with the blood and 
The main components of human cardiovasculature: H - heart, 
A - arteries, V - veins, MB – microvascular beds. 
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blood components. The endothelium lines the entire cardiovascular system and facilitates 
the above basic functions. Smooth muscle cells (SMCs) and varying levels of Type III 
collagen and elastin (for vessel tone) characterize the medial layer. SMCs contain actin 
and myosin, providing vasoconstriction and dilation functions in response to 
physiological or pharmacological stimuli as well as motility, produce collagen, and are 
capable of secreting growth factors. The adventitia, the outermost layer, is characterized 
by additional collagen (Type I) and elastin, and smooth muscle cells and may contain 
vasa vasorum (lit. vessels of the vessels, e.g., aorta has small arterioles that feed the outer 
half to two-thirds of the medial layer).  Connective tissue and nerve fibers are also found 
in the adventitia. The size and cellular components of each layer establishes the vessel’s 
functional capability.  The relative sizes and musculature of both the macrovessels and 
microvessels are shown in Figure 4.1.3. 
 
Figure 4.1.3: Relative sizes and cellular components of blood vessels. [37] 
 
 
Elastic arteries (i.e., the aorta, common carotid and pulmonary arteries, and the beginning 
of the major branches) convert large pressure changes in pulsatile blood flow into a 
steady continuous stream. These arteries have a high proportion of elastic fibers in the 
medial layer; the walls appear yellow due to the abundance of elastic tissue. Smooth 
muscle indirectly regulates the recoil of the artery, and Type I collagen in the adventitia 
prevents further distention.  The vasa vasorum supply blood only to the outermost layers 
(adventitia and outermost media layers).  As a result, the walls are under relatively low 
oxygen tension in normal elastic arteries. Certain elastic arteries contain functional 
specialization. For example, at the carotid sinus (where the common carotid artery 
bifurcates into the external carotid and internal carotid arteries) there are baroreceptors 
and chemoreceptors that have additional functions and can affect systemic blood pressure 
and respiratory factors (for example, based on pH, partial pressure of oxygen in the 
blood). The carotid sinus is also innervated and has reflex-like activity to increasing 
blood pressure and chemical stimuli independent of the brain’s neurohormonal 
sympathetic drive.  
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Muscular arteries (i.e., the brachial, femoral, radial, popliteal, renal, and coronary arteries 
and their branches) adjust the blood distribution from the heart to the major areas of the 
body.  These arteries have a higher proportion of smooth muscle and less elastic tissue in 
the medial layer than elastic arteries. The adventitia, in comparison, is less structured; it 
is oriented longitudinally which allows for continuous changes in diameter. Structure 
varies considerably depending on the internal and external forces to which a particular 
muscular artery is subjected.  
 
In addition to the different pressures and chemical stimuli that any single vessel may 
experience, structural changes also occur in the macrovasculature with age. From birth to 
approximately 25 years of age, the elastic arteries first have the histological appearance 
of a muscular artery (esp. the aorta) and then the wall thickens as there is an increased 
amount of elastic layers developing as the individual grows. Throughout adulthood, all 
arteries undergo normal, controlled, remodeling for various physiological and 
developmental reasons. In muscular arteries, the media thickens with increasing smooth 
muscle content but not as rapidly or to the same extent as the elastic arteries. From 
middle age and above, more connective tissue forms in the vessel wall (collagen, elastin, 
and proteoglycans). This causes the walls of the largest arteries to become less compliant 
or stiffer to changes in blood flow.  The intimal layer however, thickens from birth on. 
The thickness varies along different parts of the arteries; in certain areas where tensile 
stresses are high, or flow is turbulent, the intima has a normal adaptive thickening 
response (esp. carotid bifurcation, coronary arteries). It is difficult to differentiate 
between development, early regression, or atherosclerosis in the intimal layer. In a sense, 
each artery has its own “aging pattern”. The coronary vessels seem to “age” at a younger 
age than other vessels. [20] Therefore, the relation between structure and function is 
further complicated by developmental factors.  
4.1.2. Pathological Basis 
 
Atherosclerosis affects primarily the large and medium-sized arteries (> 2mm in 
diameter) [22]. It is the underlying cause of most cardiovascular diseases. Clinically, it 
may manifest itself as luminal narrowing of the artery (stenosis), myocardial infarction 
(heart attack), cerebral infarction (stroke), claudications and aneurysms, among other less 
obvious effects [1]. However, the exact mechanisms of atherosclerosis are not well 
understood. At present, histological identification of the diseased vessel wall after 
surgical excision or post-mortem is the only way atherosclerotic lesions can be 
investigated and classified. Based on these histological studies of varying ages and 
disease states, the most accepted theory for atherosclerotic initiation and progression is 
called the “response to injury” theory, i.e., atherosclerosis may be thought of as a chronic 
inflammatory response of the arterial wall initiated by endothelial dysfunction [22, 23]. 
The atherosclerotic vessel wall may be ischemic (lack of oxygen), and the molecular and 
cellular responses of the endothelium and smooth muscle cells are activated [39, 40]. The 
importance of the endothelium and its contribution to metabolic stress is discussed. 
 
The endothelium acts as a semi-permeable barrier between the blood and tissue. It has 
significant implications in the mechanism and progression of many diseases. The main 
functions of the endothelium are: 
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• Control the transfer of small and large moieties into the vessel wall 
• Maintain a non-thrombogenic (not clot prone) interface by regulating, in part, 
platelet adherence 
• Control vascular tone and blood flow 
• Metabolize hormones 
• Regulate immune and inflammatory cell reactions through receptor-mediated 
interactions 
• Modify lipoproteins in the artery wall 
• Regulate the growth of smooth muscle cells 
 
The response of the endothelium is defined by what kinds of properties are induced (see 
Figure 4.1.4) [22].  In general, endothelial dysfunction refers to potentially reversible, 
functional changes that occur due to the local environment. Endothelial stimulation is a 
transient functional change that occurs within minutes, is reversible, and does not result 
in any new protein synthesis. These changes can be caused by either short-lived, vaso-
active substances in the blood or temporary mechanical stress. Endothelial activation, 
however, requires hours or days to occur and results in changes in gene expression and 
protein synthesis.  It is this activation that is thought to contribute to the progression of 
many vascular diseases [22]. 
Figure 4.1.4: Endothelial activation and induced properties. 
 
 
 
 
The normal and inflammatory responses of the endothelium both culminate in the 
retention of lipoproteins in the arterial wall. Plaques occur as a result of chronic oxidative 
stress (initially, lipid oxidation) in the arterial wall, and other factors beyond cholesterol 
deposition, especially in sites that are predisposed to thickening due to normal vessel 
function or location in the body. This oxidative stress is thought to in turn stimulate more 
inflammatory responses from the endothelium and smooth muscle activation/migration 
into the intima [39, 40]. This process can lead to cell death (necrosis and/or apoptosis), 
where cell lipids and debris accumulate deep in the vessel wall.  These deposits are 
Several activators found in the blood can cause long term endothelial dysfunction or activation.  
Gene expression or protein synthesis occurs as a result of endothelial activation. MHC – major 
histocompatibility complex. Partial list.  
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responsible for vessel dysfunction and when disrupted, lead to acute blockage of the 
artery. 
 
However, it has not been possible to predict which plaque deposits will cause clinical 
events. It has become a research imperative to develop blood tests, instruments, and/or 
drug therapy protocols that will allow clinicians to understand atherosclerosis better, 
effectively manage patients, and ultimately reduce acute events that impair life and 
increase the cost of care.   It should be possible to develop an intravascular device based 
on the living, physiological effects of atherosclerosis on the vessel wall to identify 
vulnerable plaque. Such a device should be able to elucidate silent lesions that will cause 
death if not diagnosed and treated, be minimally invasive, and cost-effective in order to 
save lives. The clinician, armed with such a device, will be able decrease cardiovascular 
disease morbidity in their community.  
 
4.1.3. Cardiovascular Disease – Risk Factors 
 
There are several environmental risk factors for cardiovascular disease (or CVD; includes 
coronary heart disease among several other disease states). Some are uncontrollable, such 
as increasing age, male gender, family history, and genetic abnormalities. Some are 
potentially controllable, such as hyperlipidemia, hypertension, cigarette smoking, and 
diabetes.  The American Heart Association’s 2002 Heart and Stroke Statistical Update 
lists the five major risk factors for cardiovascular disease physicians consider in diagnosis 
and treatment [1]: 
 
• Smoking 
• High blood cholesterol and other lipids 
• Physical inactivity  
• Overweight and obesity 
• Diabetes mellitus 
 
Disease progression can be slowed down, and even reversed in some cases for gross 
lesions with drug therapy (e.g., statins such as LIPITOR®, ZOCOR®). The removal of 
risk factors such as smoking is very important. Surgery, drugs, and lifestyle changes 
prolong and improve the quality of life in most cases. However, when the disease is 
asymptomatic, which is the norm rather than the exception, it can only be silently 
managed. No one knows when or to whom a heart attack will occur. Symptoms may go 
on for days before the individual realizes he/she is having a heart attack. Detecting these 
high-risk or “vulnerable” atherosclerotic lesions (lesions that suddenly rupture or block 
the flow of blood) before the acute event ever occurs has become a global scientific 
imperative.   
 
4.2. Natural History of Atherosclerosis: Concept of the Vulnerable Plaque 
 
Dr. James Muller first introduced the concept of “vulnerable” atherosclerotic lesions in 
1992 [41, 42]. Since then considerable debate has occurred as to whether this lesion 
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exists, or can even be defined with current technology. In this section, the vulnerable 
plaque concept is reviewed. The medical necessity to understand atherosclerosis in-vivo 
drives much of the current research efforts to develop diagnostic instruments. Finally, the 
justification for looking at the metabolic status of atherosclerotic vessels through 
spectroscopy is discussed, as well as its potential benefit to the field of vulnerable plaque 
research.   
 
The current scientific consensus from Virmani et al [25] defines vulnerable plaques as 
“precursor lesions” that ultimately end in acute coronary thrombi (clots) that create a 
heart attack. These plaques are further classified as ruptured, eroded, or calcified nodules.   
The most common of these are the ruptured plaque. Its precursor, the thin-cap 
fibroatheroma (TCFA), is defined as a plaque with less than a 650 micron thick fibrous 
cap. The identification of these vulnerable plaque(s) in the asymptomatic population may 
be better resolved by knowing the chemical composition instead of or in addition to the 
structural size [25].  
 
The atherosclerotic process in the arterial walls starts at an early age where some initial 
injury is presumed to cause endothelial dysfunction. Embryonic studies show that there is 
a difference between vasculature at birth versus young children. Fatty deposits or streaks 
characterize early lesions in teens. By young adulthood, the fatty deposits become more 
pronounced and frequent the more disruptive parts of artery walls, areas of high shear 
such as bifurcations and large vessel divergence. Diet, lifestyle, and genetic 
predisposition are some of the factors that may account for the different pathology in 
young adults.  As the population gets older, disease progression continues as 
inflammatory responses, ischemic injury and/or tissue repair mechanisms affect the 
vessel wall and loses it ability to function properly.  Calcification and necrosis occur as 
these fatty deposits make the intimal layer and/or medial layer dysfunctional [22]. 
Structural changes accompany the dysfunction, resulting in both luminal narrowing 
(stenosis) and wall thickening. However, it has been shown that having less than 50% 
stenosis of a vessel does not completely remove the risk of having a heart attack [23].  
 
Figure 4.2.1: Plaque progression (left) and rupture (right). Plaque progression from stable plaque with 
a thick fibrous cap and fatty core, active cells in the core create changes that lead to rupture. Rupture is 
indicated by breakage of the fibrous cap and release of core materials into the bloodstream A blood clot 
or thrombus can form at this site, further limiting the blood flow in the lumen or causing acute 
blockage.  
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The plaque itself may have asymptomatic or symptomatic consequences. Asymptomatic 
consequences imply that the disease progression continues undetected and untreated, 
creating a possibly inferior cardiovascular system that would be unable to respond 
properly to further traumatic injury. Symptomatic consequences are clinically apparent 
when a proper medical history is taken. Symptoms range from angina (chest pain, both 
stable and unstable), clots, stenosis, reduced blood flow, heart attack, ischemic heart 
disease, and in the case of cerebral vasculature, transient ischemic attacks and stroke.  
The symptomatic consequences of atherosclerosis also create an inferior cardiovascular 
system, but at least it is detectable and treatable through differential diagnosis, lifestyle 
modifications, and FDA-approved drug or surgical technologies.  
 
Up until recently, post-mortem studies have provided all the information regarding 
atherosclerotic plaque composition. Plaques may contain stabilizing fibrous caps 
(collagen, fibrin) that encompass the milieu of inflammatory cells (most notably 
monocyte-derived macrophages), fat, regions of calcification, necrosis, or even 
neovascularization (uncontrolled angiogenesis) within the diseased vessel wall. However, 
histological identification of the atherosclerotic plaque is an imperfect gold standard. 
Plaque histology, not only being very technique dependent, is a fairly qualitative measure 
of plaque composition and is subjective from pathologist to pathologist.  It also is not a 
proactive diagnostic tool. Supplemental biochemical data of blood components have 
show strong correlations between circulating total blood cholesterol, high-density 
lipoproteins (HDL), low-density lipoproteins (LDL), and triglyceride levels and the lipid 
deposition seen histologically in the arterial wall. Blood markers of inflammation may 
also indicate the presence of vulnerable atherosclerotic lesions.   
 
It is understandable then why much research in the area of identifying the chemical 
composition of plaques has focused on lipid accumulation of cholesterols or calcification 
[32, 34, 43, 44]  However, a large lipid core alone is not significantly correlated with 
sudden plaque rupture or thrombosis (i.e. the vulnerable plaque). Since inflammatory 
responses are correlated with the incidence of plaque rupture, research has shifted in 
finding suitable markers for inflammation. Several molecular or immunological markers 
have been proposed (metallomatrix proteases, antibody staining, IL-6, etc.).  Since 
inflammation characteristically produces heat, metabolic parameters--such as temperature 
[45], tissue pH [36], and metabolic by-products of inflammatory cells [46] have also been 
suggested as inflammatory markers, on a thermodynamic or tissue energetics basis.   
 
Activated macrophages, an inflammatory cell type, play an important role in the plaque’s 
susceptibility to rupture. In a large histological survey, plaques that had a high degree of 
activated macrophages, indicating an inflammatory response to plaque disruption, were 
more often responsible for an acute coronary syndrome versus lesions responsible for 
stable angina (14% versus 3% of plaque tissue occupied by macrophages) [21]. Cell 
density and temperature may also be indicators of the inflammatory response [45].  
Macrophages, whose duty is to repair and remove fibrous tissues, infiltrate the cap region 
and affect the thickness, strength, and collagen content of a developing plaque. Plaque 
rupture would release the lipid core contents, which may cause an acute blockage 
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downstream (see Figure 4.2.1). Macrophages are working typically under conditions of 
low oxygen tension and metabolize glucose as their main source of energy. Anaerobic 
metabolism occurs due to lack of oxygen delivery, as the intimal layer gets most of its 
oxygen through simple diffusion from the blood. Lactate, a product of anaerobic 
metabolism, has been found in atherosclerotic plaques [47-49]. It also has been 
demonstrated that plaques with large lipid cores and low calcifications are associated 
with lower pH [36, 50]. A higher lactate or hydrogen ion concentration may indicate 
higher macrophage activity and acidic conditions, and therefore, be potentially associated 
with an increasing risk of rupture or vulnerability.  
 
Early studies of atherosclerosis in the 1950’s attempted to assess various enzymatic 
activities in the vessel wall of normal and atherosclerotic human vessels. The enzyme 
lactate dehydrogenase (LDH) catalyzes the reversible reaction of lactate to pyruvate by 
means of hydrogen transfer to and from NAD: 
 
L-lactate + NAD+  ⇔ pyruvate + NADH + H+ 
 
In alkaline conditions and at high lactate and NAD concentrations, the reaction proceeds 
left to right and pyruvate returns to the Krebs cycle. Kirk et al demonstrated using LDH 
activity that lactic acid production predominates in human aortic tissue and high 
glycolysis occurs both under aerobic and anaerobic conditions. It was proposed that lactic 
acid production arose from “originally neutral compounds”, causing low pH of the tissue, 
which in turn may be important in preventing insoluble calcium deposits in the wall [51]. 
Zemplenyi et al used a microenzymatic method to quantify lactate in atherosclerotic 
plaques in rabbits [48] [49]and in rats [47]. A significant difference in lactate levels was 
demonstrated between normal and experimental atherosclerotic White New Zealand 
rabbit aortas (278 and 474 nmole/100 µg DNA mean values, normal and atherosclerotic 
respectively) [48].  The biochemical pathway for lactate production and anaerobic 
metabolism is summarized below:  
 
Glucose aerobic oxidation: [52] 
Glucose + 2NAD+ + 2ADP + 2Pi → 2NADH + 2pyruvate + 2ATP + 2H20 + 4H+ 
 
Anaerobic glycolysis: NADH free energy of oxidation is dissipated as heat, regenerate 
NAD+ 
 
Pyruvate + NADH → L-lactate + NAD+ 
Overall anaerobic process: 
Glucose + 2ADP + 2Pi → 2lactate + 2ATP + 2H20 + 2H+ 
 
A more recent study of acidity in atherosclerotic lesions showed that the pH in lipid cores 
were significantly lower than the pH in calcified and thrombosed areas of 35 human 
carotid endarterectomized atherosclerotic plaques [50]. Similar results in atherosclerotic 
Watanabe rabbits, which exhibit more lipid cores in the aortic lesions formed, showed pH 
LDH 
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was lower in the plaque than in the normal vessel wall. Inflammation and macrophage 
cell density was considered by collaborating investigators to be a source of temperature 
heterogeneity in plaques [45]. These studies indicate that pH and temperature may play 
an indicative role in plaque vulnerability. 
 
4.3. Available Technology  
 
Presently, there is no FDA-approved monitoring technique or instrument that meets the 
requirements of a cost-effective, clinically acceptable, and useful instrument to assess 
plaque vulnerability. A comprehensive exam by a cardiologist or family physician must 
be performed in order to determine diagnosis, prophylaxis, and/or treatment. No one 
device can be used alone, especially without knowledge of family history and lifestyle. 
Blood tests for cholesterol, HDL/LDL ratio, and triglycerides can be predictive of 
cardiovascular disease in general. A new blood test for C-reactive protein (relative 
measure of inflammation) is being integrated into clinical practice as a predictor of acute 
myocardial infarction. [53, 54]Current clinical practice for coronary artery disease 
diagnosis uses either x-ray angiography or trans-esophageal echocardiography (TEE), 
which provide the clinician with degree of stenosis and approximate lumen size based on 
flow of contrast media or echogeneicity.  There are several methods under research to 
locate gross lesions and stenoses, however, none predicts plaque vulnerability adequately.  
 
Table 4.3.1 summarizes the advantages and disadvantages of both optical and non-optical 
techniques currently in the research stage for vulnerable plaque detection.  The optical 
techniques—angioscopy [15], optical coherence tomography (OCT) [9], and photonic 
spectroscopy (including Raman [24, 33, 55-57], fluorescence [58-60], and near infrared 
[12, 32, 34])--are of great interest as they have the potential to provide both chemical and 
structural information at relatively low cost and are fairly intuitive. Raman spectroscopy 
initially was developed as an adjunct to histology, a destructive micro-analytical 
technique that was intended to remove the subjective nature of the standard H&E 
staining.  Now, fiber optic Raman spectroscopy is being developed, using laser and 
graded-index fiber technologies reducing the inherent dispersion of the Raman scattered 
signal in standard optical grade materials. Fiber optic Raman spectroscopy has been used 
to quantify cholesterol and structural components in a small set of human coronary 
plaques [44]. Fluorescence spectroscopy can be used, however, it requires injection of a 
contrast agent (such as Antrin®, a hematoporphyrin derivative) that will have preferential 
uptake in the plaque. Some endogenous fluorophores exist in the lipid core of 
atherosclerotic plaque that may adversely affect the signal from the contrast agent as 
well.  The fluorphore contrast agent is used to gain signal-to-noise and improve the 
consistency of this technique. Plaques that have neovascularization or intra-plaque 
hemorrhage have improved detection with fluorescence spectroscopy in animal models 
and in in-vitro human plaque studies [60, 61]. Near infrared spectroscopy techniques 
have historically looked at cholesterol deposits, oxidized LDL, or other morphological-
related chemical species such as collagen [12, 34, 62, 63].   This research focuses on 
using near infrared spectroscopy to assess the metabolism of the atherosclerotic plaque, 
rather than a relatively static chemical species such as lipid content.  All the optical 
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techniques are still in research phase and have yet to show whether the new metric will be 
an accurate predictor of vulnerability.  
 
Out of the non-optical techniques, the issues of cost and ease of use currently make them 
restricted to large medical centers or research facilities. Intravascular ultrasound (IVUS) 
is being used more frequently outside of the U.S., however, its lack of specificity to 
chemical constituents is the main reason for poor predictability of vulnerability.  Recent 
MRI research developments show biochemical profiles may be possible in small regions. 
Technical challenges such as small slice sizes and motion artifact currently preclude its 
use as a rapid in-vivo analyzer for vessels that are not superficial. Nuclear medicine 
techniques such as scintigraphy are also plagued with poor resolution and require more 
radioactive injections over and above the concurrent fluoroscope use in the 
Catheterization Lab [21].  
 
Spectroscopic measurement of metabolic derangements such as tissue pH or lactate, in 
combination with one of the localization techniques, such as angioscopy, would be 
superior to cholesterol concentration determinations alone. Such an optically based, 
spectroscopic measurement would indicate macrophage activity and acidic plaque, as 
well as the influence of hypoxic cells on their way to necrosis or apoptosis.  A catheter-
based fiber optic, near infrared spectroscopy system is ultimately envisioned to assess the 
metabolic status of atherosclerotic plaques.  Cardiac catheterization offers minimally 
invasive access to coronary arteries and can be used to evaluate multiple sites in one 
session. 
 
Near infrared spectral data contain a wealth of chemical information that, if extracted 
properly, could provide a robust chemical assessment of vulnerability. The spectroscopic 
measurement can potentially be coupled with other clinical correlations to provide 
additional information about the plaque(s) and guide the clinician in preventing 
thrombosis and heart attacks. The ultimate design concept of an in-vivo spectroscopic 
catheter would be to adapt a Fogarty-type balloon angioscope to include near infrared 
spectroscopic transmitting/receiving fibers. Spectroscopic examination could potentially 
identify the extent of metabolic derangement in the arterial wall. Metabolic status of the 
diseased vessels and clinical presentation could be combined to construct a vulnerability 
score from a longitudinal clinical trial [36].  
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Table 4.3.1: Advantages and disadvantages of techniques for vulnerable plaque detection [2]. 
INVASIVE 
TECHNIQUES 
Advantages Disadvantages Projected Use 
Intravascular 
Ultrasound (IVUS) 
Morphology of vessel 
wall/plaque not just the 
lumen or surface; 
echogenic density for 
fibrous cap 
Echolucent areas cannot be distinguished as 
to composition; spatial resolution can not 
distinguish cap thickness with accuracy; 
calcium deposits cause “shadow” effect, 
such that deeper into the plaque can not be 
imaged; can not identify inflammation 
In clinical testing stage; with additional 
B-mode specialized algorithms may be 
able to obtain more information 
towards identifying vulnerable plaque 
(elastography, tissue Doppler, shear 
stress imaging) 
Intravascular 
Thermography 
Sensitive thermistor 
technology; powerful 
clinical correlations to 
outcome; inflammatory 
response theory 
Requires proximal occluding balloon; 
inflammation versus blood flow 
confounders; may not provide information 
about eroded but not inflamed plaques 
Use in conjunction with IVUS; in 
animal testing stage 
Intravascular and 
Transesophageal MRI 
High resolution images and 
lack of ionizing radiation or 
exogenous compounds 
Long acquisition times; cost; need in 
Catheterization Lab for other cardiovascular 
testing; patient ineligibility (metal implants, 
pacemakers) 
In research phase; combine with 
thermometry 
Angioscopy Intuitive, simple to use Visualizes only surface of vessel wall 
plaque; requires proximal occluding balloon; 
limited spatial resolution with imaging fibers 
In clinical testing stage in Japan [21]; 
as technology improves and catheters 
can go down to 1-3 Fr without 
perceived operator loss of information; 
new algorithms in research stage for 
automated colorimetric detection 
Optical Coherence 
Tomography (OCT) 
Excellent spatial resolution 
for plaque surface and cap 
fissuring; anatomic 
imaging 
May require proximal occluding balloon or 
saline flush (index matching); long 
acquisition times; cost; limited penetration 
(<200 um); no composition info 
In research phase 
Photonic Spectroscopy 
A. Raman  
B. Near Infrared 
Diffuse Reflectance  
C. Fluorescence / 
Exogenous Tracers 
Can potentially measure 
both morphological and 
physiological data for 
vulnerable plaque detection 
May require proximal occlusion; size of 
fibers competitive with angioscopy 
In research phase; use in conjunction 
with IVUS or angioscopy 
NON-INVASIVE 
TECHNIQUES 
   
Magnetic Resonance 
Imaging (MRI) 
A. Contrast Media – 
Gadolinium, SPIO, 
others 
High resolution images 
(slice to slice); additional 
flow information 
Long acquisition times; ineligibility of 
patients with metal prosthetics; cost; 
currently unable to provide in-plane 
resolution less than 300 microns 
Algorithm development in research 
phase; current clinical instruments must 
be upgraded to perform cardiac 
imaging; Possibly combine with NMR 
spectroscopy for increased accuracy 
(magnet size issue) 
Electron Beam 
Computed 
Tomography (EBCT) 
Detects advanced 
atherosclerosis based on 
calcium content (Calcium 
Score) 
Have not shown predictability for vulnerable 
plaque sub-types 
IN USE: Calcium Score; new 
algorithms being developed for 3D 
images 
Multi-Slice / Helical 
CT 
High resolution 
(comparable to MRI), 
provides increased 
accuracy in Calcium Score; 
simultaneous recording of 
ECG 
Ionizing radiation; may not characterize the 
vulnerable plaque sub-type well; cost 
Unknown 
Nuclear Imaging Provides metabolic 
information when using 
tracers; allows serial 
monitoring of progression 
and regression 
Ionizing radiation; limited spatial resolution; 
cost  
In animal testing stage 
OTHER    
Blood Tests and 
Serum Markers 
Simple test; lowest cost Need supplemental patient data; history IN USE: C-reactive protein (CRP), 
other markers in research stage 
Endothelial Function 
Test  
- Non-invasive 
ultrasound test of 
brachial artery 
Simple test; low cost Lack of specificity IN USE 
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4.4. Reflectance Spectroscopy and Tissue Optics 
 
The optical measurements of choice in this research are the pH and lactate concentration 
of plaque tissue. Using diffuse reflectance near-infrared spectroscopy, these metabolic 
parameters will be determined optically, based in part on the expected optical properties 
and the spectra of normal versus atherosclerotic tissues. Human atherosclerotic plaques 
are investigated using both Fourier-transform near infrared spectroscopy (FT-NIR) and 
visible/near-infrared (NIR) spectroscopy, spanning the wavelength region of 
approximately 400 to 2400 nm, using a custom designed fiber optic probe. By collecting 
a large wavelength range, the spectral data collection is maximally efficient for the 
number of specimens expected. The plaque’s metabolic data (tissue pH, temperature, and 
lactate concentration) are measured at the same location as the optical spectra.  
 
One important factor in the design of a spectroscopic, fiber optic, catheter-based sensor 
that can determine concentration of specific molecules (and/or chemical shifts) is to 
understand the differences between the optical measurement volume and the reference 
measurement volume. The underlying principles of reflectance spectroscopy, photon 
migration in tissue, fiber optics, and system signal-to-noise all play an important role in 
the design and performance of the prototype device.  In this section, these concepts are 
reviewed. 
4.4.1. Reflectance Spectroscopy 
 
Spectroscopy – the study of energy interaction with matter – is useful in several 
applications to identify good products from bad products, purity of component, etc. There 
are four basic interactions involved: 1) reflectance, 2) absorbance, 3) scattering, and 4) 
transmission. These basic interactions on a homogeneous medium are depicted in Figure 
4.4.1.  The refractive index of the external and internal medium is represented by n1 and 
n2 respectively. If n1 = n2, then the reflection off the incident surface (termed specular 
reflection) is negligible. 
 
In classical absorption spectrophotometry, one is interested in how much light at a certain 
wavelength or energy is absorbed by a homogenous (i.e., isotropically scattering) 
Incident light
Reflection
Scattering
Absorption
Transmitted light
n1 n2
Figure 4.4.1: Energy interaction (incident light) with homogeneous medium. 
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medium in a fixed pathlength (for example, in a 1-cm cuvette). Since absorption and 
scattering are two different events, the scattering effect can be ignored only in an 
isotropically scattering medium. Absorbance of the light is calculated by using Beer’s 
Law.  Beer’s Law states that the absorbance at a certain wavelength is proportional to the 
thickness of the sample (i.e., the pathlength the light travels from the incident position to 
the transmission position). The proportionality constant is a characteristic parameter of 
the pure absorbing species. The analogous equation, the Lambert Law, states that the 
amount of light transmitted through a homogenous medium is proportional to the number 
of molecules of absorbing species in solution. The Beer-Lambert Law combines the two 
equations under the assumption that the probability of absorption is unaffected by the 
absorbing species concentration (i.e., it can be considered a molecular process that only 
involves the number of the absorbing species molecules traversed in a fixed depth per 
fixed unit cross sectional area of light; the probability remains the same whether there is 
5 moles per liter (molarity, M) or 1 mole per liter of the absorbing species of interest. The 
probability is affected only by wavelength in an isotropic, homogeneous medium. The 
derivation is as follows: 
 
Beer’s Law: 
kl Probability that light at a given wavelength will be absorbed per unit 
length of matter [cm-1] 
δ Infinitesimally small distance, [cm] 
 
δ⋅lk  Probability of absorption in some small 
distance, δ 
δ⋅− lk1  Probability of not being absorbed in δ 
( )21 δ⋅− lk … ( )nlk δ⋅−1    Probability of not being absorbed for 
increasing increments of distance δ, 2 ….n   
 
Let δ⋅= nl  and take limit as ∞→n , making substitutions 
 
e lk
n
l l
n
lk
n
⋅−=

 ⋅−∞→ 1
lim
 
 
Note bene: lim 11
n
n n e
 + = →∞ 
 
 
∴ Probability that light will not be absorbed in total distance, l is e lkl ⋅−  
 
Lambert’s Law: 
 
Ii   Incident light  (intensity or irradiance units) 
Io  Transmitted light (same units as transmitted light) 
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i
o
I
I  Fraction of light transmitted, equivalently 
 
 eII lkio l ⋅−⋅=    Transmission (light not absorbed) 
 
Molecular process of light absorption (single absorbing species in solution): 
 
N Number of molecules of absorbing species in solution 
ρ Molecular density [kg/cm3] 
m Molecular mass [kg] 
m
l ρ⋅  Number of molecules traversed in depth l per unit cross section [cm-2] 
 
Let 
l
mkk lN ⋅
⋅= ρ  Define kN  as the molecular absorption 
coefficient, assumed to be unaffected by 
concentration, [cm-1] 
 
 
∴  Nk
i
o Ne
I
I ⋅−=   
 
Beer-Lambert Law: 
 
NA Avagadro’s Number, [6.02x10-23 molecules/mole] 
ε  Extinction coefficient of the absorbing species [L/(mole ⋅ cm)], function of 
wavelength  
c  Molar concentration of the absorbing species, [mole/L] 
l   Pathlength, [cm] 
λ  Wavelength 
A  Absorbance, function of wavelength, arbitrary units 
 
1000
lcNN A ⋅⋅=  (by definition) 
 
1000
AN Nk ⋅=α  Molar absorption coefficient 
 
lc
i
o e
I
I ⋅⋅−= α  and 
303.2
αε =  
 
lc
i
o
I
I ⋅⋅−= α10  or lc
I
I
o
i ⋅⋅=


 εlog  
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Since ε is a function of wavelength, λ, the absorbance, A, as a function of wavelength is 
defined in a homogeneous medium: 
lc
I
IA
o
i ⋅⋅=


= )(
)(
)(log)( λελ
λλ     
 
 
In reflectance spectroscopy, one measures the amount of light reflected back by the 
sample medium at its incidence interface. The source and receiving cross-sectional 
geometry becomes important, as scattering and absorption losses are separate events that 
need to be understood and optimized for a particular application. Conventionally, this 
requires a measurement of a reference material of known intensity to obtain the relative 
absorbance of the sample. In the ideal case (homogenous, isotropic medium), what is not 
absorbed (A) or transmitted (T) must be reflected (R) and all incident light is conserved.  
However, it may not be possible to measure all the transmitted light due to a large sample 
thickness, source or receiving hardware limitations, or other design constraints. In this 
research, it would not be feasible to measure the light transmitted through the vessel wall 
and the desired intravascular catheter requires that reflectance-mode spectroscopy be 
used.  The anisotropic nature of tissue scattering affects how much light will be reflected 
back to the receiving geometry after any absorption events have occurred.  This diffuse 
reflectance may contain both specular and higher-order reflectance interactions with the 
sample, depending on the relative indices of refraction at the interface (n1 and n2, for an 
air-sample interface n1, air=1, n2 may be a function of wavelength for tissues). 
 
Iincidence(λ) Incidence intensity, fixed source geometry, constant or known 
Ireflectance(λ) Measured reflected intensity, fixed receiving geometry 
 
)(
),(
incidence
ereflectanc
λ
λ
I
referenceI
 Fraction of light reflected by the reference 
material 
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ereflectanc
λ
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 Fraction of light reflected by the sample 
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The logarithm of the inverse of the measured sample diffuse reflectance, R, (log (1/R)) at 
incident wavelength(s) is defined as the absorbance, A, of the sample at that wavelength 
when the incident intensity is known and normalized (for example, using a blank in a 
cuvette-based, monochromatic spectrophotometer).  A univariate calibration curve is 
typically constructed from knowing absorbance versus concentration over a specified 
range. The concentration of the desired analyte can be deduced from this curve. The more 
complicated the sample, the more the desired analyte becomes buried in the measured 
diffuse reflectance, making it difficult to derive a univariate calibration curve. Tissue 
samples are notorious for being complicated; they have many different absorbing species, 
scattering components, and possible physiological or other unknown effects on the 
desired analyte or signal needed for calibration. The design of a reflectance-mode fiber 
optic probe for the determination of metabolically active analytes in an inhomogeneous, 
anisotropic tissue bed is therefore inherently complex. In this research, the optical design 
must be aided not only by the practical considerations of reflectance-mode spectroscopy 
but also the theoretical optical properties and how light might travel (photon migration) 
in the atherosclerotic vessel wall.  
 
4.4.2. System Considerations 
 
Near infrared spectroscopic measurement of tissue pH, developed in Dr. Soller’s 
laboratory, can provide a minimally invasive assessment of tissue ischemia in the 
myocardium [28]. Improvements in the accuracy and reliability of this method for 
myocardial pH were required. The initial feasibility study performed in the canine 
myocardium used an approximately 6 mm diameter NIR reflectance fiber-optic probe 
(Remspec, Inc. Sturbridge MA) to illuminate and collect light in the 575-1100 nm region.  
The studies with this probe show that reflected light was collected down through a 5 mm 
thick layer of myocardium. Electrochemical tissue pH measurements (1.2 mm diameter, 
Microelectrodes, MA) were collected simultaneously with NIR spectra and multivariate 
calibration models were developed.  
 
One factor affecting the accuracy of these models is the depth-dependent tissue pH levels 
that exist in the normal [64] and ischemic heart.  It has been shown that tissue pH 
declines more in the endocardium than in the epicardium during coronary occlusion [65].  
Impaired metabolic response and the duration of ischemia are more severe in the 
endocardium as evidenced by pH electrodes placed 8-10 mm in the left ventricular 
anterior wall (subendocardial) than 2-3 mm below the surface (subepicardial) after repeat 
occlusions. In this earlier work, reference pH electrodes were placed 5 mm into tissue, at 
the boundary between the epicardium and endocardium. Similarly, light was collected 
from both layers, merging the different pH values from the separate layers of tissue. An 
accurate optical pH measurement can only be made in the heart when light is collected 
from a known volume of tissue. Analyzing photon migration in the tissues and optimizing 
the probe geometry to localize the collected light from a smaller region can provide better 
calibration and ultimately improve performance.  
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An additional constraint is imposed on the optimal probe size for the vulnerable plaque 
research.  As it is intended to be intravascular, the working optical area should be less 
than 2 mm in diameter or 6 French (the French scale, unit of measurement typically used 
to for catheters, is defined as 1 French ≈1/3 mm). For this geometry, the realizable 
source-receiver separation is on the order of 1-2 mean free path of most biological 
tissues. This makes the diffusion approximation of photon transport invalid. The Monte 
Carlo Method is recognized as an appropriate, statistically based model for light transport 
for a small geometry. Monte Carlo simulations provide a “random” walk assessment of 
the migration of photons at a specific wavelength in a complex absorbing and scattering 
medium, defined by its optical absorption and scattering coefficients, and the tissue 
anisotropy factor. The results of diffuse reflectance as a function of radius, and the 
absorption as a function of depth are interpreted in terms of probabilities.   Monte Carlo 
simulations of source-receiver separations for optimization of other optical spectroscopy 
methods [66] and tissue optical property measurements [67] have shown that there exists 
an optimal separation such that the pathlength dependence on scattering is minimized for 
the specified tissue layers.  
 
Khan et al [68] have shown that in a Monte Carlo simulation of both purely scattering 
(Intralipid), and absorbing and scattering medium, the simulated diffuse reflectance as a 
function of radial distance can be obtained. The minimization of scattering was 
demonstrated and the localization of the light entering and exiting the tissue was shown 
to be less than 1 mm3 from simulated data for a two-fiber system in a myocardial tissue 
pH application. The simulations for normal and atherosclerotic vessel wall also provide 
further evidence that the optimal source-receiver separation can be achieved given the 
design constraints for the vulnerable plaque.  
 
4.5. Multivariate Calibration Methods 
 
Spectroscopic determination of one chemical component in a complex, scattering and 
absorbing mixture such as the vessel wall or other tissue beds can be achieved by the use 
of multivariate calibration.  Using a spectral calibration set, a model is generated to 
correlate the tissue spectra to the reference measurements. In this manner, the model is 
trained to recognize features that are highly correlated with the reference measurement.  
Partial least-squares (PLS) data analysis is an extensively used mathematical technique in 
the analysis of spectroscopic data [69, 70]. It extracts information from the spectra that is 
most correlated to the reference measurement of interest by decomposing the data into 
loading vectors (spectral B, chemical v) and scores (T), the linear combination of which 
represent the original spectrum (see Figure 4.5.1). Some residual error always exists. 
Inclusion of too much of this residual error may cause overfit of the data, and necessitates 
that the calibration process be closely monitored. Mean centering is typically used to 
eliminate the need to fit to a nonzero intercept in the calibration model and it decreases 
the complexity of the model by one factor (i.e., degrees of freedom reduced in the 
number of linear combinations needed) [71]. The optimum number of factors (and the 
subsequent loading vectors that describe the model) used in the final calibration equation 
is determined by how well the model predicts the concentration from an independent, 
unknown spectrum. Acceptable models should contain a low number of factors, with at 
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most 5 to 6 points per factor used [26]. Qualitative assessment of the loading vectors 
should provide some insight of the absorbance of the specific chemical species being 
calibrated, otherwise the loading vector contribution could be coincidental and noise-
related [70].  
 
The optimal number of factors for each calibration will be calculated using the leave-one-
point-out (or cross-validation) procedure, calculating the Predicted Residual Sum of 
Squares (PRESS) for each factor, and using a F-test (alpha level of 0.25) to identify the 
smallest number of factors where the PRESS minimized [71]. Cross validation 
methodology is used to assess the ability to predict the nth reference concentration of one 
specimen in the calibration set based on the spectral decomposition of all the other 
calibration spectral pairs. This is performed successively for each spectrum in the 
calibration set until all spectra have been predicted based on n-1 calibration spectra. The 
R2 and standard error of cross-validation (SECV) are calculated from the actual versus 
predicted values.  These parameters provide a measure of the accuracy and predictive 
ability of the calibration equation.  
 
The calibration set should span the variability expected in the entire population in order 
to be robust.  Therefore, a significant number of atherosclerotic areas must be studied to 
span the variability expected in lesion types. The variance in the data set should be 
related to the desired reference measurements; however, other chemical compositions and 
instrumental noise affect the spectra and ultimately, the optical determinations.  Different 
pre-processing algorithms can be used to remove some of the variability unrelated to the 
reference measurements (e.g., baseline correction or multiplicative signal correction) in 
the wavelength region of interest. The information content in the final calibration model 
ultimately should be related to real physical or chemical absorption changes in the 
atherosclerotic plaques that are indicative of the desired reference determination of either 
tissue pH or lactate concentration.   
 
 
+
+
EA
Ec
Figure 4.5.1: Partial least-squares illustrated. PLS regression technique is effective in establishing 
relationships between spectral changes and reference values. Using multivariate regression (white arrow), it 
is a non-iterative, factor analysis based decomposition of the spectra data (A) using reference values denoted 
as C.  T are the scores,  B and v are the  loading vectors, E is the residual matrix of either the spectra Ea or 
the concentration (reference values) Ec.  
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4.6. The Near-IR Characteristics of Vessel Wall and Atherosclerotic Plaques 
 
In this section, the visible and near-infrared characteristic absorption spectra of the vessel 
wall available in the literature are briefly reviewed in terms of the major absorbing 
components. The multiple components and overlapping peaks in normal and diseased 
vessels support the hypothesis that a multivariate, multi-wavelength approach may be 
required to deconvolve spectra into factors that are relevant for the optically determined 
plaque tissue pH and lactate concentration in atherosclerotic plaques. 
 
Cholesterol and its esters have significant absorbance peaks in the NIR. Plaque spectra 
collected by Jaross et al [34] are shown in Figure 4.6.1(d).  They reported cholesterol 
absorption peaks at 1750 nm. These spectra from 1000 to 2500 nm show the two water 
bands (~1450 and ~1950 nm) in the region as well. The effects of other absorbers (Figure 
4.6.1 (a)) in the atherosclerotic vessel wall on the optical determination of tissue pH and 
lactate are assumed to be minimal, based on their pure component spectra in the 
wavelength region of interest, and their relative importance to the expected predictability 
towards metabolic status.  
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Figure 4.6.1 From Jaross et al a) NIR spectra of several pure compounds of an arterial intima. From bottom to top: 
Water, cholesteryl-linoleate/oleate 2/1, cholesterol, triolein, lecithin/sphingomyelin 3/1, chondrosulfonate A, 
collagen. These compounds were identified by Jaross  et al as important components of arterial intima.(b) NIR 
spectra of the model mixtures without water; (c) NIR spectra of the model mixtures with water; (d) NIR spectra of 
aortic specimens. (1 Micron=Wavelength 1000 nm).  
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Lactic acid (C3H6O3) is a metabolic by-product of anaerobic glycolysis, and healthy 
levels are found in blood, exercising muscles, sweat, and tears [31]. The two peaks at 
~2250 and ~2295 nm are important in the optical determination for lactate concentration 
in the atherosclerotic plaque (lactic acid solution spectra, Figure 4.6.2).  
 
 
 
Figure 4.6.2: Lactic acid (70% solution in water, CAS#50-21-5), FOSS NIRSystems commercial 
spectrometer, resolution = 7 nm [72]. Water peaks at 1450 and 1950 nm, the two characteristic 
lactate peaks at 2250 and 2295 nm are circled.  
 
 
 
Keijzer et al [73] measured the absorption coefficients in the intima, media, and 
adventitia of human aorta.  Between 400-600 nm, hemoglobin absorption is observed in 
the vessel wall. The absorption coefficients increase toward 200-400 nm due to protein 
Figure 4.6.3: : Major biological absorbers in the visible to near 
infrared spectrum of de novo tissue.  
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absorption, and again past 1300 nm, due to water absorption. In the 600-1300 nm region, 
tissue absorption is the lowest; the major absorbers include hemoglobin, both oxygenated 
and deoxygenated states, and water (Figure 4.6.3) [74].  These constituents, due to pH-
induced changes in hemoglobin spectra, contribute to the optical determination of tissue 
pH. 
 
4.7. Experimental Factors 
 
In this section, an introduction of the known experimental factors that affect optical tissue 
spectra is made. Background information on the in-vitro temperature, the overall 
experiment time, and the gross pathology of atherosclerotic plaques is presented as to the 
impact these variables may have on the accuracy of the optical determinations.   
4.7.1. Temperature 
 
Temperature is known to affect optical spectra.  Water and hemoglobin have significant 
peak shifts with temperature; however, the effect is over a large temperature range 25-
40°C [75]. The less the temperature is allowed to fluctuate the less likely the shift will be 
apparent. The in-vitro media temperature is set to ~37°C for the final set of experiments.  
This also helps mimic in-vivo conditions for optical spectroscopy, where tissues and cells 
are constantly bathed in oxygenated, nutrient-rich blood or interstitial fluids at a nominal 
human body temperature of 37°C. It must be noted however, that the plaque tissue, due to 
inflammatory response, may have real, physiological fluctuations in temperature [45].  
Measured tissue pH and temperature for different plaque types showed clustering of the 
range over which these metabolic parameters may change. (Figure 4.7.1.). Therefore, the 
accuracy of the optical determinations must be reviewed with respect to the measured 
tissue temperature.  
 
Figure 4.7.1: Tissue pH and temperature measurements in grossly pathological different areas of plaque. Yellow- lipid 
laden, Blue-calcified, and Red-thrombosed. Tissue pH and temperature are inversely correlated.  
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4.7.2. Experiment Time Course 
 
Inadvertent time correlation of spectra has been shown to be a significant challenge in 
chemometric methods and multivariate calibration [76].  The complexity of physiological 
events and their time course, mostly unknown in atherosclerotic plaques, makes the 
collection of tissue spectra dependent on the rate of change of the metabolic and physical 
parameters.  To remove the time correlation effect as much as possible, the metabolic 
parameters that are measured should remain stable as possible from their starting points 
as the plaque tissue is removed from the body into the in-vitro environment.  The optical 
spectra should be taken as quickly as possible, and the reference measurements should be 
taken immediately after (simultaneous measurement is not possible in this case due to the 
destructive nature of the reference measurements).  The stability of the plaque tissue was 
validated in an optically transparent, oxygenated physiological nutrient media at 37°C 
(Chapter 6).  The effect that the duration of the experiment has on the multivariate 
calibration will be reviewed and shown to be minimal.  
4.7.3. Gross Pathology 
 
It has been demonstrated there exists a correlation between the gross pathology and the 
tissue pH and temperature of the atherosclerotic plaque ex-vivo. [36].  There is 
considerable histological evidence of structural heterogeneity [21, 23, 25]. Moreno et al 
have also demonstrated that it is possible to make an optical determination of the 
pathology [32].  In making an optical determination of plaque tissue pH or lactate, it is 
unknown how the unmodeled variable of the gross pathology may affect the accuracy.  
Whether the accuracy of the reference measurement of lactate concentration is dependent 
on the gross pathology is unknown [77], primarily due to the technological hurdles in 
refining the biochemical assay resolution. The following characteristics are qualitatively 
assessed for each plaque:  
 
• Yellow or lipid-laden area (glistening yellow or “fibrofatty”) 
• Calcified (hard, white, rough, rocky, “crunchy”) 
• Thrombosed (reddish/reddish brown, bloody, “raspberries”) 
 
A value of 1 is marked for the most prominent feature of the measured location, the 
others are marked 0.  In this manner, each point measured will be scored.  The effect that 
the gross pathology has on the optical determination will be reviewed.  
 
4.8. Summary 
 
Presently, there is no monitoring technique that meets the major requirements of a cost-
effective, clinically acceptable, and useful instrument to assess atherosclerotic plaque 
vulnerability. Spectroscopic measurement of tissue pH using multivariate calibration 
techniques is a feasible method for assessing metabolic status of tissue. With advances 
and understanding of interferents, both experimental and physiological, one can monitor 
tissue pH and/or lactate concentrations in various tissue beds. The application for 
atherosclerotic vessel walls is the main focus of this research. 
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5. OPTICAL DESIGN  
5.1. Rationale 
 
Optical spectroscopy is one of the few available non-destructive techniques for in vivo 
determination of tissue pH and lactate.  Atherosclerotic plaques have various levels of 
inflammation, calcification, fibrosis/necrosis, and neovascularization as demonstrated by 
histological record [25]. They are considered structurally heterogeneous. It has also been 
demonstrated that metabolic heterogeneity exists.  Significant tissue pH heterogeneity has 
been shown in both human carotid endarterectomized atherosclerotic plaques and 
Watanabe heritable hyperlipidemic (WHHL) rabbit aortas as compared to control non-
atherosclerotic vessels [36]. Lactate concentrations, however, may be more homogenous, 
as it is not as well resolved or compartmentalized in the interstitial space [77]. Due to this 
known heterogeneity, an accurate optical tissue pH or lactate determination can only be 
made in the atherosclerotic plaque when the light is collected from a small volume of 
tissue. 
 
The objective of the design process is to produce a probe that has the appropriate spatial 
resolution for accurate optical measurements in plaque. Photon migration simulation and 
analysis, using various tissue optical property data, combined with the appropriate 
modification of the probe geometry to optimize the collected light from a smaller volume, 
can provide better calibration spectra and, ultimately improve performance. In this 
section, the theoretical and practical optical data used to design such a probe that can 
achieve light collection from a localized volume of atherosclerotic tissue are reviewed 
and discussed. 
 
5.2. Monte Carlo Simulations Setup 
 
Monte Carlo simulations provide a “random” walk assessment of the migration of 
photons at a specific wavelength in a complex absorbing and scattering medium. A 
random number generation for each photon determines the event (i.e., reflection, 
absorption, scattering, or transmission) that will occur in a probabilistic fashion, given the 
optical properties of the medium. This process is repeated and each photon is followed 
until it leaves the defined grid geometry (by a reflection, transmission, or scattering 
event) or the photon is absorbed. All photons are conserved. The medium is defined by 
its optical absorption and scattering coefficients (µa (1/cm) and µs (1/cm) respectively, at 
a specific wavelength), and the tissue anisotropy factor, g. (direction of scattering, g=0 is 
defined as isotropic scattering). The outputs of the simulation are the probability of 
diffuse reflectance as a function of radius, and the probability of absorption as a function 
of depth. This is done for a number of wavelengths in the region of interest where optical 
property data is available.  The simulations aid in the practical design of the probe by 
providing a starting point for the testing of different source-receiver separations.  
 
All Monte Carlo simulations were performed with the ANSI Standard C code provided 
by Wang and Jacques on the Internet [78, 79].  A cylindrically symmetric geometry is 
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assumed with a point source at radius r=0.  A matched refractive index between the 
probe-tissue interface (n1=n2, i.e. direct probe-to-tissue contact or an appropriate fluid 
index matching) and an anisotropy factor of 0.9, which simulates the typical anisotropic 
scattering properties of tissue [80], were used. The diffuse reflectance and absorption per 
area as a function of depth are normalized by the number of incident photons, N, to 
obtain probability per unit volume.  The number of events or light interactions to follow 
was set to 10,000. To investigate possible source-receiver separations, simulations were 
performed with changes in absorption and scattering coefficients as a function of 
wavelength taken into account. Four separate simulations were performed: 
 
• Scattering only 
• De-oxygenated hemoglobin and scattering  
• Normal aorta at specific wavelengths 
• Atherosclerotic aorta at specific wavelengths 
 
First, purely scattering models of Intralipid were performed using the measured scattering 
coefficients (500 – 900 nm) provided by van Staveren et al [81] and absorption 
coefficients from Flock et al [82] These values are valid for actual Intralipid-10% 
concentrations between ~ 4 and 17 volume percent. The optical properties of Intralipid 
are approximate, due to real variation in scatterer size and preparations. Intralipid is also 
known to have some absorption at the longer wavelengths (>900 nm) due to water. The 
absorption (µa) and the scattering (µs) coefficients input to the code were between  
5.5x10-3 to 0.06 cm-1 and ~206 to 846 cm-1 respectively. The standard deviation across 
the simulated wavelengths was used as a measure of the wavelength dependence of 
scattering for each radial distance. To estimate the effective penetration depth (i.e., 
reflected photons return from a depth z, as a function of source-receiver separation), the 
absorption probability as a function of depth was calculated for each wavelength. The 
penetration depth was estimated by identifying the depth, z, to which at least 90% of the 
total absorption probability had occurred.  
 
Second, absorption and scattering models were performed using absorption coefficients 
for a 2 mM deoxy-hemoglobin tissue concentration (hemoglobin (Hb) protein without 
oxygen attached, Fe2+ conformation) with the same scattering coefficients used from the 
Intralipid simulations. Tabulated molar extinction coefficient values [83] of deoxy-Hb 
were converted to absorption coefficients by 2.303*(molar concentration). A 2 mM 
concentration is approximately 13 g/dl, which is physiologically relevant for blood-
containing tissue. The absorption coefficients input to the code were between 3.5 and 246 
Probe – tissue interface 
n1=n2 
dr= ∆25 µm
dz=∆5 µm 
Source 
Diffuse 
Reflectance(r)
Figure 5.2.1: Monte Carlo grid geometry for all simulations. Symmetry in the x-y plane at the  probe-tissue 
interface was assumed. The grid size was 25 microns x 5 microns (radius x depth). 
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cm-1 for the deoxy-Hb models between 500 – 900 nm. The absorption probability as a 
function of depth was calculated for each wavelength. The penetration depth was 
estimated by identifying the depth, z, to which at least 90% of the total absorption 
probability had occurred.  
 
The last two simulations used optical property data collected at three different 
wavelengths for normal aorta, and five different wavelengths for atherosclerotic aorta 
[84-86]. The radial resolution, or x-y plane, of the simulation was set to 0.025 mm (25 
microns). The depth resolution, or z-plane, was set to 5 microns (approximately the 
typical histology resolution). The grid was set to follow photons to a 1.5 mm radius (3 
mm diameter) and a 1.5 mm depth away from the source (Figure 5.2.1). Absorption and 
scattering coefficients used for all simulations are summarized in Table 5.2.1.   The 
diffuse reflectance as a function of source-receiver separation (radial distance away from 
source) and the effective penetration depth were calculated. 
Table 5.2.1: Absorption and scattering coefficients used for Monte Carlo simulations. 
Simulation µa (1/cm) µs (1/cm) Wavelength (nm) Reference 
Scattering only 5.5x10-3 – 0.06 206 - 846 500 – 900 (50 nm increments) 
[82] 
[81] 
De-oxy Hb + 
scattering 3.5 – 256 206 –846 
500 – 900  
(50 nm increments) 
[83] 
[81] 
Normal Aorta 6.856 
0.88 
0.508 
148.7 
86.21 
42.85 
514 
633 
1064 
[85] 
 
Atherosclerotic 
Plaque 
54 
10.98 
1.076 
10.0 
0.9 
8.0 
290.6 
142.9 
8 
33.54 
470 
514 
633 
1050 
1064 
[84] 
[85] 
[85] 
[84] 
[85] 
 
5.3. Experimental Optical Setup 
 
The optimal probe geometry that can be achieved given the practical considerations of 
designing a probe for intravascular use, and the additional requirement that the light be 
collected from a small, well-defined region of the heterogeneous plaque tissue, were 
investigated simultaneously. All probes that were studied were of the reflectance-mode 
design. By exploiting the combinations of the key variables that affect the optical signal 
in both the commercial probe that was available (FOSS NirSystems, MD) and the 
custom-manufactured optical probes (i.e., fiber size and types, optical attenuation, 
collection efficiencies, etc.) an optimal set of materials and design geometry was realized.  
All optical tests were performed on a FOSS NirSystems 6500 scanning 
spectrophotometer with 32-bit ADC and a fiber optic adapter.  A Si detector covers the 
wavelength region 400-1100 nm; a PbSe detector covers the wavelength region 1100-
2500 nm. Both detectors are uncooled (room temperature ~ 19-27°C). The source is a 75 
W tungsten-halogen lamp that is filtered using a monochromator, and the wavelength 
calibration is factory set. The spectrometer has a set 2 nm wavelength resolution across 
both regions. Signal-to-noise ratio (SNR) as a function of wavelength was evaluated for 
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each probe.  The tissue penetration test (Section 5.3.3) was performed only on the probe 
that eventually demonstrated an adequate SNR and had a working optical area small 
enough for the practical measurement in plaque.    
 
5.3.1. Source-receiver optics test probes characteristics 
 
Source-receiver fiber separation is assumed to be the critical factor in determining 
performance based on Monte Carlo theory. However, in practicality, other variables may 
exist.  Seven different probes were tested that had varied fiber size/type, fiber number, 
collection interface, collection geometry, and source-receiver fiber separation. The 
working optical diameter is determined by fiber number (size), collection interface, and 
the nominal separation. Table 5.3.1 summarizes each optical probe’s characteristics. Each 
probe was evaluated as to its contribution in improving optical signal collection and 
adhering to design constraints.  
 
5.3.2. Signal-to-Noise Ratio (SNR) testing 
 
For each probe (except probe #8), fibrofatty plaque tissue at 37°C was used to collect  
representative absorbance spectra. All absorbance spectra were collected at 60 scans for 
the full range (400-2500 nm) by ratioing to a Spectralon 50% reflectance standard (or 
Ireflectance(λ),referenceo) collected earlier on the same day.  Since single-beam spectra  
(raw counts per wavelength) could not be collected with the spectrometer software, the 
tissue absorbance spectrum and a “noise” absorbance spectrum, i.e., an absorbance 
spectrum of the Spectralon 50% reflectance standard, were both measured. The “noise” 
spectrum was collected independently to assess the effect of the spectrometer change 
without the added tissue variation before (Ireflectance(λ),reference1) and after 
(Ireflectance(λ),reference2) a tissue spectrum was taken. The tissue absorbance spectrum was 
measured on an representative area of plaque as: 
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The “noise” spectrum as defined above was measured as:   
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The “signal-to-noise ratio” or SNR, for the purposes of this study, was calculated using a 
4 nm bandwidth, as the average absorbance of the tissue over the average absorbance of 
the “noise” (spectrometer changes in measuring the reflectance standard): 
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A nm tissueSNR
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λ
λ
< ± >= < ± >  
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In other words, the signal-to-noise ratio was calculated as the ratio of the average 
absorbance collected from a representative piece of tissue to the average absorbance 
collected from the same reference material used to make the absorbance calculation at 
different time points. The center wavelengths chosen, λ, are those where a maximal SNR 
is desired for atherosclerotic plaque optical collection, that is, where the important 
absorbers are found (e.g., hemoglobin, water, lipids, lactate). The average is done using a 
4 nm bandwidth (center wavelength, λ ± 2 nm). The average absorbance was chosen 
instead of the standard deviation to ensure the SNR values were not inadvertently inflated 
due to the non-standard methodology. By using relative SNR values, different probe 
configurations can be compared.  
 
In addition, the average detector voltage readings for each wavelength region were 
collected for all seven probes.  Performance factor multipliers for each wavelength range 
(visible and NIR) were derived with respect to a significant numerical improvement over 
the first design probe (Probe #2) and was calculated as such: 
 
Factor Multiplier = (Receiver Area Improvement, if any) x (Relative Voltage 
Improvement) x (Optical Window Improvement, if any)  
 
These performance factors were assessed for the first seven probes’ characteristics 
outlined in Table 5.3.1 (a schematic illustration of the probe iteration and evolution is 
shown in Figure 5.3.1). The factor multipliers assisted in the decision to identify and 
incorporate those probe characteristics that would be best in combination for the ultimate 
performance of a final probe design, based on the absorbance signal collection on 
representative spectrometer(s). The actual SNR and average voltage readings were 
measured for probe #8 on a fresh fibrofatty plaque tissue.   
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Figure 5.3.1: A schematic illustration of different probe configurations as described in Table 5.3.1. From 
left to right: Probe 1 with optical window, Probe 3 - 360° side-illumination and collection 3 French 
catheter prototype, Probe 2 without optical window, and Probe 8, forward viewing with mounted quartz 
optical window.  
Large OD 
Probe 
360 degree 
illumination w/ optical 
window 
Forward illumination 
No optical window 
Final probe  
W/ optical window 
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Table 5.3.1: Optics test probes described as part of the optical design process. For all fibers NA=0.22.  
Probe ID 
(Manufacturer, 
description) 
Fiber Core 
Diameter/Type 
Fiber 
Number 
Collection 
Interface 
Collection 
Geometry 
Source-
Receiver 
Fiber 
Separation 
Working 
Optical 
Diameter 
1 
(FOSS 
commercial 
probe, large 
outer diameter) 
200 micron 
extended 
transmission to 
2400 nm (low 
OH) 
Source: 
210  
Receiver: 
210  
7 mm thick 
sapphire optical 
window; flat 
optical surface 
Forward-
viewing 
1 mm 25 mm  
(2.5 cm) 
2 
(Multimode 
(NJ), first 
custom design 
iteration) 
200 micron 
(source, low OH); 
100 micron 
(receiver), limited 
transmission 
above 1400 nm 
(low OH) 
Source:  
7 
Receiver: 
37  
Flat optical 
surface 
Forward-
viewing 
0.5 mm 
(500 
microns) 
5 mm  
(0.5 cm) 
3 
(Remspec (MA), 
360° catheter 
prototype) 
100 micron fibers, 
extended 
transmission to 
1700 nm 
Source: 
26 
Receiver: 
13 
0.5 mm thick 
quartz optical 
window; radial 
optical interface 
Side-
viewing 
(360°) 
0.05 mm 
(50 
microns) 
1.2 mm 
(0.12 cm) 
4 
(FOSS 
commercial 
probe, optical 
window sheath 
removed) 
200 micron 
extended 
transmission to 
2400 nm (low 
OH) 
Source: 
210  
Receiver: 
210  
Flat optical 
surface 
Forward-
viewing 
1 mm 25 mm  
(2.5 cm) 
5 
(same probe as 
in 2, but with 
custom optical 
window tested) 
200 micron 
(source, low OH); 
100 micron 
(receiver), limited 
transmission 
above 1400 nm 
(low OH) 
Source:  
7 
Receiver: 
37  
1.75 mm thick 
quartz optical 
window 
(transmission to 
~2500 nm); Flat 
optical surface 
Forward-
viewing 
0.5 mm 
(500 
microns) 
5 mm  
(0.5 cm) 
6 
(same probe as 
in 2, but with 
custom optical 
window tested) 
200 micron 
(source, low OH); 
100 micron 
(receiver), limited 
transmission 
above 1400 nm 
(low OH) 
Source:  
7 
Receiver: 
37  
0.5 mm thick 
sapphire optical 
window 
(transmission to 
5500 nm); Flat 
optical surface 
Forward-
viewing 
0.5 mm 
(500 
microns) 
6.35 mm  
(0.635 
cm) 
7 
(same probe as 
in 2, but with 
custom optical 
window tested) 
200 micron 
(source, low OH); 
100 micron 
(receiver), limited 
transmission 
above 1400 nm 
(low OH) 
Source:  
7 
Receiver: 
37  
1 mm thick 
sapphire optical 
window 
(transmission to 
5500 nm); Flat 
optical surface 
Forward-
viewing 
0.5 mm 
(500 
microns) 
5 mm  
(0.5 cm) 
8 
(Remspec, 
forward-viewing 
mounted optical 
window) 
200 micron, 
extended 
transmission to 
2400 nm 
Source: 
7 
Receiver: 
13 
0.5 mm thick 
quartz optical 
window 
(transmission to 
~2500 nm); Flat 
optical surface 
Forward-
viewing 
0.05 mm 
(50 
microns) 
2.0 mm 
(0.2 cm) 
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5.3.3. Tissue depth penetration testing 
 
The measurement and calculation of depth penetration was adapted from Jaross et al [34].  
All spectra were collected on the FOSS NirSystems spectrometer using a combination 
probe (probes #5 and 8) trifurcated with two concentric rings of receiver fiber optics 
containing the two source-receiver separations (the 50 micron and 500 micron 
configurations) at the common end or probe-tissue interface.    First, reference spectra 
(50% Spectrolan, Labsphere, NH) were measured for each configuration. A 50-micron 
piece of tissue from frozen section, O.C.T. embedded (Sakura Finetek, CA), fresh cow 
aorta (cut longitudinal into vessel wall using a microtome, first slice is the luminal side of 
vessel) was used. Tissue-Tek® O.C.T. Compound is an optically clear embedding 
substance routinely used for optical microscopy of fresh-frozen tissue sections. It is made 
of less than 10% each of polyvinyl alcohol and polyethylene glycol (and other water-
based non-reactive substances). The tissue slice was first washed with DI water three 
times (to remove the water-soluble embedding compound), and then stacked on the face 
of the probe (see Figure 5.3.2).  
 
Next, absorbance spectra were taken with both configurations using the appropriate 
reference signal. After one absorbance spectrum was taken with tissue only, another 
spectrum was taken, using the 50% reference standard as the backing for the diffuse 
tissue reflectance (that is, the reference was placed on top of the tissue and another 
spectrum taken with the tissue plus the reference). The reference was then removed, and 
another 50-micron piece was stacked on top of the previous one. Care was taken to 
remove wrinkles, and excess water, if any, was gently squeezed out with Kim wipes. This 
procedure was repeated; two spectra for each configuration and thickness, up to a total of 
1.0 mm thickness, were collected. The difference spectrum was taken, i.e. the absorbance 
signal from the tissue only minus the absorbance signal from the tissue plus reference. 
For each of the wavelengths used in the SNR calculation, the average difference spectra 
Figure 5.3.2:  Depth penetration test method. 1) Reference spectra collected for each optical configuration. 2) 
Absorbance spectra collected with n-th slice of 50 micron tissue.  3) Second absorbance spectrum collected with 
n-th slice plus diffuse reflector. Both absorption and scattering attenuate tissue signal. 
Optical Probe 
1) 2) 3) 
To spectrometer 
Diffuse Reflector
~50 um slices
Aortic tissue 
Light source  
(source fibers) 
Diffuse Reflector 
45 
(4 nm bandwidth) for each tissue thickness was calculated. The percent difference (or 
attenuation) was calculated using the 50 um tissue signal as zero attenuation. When the 
percent difference is over 90%, this was considered to be the penetration depth for that 
wavelength. 
 
5.4. Monte Carlo Simulations Analysis 
 
Intralipid Simulations 
Table 5.4.1 shows that the relative diffuse reflectance profiles have a weak wavelength 
dependency for source-receiver separations less than 0.75 mm. For source-receiver 
separations between 0.45 and 0.75 mm, scattering effects, as measured by the standard 
deviation from the nominal 500 nm wavelength, was minimized. At a 750 nm 
wavelength, the Intralipid simulation showed that the total absorbed fraction of incident 
photons was 6.4%. Ninety percent of the 6.4% total absorbance probability occurs up to 
the depth of ~ 1.2 cm (i.e., the other 10% of the 6.4% total absorbance occurs greater than 
a depth of 1.2 cm or 12 mm). Therefore, the effective penetration depth at 750 nm is 1.2 
cm. Further decomposition of the data into its radial (r) and depth (z) components showed 
that the probability of absorption increases, then decreases, at a depth of 0.75 mm as the 
radial distance away from the source increases (i.e. the source-receiver separation 
increases).  
Table 5.4.1: Minimization of scattering as measured by the reduction of standard deviation from 500 
nm of the diffuse reflectance profiles as a function of source-receiver separation. Scattering is 
minimized with a source-receiver separation of 0.65 mm [68]. 
Source-Receiver 
Separation (mm) 
Standard Deviation 
Of Diffuse Reflectance 
from 500 nm (λ) 
0.25 0.235 
0.35 0.199 
0.45 0.133 
0.65 0.114 
0.75 0.139 
1.05 0.331 
1.75 0.641 
 
De-oxy Hb Simulations 
Deoxy-Hb simulations at λ=750 nm showed that the total absorbed fraction of incident 
photons was 72.5%.  Deoxy-Hb has a strong absorbance at 760 nm. The probability of 
absorption at 750 nm in the deoxy-Hb simulation is therefore naturally much higher than 
the purely scattering model. In the deoxy-Hb models, all of the absorption occurs by a 
depth of 3 mm, and 90% of the total absorption occurs by a depth of 0.75 mm (Figure 
5.4.1a). Therefore, the effective penetration depth at 750 nm for de-oxy Hb is 
approximately 0.75 mm. Similar trends, as in the Intralipid-only models, occurred for 
increasing source-detector spacing when the deoxy-Hb data was decomposed into its 
radial and depth components (Figure 5.4.1b). 
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Normal and Atherosclerotic Aorta Simulations 
The diffuse reflectance (1/cm2) as a function of the source-receiver separation and 
wavelength for the normal and atherosclerotic aorta simulations are shown in Figure 5.4.2 
a) and b), respectively. Diffuse reflectance drops off fairly quickly as the source-receiver 
Figure 5.4.2:  Diffuse reflectance (1/cm2) as a function of radius (cm) , or source-receiver separation, for five 
different wavelengths. a) Normal aorta. b) Atherosclerotic aorta. Diffuse reflectance drops off fairly quickly 
as the source-receiver distance is increased).  The probability of diffuse reflectance is actually higher at small 
source-receiver separations (<0.005 cm or 50 microns) for the atherosclerotic aorta at 514 nm.   
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Figure 5.4.1: 2mM deoxy-Hb in Intralipid scatterer at λ = 750 nm. P(A), probability of absorption  a) versus 
depth; represents 72.5% total absorption at 750 nm b) spatial decomposition of probabilities as a function of 
depth in a) as the distance away from source increases, e.g. source-receiver separation. Source is at (r,z)=(0,0). 
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distance is increased in both cases.  The probability of diffuse reflectance is actually 
higher at small source-receiver separations (<0.005 cm or 50 microns) for the 
atherosclerotic aorta at 514 nm.   
   
The depth penetration in the simulated normal and atherosclerotic aorta as a function of 
wavelength, as calculated as the depth where 90% of the total absorption probability 
occurs, is summarized in Table 5.4.2 for a 50 micron source-receiver separation. The 
atherosclerotic aorta consistently showed less penetration depth versus the normal aorta 
at the same wavelength for all other source-receiver separations. 
Table 5.4.2: Estimated penetration depth for a 50 micron source-receiver separation based on Monte 
Carlo simulations of normal and atherosclerotic aorta optical property data. 
Wavelength (nm) Normal Aorta (microns) Atherosclerotic Aorta (microns) 
470 -- 417.5 
514 1063 722 
633 1338 1197 
1050 1333 1187 
1064 -- 927 
 
5.5. Optical Probe Analysis 
 
Signal-to-Noise Ratios (SNR) 
The relative signal-to-noise ratios at 420, 550, 760, 970, 1450, 1750, and 2250 nm with 
respect to probe #2 (first design iteration) are shown in Figure 5.5.1. The relative N-fold 
improvements in noise alone over the first design iteration probe is shown in Figure 
5.5.2.  
 
 
Figure 5.5.1:  Relative SNR compared to Probe #2 (first design iteration probe): Log Scale. For specific 
wavelengths. From left to right, probes #1 to #7 as described in Table 5.3.1.  
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The average detector voltage reading in millivolts (visible, Si; NIR, PbSe) and the 
performance factor multipliers with respect to probe #2 are tabulated in Table 5.5.1.  
Table 5.5.1: Performance factor multipliers with respect to first design iteration probe (probe #2). 
Probe 
ID 
Relative 
Receiver Area 
Improvement 
Average Voltage 
Reading (mV) 
 
Visible     NIR 
Relative Voltage 
Improvement 
(500 um separation) 
Visible          NIR 
Optical Window 
Improvement 
(for same probe) 
1 23 2.39 323.2 122 71.5 90 
2 1 0.01963 4.519 1 1 -- 
3 (0.3513) 0.04138 12.50 2.1 2.8 -- 
4 23 0.02998 3.573 1.5 (0.79) -- 
5 1 0.03363 7.638 1.7 1.7 1.7 
6 1    1.4 1.9 
7 1 0.0223 5.45 1.1 1.2 1.2 
 
The second design iteration probe, requiring a 50-micron separation (probe #8), had an 
estimated relative receiver area improvement factor of 4 over probe #3, the only other 
probe tested with a 50-micron separation (that is, thirteen 200 micron fibers versus 
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Figure 5.5.2: Relative N-fold improvement in noise (reduction) with respect to probe #2 (first design 
iteration probe) for specific wavelengths.  From left to right, probes #1 to #7 as described in Table  5.3.1. 
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thirteen 100 micron fibers), a relative voltage improvement in the NIR of 1.4, and a 
estimated optical window improvement in the NIR of 1.9, based on the results with 
respect to the first design iteration probe (probe #2). The actual SNR and average voltage 
readings were measured for probe #8 on fresh fibrofatty plaque tissue.  The actual SNR, 
relative SNR, average voltage readings for the visible and NIR detectors, and the relative 
voltage improvement over the first design iteration probe are summarized in Table 5.5.2. 
Figure 5.5.3 is identical to Figure 5.5.1, with the data for probe #8 added. 
Table 5.5.2: Analysis for probe #8, 50 um separation. 
Wavelength 
(nm) 
Actual 
SNR 
Relative SNR (w/ 
respect to probe #2) 
Average Voltage 
Reading (mV) 
Relative Voltage Improvement 
(w/ respect to probe #2) 
420 1742 92 0.2345 (visible) 12x 
550 3528.5 30.7   
760 1101 9.1   
970 4187 18.95   
1450 299 12.5 87.3 (NIR) 19x 
1750 740.5 370   
2250 142 71   
 
 
 
 
Figure 5.5.3: Relative SNR log scale with respect to Probe #2 (first design iteration). Results of Probe #8 
added. Probe #8 has adequate signal-to-noise and it is appropriately sized for the research applications. 
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Tissue Depth Penetration Testing  
 
The results for the tissue penetration tests using O.C.T. embedded frozen section, 50-
micron pieces of normal aortic tissue (as described in Section 5.3.3) are shown in Figure 
5.5.4 for the 50 and 500 micron source-receiver separations. The 50 micron separation 
(black bars) showed deeper light penetration at λ=2250 nm, which is the wavelength 
where lactate absorbance would occur.  At least a 300 micron depth penetration is 
achieved for all other wavelengths with either separation, which is useful information for 
the optical tissue pH determination.  
 
5.6. Discussion 
 
The Intralipid simulations demonstrated that minimization of the wavelength dependence 
of scattering was possible for source-receiver separations between 0.45 and 0.75 mm.  
However, the probability of absorption of a 2 mM deoxy-Hb containing tissue is high 
between 500-900 nm, therefore the amount of light returning to receiving interface is low 
over the same range of source-receiver separations due to added absorber. By minimizing 
the scattering for spectroscopic measurement, it is expected that the contribution in 
absorbance due to small changes in the optical spectra will be improved when 
interrogating a small volume.  However, it must be realized that the benefit of high 
backscattering geometry provided by small source-receiver separations is offset by the 
Figure 5.5.4:  Measured tissue penetration depth (in microns) as a function of wavelength and 
source-receiver separation (0.05 mm = 50 microns). 
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information loss of principal absorbers.  Measuring small changes in absorbance may 
require two different separations—one to account for scattering, and one to collect a large 
variation in reflectance to be sensitive to the main absorbers.  
 
From the Intralipid and de-oxy Hb simulations, it was concluded that the tissue depth 
interrogated by a source-detector separation of 0.75 mm is approximately 1.25 mm in a 
one-component absorbing medium between 500-900 nm. For source-receiver separations 
less than 0.75 mm, the penetration depth should be smaller as the probability of 
absorption increases. The propagation was modeled as forward directed (anisotropy 
factor, g=0.9), therefore this depth may appropriately be taken as the most likely deepest 
layer of tissue from which photons could scatter back to the detecting layer. For 
comparison, diffusion theory predicts a penetration depth (defined as δ=1/(3µa(µa+µs(1-
g)))1/2) of 0.04 to 0.64 mm for the optical properties simulated. Ninety percent of the 
absorption occurs by a depth of 0.75 mm; after that the probability is reduced 
significantly such that the probability of absorption, (P(A)),  at 1.25 mm is ½ that of the 
P(A) at 0.75 mm. Stated another way, the probability of photons visiting a depth of 1.25 
mm and returning back to the detecting layer is severely reduced. This “detection” limit 
(spherical volume πd3/6, d=1.25 mm) corresponds to interrogating ~1 mm3 tissue volume 
for a 0.75 mm source-detector spacing. The limitation in this simulation was that only the 
highest absorbing species was modeled and any effects of concentration and scattering 
were considered static.   
 
Additional simulation data using normal and atherosclerotic aorta absorption and 
scattering coefficients provided more relevant depth penetration for the assessment of 
spatial resolution versus the source-receiver separation for this research. The 
atherosclerotic aorta consistently showed less penetration depth versus the normal aorta 
at the same wavelength for all source-receiver separations (Table 5.5.2, shown for the 50 
micron separation). The diffuse reflectance provided an additional piece of information 
for the optimal source-receiver separation (Figure 5.4.2).  The amount of diffuse 
reflectance is actually higher at small source-receiver separations (<0.005 cm or 50 
microns) for the atherosclerotic aorta at 514 nm.  At 1064 nm, however, the normal aorta 
has a higher diffuse reflectance probability per cm2 less than <0.005 cm source-receiver 
separation, and falls off less sharply than the atherosclerotic data. Greater than 0.03 cm 
(or 300 microns radius), both diffuse reflectance probabilities across all wavelengths are 
very low, in contrast to the Intralipid and de-oxy Hb simulations. It can be concluded that 
the source-receiver separation must be much smaller than anticipated (in comparison to 
the first design iteration based on the Intralipid and de-oxy Hb simulations).  The 
penetration depth is smaller, as expected for a smaller source-receiver separation.  There 
should be adequate signal however based on the relative magnitudes of the diffuse 
reflectance probabilities for separations ~ 0.005 cm (50 microns).  The optical property 
data for normal and atherosclerotic aorta were primarily different in the scattering 
coefficient. The amount of scattering seems significantly higher in the atherosclerotic 
aorta, possibly creating more events for the light to backscatter towards the receiving 
plane, resulting in a higher diffuse reflectance probability at small source-receiver 
separations.  
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The simulations shown above are for a point source. However, optical fibers have finite 
diameter (e.g., a standard medical-grade, multimode glass fiber has 200/225 um core and 
cladding diameter, respectively), small numerical aperture, and dispersion, thus, the 
realistic source is not a point source.  Data convolution to a finite Gaussian beam may be 
more precise, but the results are equivalent to point source simulations due to the 
geometric symmetry assumption in the small volume under study.  The accuracy of the 
probability (per cm3 or cm2) value is proportional to the square root of the number of 
incident photons, N.  Although larger values of N may improve the statistical error, it will 
not affect the trends, i.e., the photons will follow the same most likely paths for a given 
set of optical properties.  It was therefore assumed that the trends observed could be used 
to help estimate the spatial resolution of the first optical design (Probe 2), even in the 
absence of optical property data being available for several key wavelengths, such as for 
λ=2250 and 2295 nm, the wavelengths where lactate absorbance occurs. The theoretical 
observations are augmented and complimentary data obtained through bench tests 
performed at the wavelengths used for the simulations and additional wavelengths 
important for the optical determinations. 
 
The probe(s) signal-to-noise ratios measured on the same spectrometer were analyzed to 
aid in decision-making for the optimal optical components and configurations. The two 
factors that improved the signal the most were the fiber size and type, and the use of an 
optical window. The only factor that reduced the noise was the use of an optical window.   
This may imply that there is slightly better optical matching between the optical fibers 
and tissue when an optical window is used. The incorporation of both the larger 200 um 
core, ultra-low OH fibers, and a borosilicate or quartz optical window material in the 
second iteration design (Probe #8), showed significant improvements in both the visible 
and near-infrared regions for the same source-receiver separation (compared to Probe 
#3).  The added benefit of a simpler forward-facing optical probe (Probe #8) should make 
the spectra collection on the plaque tissue easier to identify and reproduce than the 360° 
optical probe (Probe #3).  
 
The measured depth penetration for two different source-receiver separations (50 and 500 
microns) showed that at the key wavelengths (550, 760, and 1750 nm, absorption peaks 
of oxy-Hb, deoxy-Hb, and cholesterols, respectively) the respective depth penetrations 
did not change. However, there were differences at 470, 970, 1450 and 2250 nm.  There 
was more penetration for the 50 micron separation at 970 nm (water absorption peak) and 
at 2250 nm (a trough between two large water peaks at 2000 and 2500 nm).   
 
For the optical determination of plaque lactate concentration, the depth penetration at 
2250 nm is important; this wavelength is in the region where tissue lactate would absorb.   
The estimated penetration depth based on these experimental observations at 2250 nm 
was 500 microns, for the 50 micron source-receiver separation, and only 200 microns for 
the 500 micron separation. Therefore, it was concluded that the 50 micron separation 
should be incorporated in the final design. The actual working optical diameter of the 
second design iteration probe (probe #8) is ~2.5 mm, which is less than the 4 mm 
diameter of the tissue lactate punch biopsy (interface resolution). The biopsy procedure 
requires that the entire thickness of the plaque is collected at the point being measured.  
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The depth resolution of the optical measurement will be finer than the reference 
measurement in most cases, but the interface resolution is acceptable.   The spatial 
resolution may still affect the calibration accuracy of the lactate determination. 
 
For the optical determination of plaque tissue pH, the visible wavelengths are considered 
important.  At 760 nm, both the 50 and 500 micron separation experiments demonstrated 
a penetration depth of ~650 microns.  The micro-pH electrodes are approximately 
spherical or “tear-drop” in their contact area, and require to be placed at least a depth of 
750 microns to obtain accurate readings. The depth resolution of the optical measurement 
is finer than the reference measurement.  However, the probe-tissue interface (area) for a 
50 micron separation will still be greater than the micro-electrode diameter (~2.5 mm 
versus 0.75 mm). Considerable care must be taken to register the site where the optical 
spectrum is taken on the tissue.  The interface resolution may affect the calibration 
accuracy of the tissue pH determination.  
 
5.7. Summary 
 
Based on the theoretical simulations and the depth penetration testing, it was concluded 
that by: 
 
• Using a source-receiver separation of 50 microns, adequate depth resolution could 
be achieved in plaque in both the visible and near-infrared; 
• Increasing the collection fiber core diameter size to 200 microns with improved 
transmission out to 2400 nm, higher signal-to-noise ratio is achieved by 
improving the fiber collection area by 4 times and collection efficiency; and 
• Using a 0.5 mm thick quartz optical window fused on the common end, with 
forward-viewing optics, the signal-to-noise ratio would be further improved 
across all wavelengths 
 
This probe as built would have adequate resolution for accurate optical determinations in 
atherosclerotic plaque in a controlled environment with careful registration of the optical 
and reference measurements.  It was expected that at least a ~6-fold improvement in the 
visible region (or an actual voltage of 0.24 mV vs. 0.04 mV) and ~10-fold improvement 
in the NIR region (or an actual voltage of 130 mV vs. 13 mV) would be realized for the 
source-receiver separation of 50 microns as compared to the first design iteration probe 
(Probe #2). The measured improvements were higher, (12-fold improvement in the 
visible and ~19-fold improvement in the NIR).  The practical considerations in the optical 
design process were able to improve the signal-to-noise ratio, maintain the necessary 
source-receiver separation, and collect light from a small (<1 mm3) region of tissue, 
based on both the experimental and theoretical depth penetration results. 
 
 
54 
6. METHODS 
 
Methodology to collect metabolic data from freshly excised carotid tissue is first 
described in this research. In order to obtain ~100 data points for the optical calibrations, 
verification that the laboratory setup could reproducibly maintain the status of the 
previously assumed living, metabolically active plaques had to be made first (Section 
6.1). Next, the in-vitro optical spectra collection is described using two different 
spectrometers and the proposed optical probe design built as specified in Section 5.  
Description of the methodology used to collect reference data that co-registered with the 
optical measurements is presented along with the tissue pH measurement and the lactate 
concentration assay method. Lastly, the calibration model development strategy is 
presented in Section 6.4.  Preliminary analysis was done on ~20 points for each optical 
calibration to assess data quality. Additional points were added to the initial calibration 
model results after the data collection program was completed, and the data analyzed in 
the aggregate was compared to the preliminary results. 
  
6.1. Laboratory Setup and Validation 
 
In this section, the laboratory setup is described.  The method to maintain the ~30 living 
human plaque tissues studied after surgical removal at near in-vivo, physiologic 
conditions during the optical and reference data collection is presented.  Tissue culture 
techniques and biological atmosphere gas were used to preserve the plaque tissue. 
Physiological parameters were monitored in an initial set of nine plaques (no optical 
measurements) to validate this method. The total experiment duration allowable was 
determined through this process by observing the degradation over time in physiological 
parameters of the plaque tissue. 
 
A schematic of the laboratory setup is shown in Figure 6.1.1.  The bath temperature was 
maintained at 37°C using a heating pad. The entire bath apparatus was enclosed in a 37°C 
humidified incubator. Biological atmosphere gas was bubbled in through a tube placed 
under the liquid surface (tissue culture media). The fiber optic probe, electrodes, 
thermistor(s), optical reflectance standard, and balance were configured as shown in 
diagram. A gridded ceramic plate (not shown) was used to attach the plaque tissue in a 
fixed location with respect to the micromanipulator such that co-registration of the exact 
location from which the optical spectra were collected to the gross pathology and 
reference measurements could be made (see Section 6.3 Reference Measurements). 
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An initial set of nine plaques was used to validate the tissue bath preparation. Fresh 
carotid plaque tissue was collected from UMass Memorial Healthcare University Campus 
Vascular Surgery operations over a period of three months (IRB approval 
Docket#10041). The plaque was immediately placed in a tissue culture medium 
(Minimum Essential Medium, Invitrogen, MD, pH 7.4, 5.6 mM glucose, 26.2 mM 
sodium bicarbonate, non-essential amino acids supplement) in a 37°C heated porcelain 
bath, bubbled with a 75%O2/20%N2/5%CO2 gas mixture (n=7). This particular MEM 
was chosen because it was the only available prepared sterile liquid media with high 
glucose concentration that did not contain phenol red, a colored dye that is used to 
indicate gross pH changes. The media bath was equilibrated with the gas mixture for a 
half hour prior to tissue addition. Plaque tissue that was not placed in the bath (only in the 
37°C humidified air of the incubator) served as controls (n=2). Tissue pH, pCO2, and pO2 
measurements were taken continuously by placing a 0.5 mm diameter by 25 mm long 
multi-parameter sensor (Diametrics Medical, MN) within the thickness of the plaque 
tissue in all nine plaques (Figure 6.1.2, control plaque photograph). The location chosen 
was based only on the ability to place the sensor safely within the tissue. The sensor 
readings were observed for stability during the experiments.  The media pH, pCO2, and 
pO2 values were discretely measured with a blood-gas analyzer every ~30 minutes 
Figure 6.1.1: Laboratory Setup. The tissue bath was maintained at 37°C using a heating pad. The 
fiber optic probe is shown mounted on a x-y-z micromanipulator. The gas line from the biological 
atmosphere tank is placed under the liquid surface to provide oxygenation and mixing to the 
tissue culture media. The balance is used to reproducibly maintain a constant pressure when the 
fiber optic probe is pressed down on to the tissue fixed to a gridded, ceramic plate on the bottom 
of the tissue bath (not shown). A 100 mg deflection is used for all optical measurements. The 
thermistor, micro-pH and reference junction electrodes are placed in the liquid media. The entire 
bath apparatus, Spectralon standard, and ancillary equipment are enclosed in a humidified, 37°C 
Heating pad 
Balance 
Fiber optic probe 
Gas line 
Micro pH and reference junction 
electrodes 
Thermistor 
37°C, >85% RH 
Spectralon 50% reflectance standard
Tissue bath 
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(Model IL428, Instrumentation Laboratories, MA) and compared to the tissue readings. 
The rate of change was calculated for the tissue pH and tissue temperature. The relative 
pCO2 and pO2 values were analyzed.  
 
6.2. Optical Spectra Collection 
 
Optical spectra of 30 different plaque specimens (K1-30) were collected using a 3 mm 
outer diameter optical probe (as described in Chapter 5 Optical Design, Final Probe) 
placed in the tissue bath (Laboratory Setup, Section 6.1). A photograph of the probe and a 
probe-tissue interface schematic are shown in Figure 6.2.1. The probe contains all 
multimode, 200-micron diameter core, ultra-low OH fibers bundled in a 1.5 m long 
bifurcated cable. Seven fibers (shown in orange) were arranged hexagonally as the input 
fibers in one leg, and twelve (shown in yellow) in the other leg to the receiving 
spectrometer’s detector. The center source fibers were separated from the outer 12 fibers 
by a 50-micron thin walled plastic tube. A 1 mm quartz window (not shown, refractive 
index, n=1.44) was mounted on the face of the probe (common end).   
 
The probe was cleaned with an isopropyl alcohol pad before each tissue spectrum and 
allowed to dry in the incubator. The probe was then placed a micromanipulator stage.  A 
reference spectrum was collected on a 50% Spectralon standard (Labsphere, NH). For 
tissue spectra, the probe was brought to contact the plaque through the liquid media by 
carefully adjusting the micromanipulator such that the pressure applied caused a 100-mg 
deflection of the needle on the balance carrying the tissue bath. For the first 14 plaques, 
absorbance spectra were collected only on an FT-NIR spectrometer. Due to 
circumstances beyond control, the instrumentation to collect visible spectra was not 
available until about halfway into the experimental phase. For the remainder of the 
experimentation, absorbance spectra were collected on both the FT-NIR spectrometer and 
a PDA-based dispersive spectrometer. At the end of the experiment, all spectra were 
reviewed to see if the ceramic plate was inadvertently reflected in the tissue spectrum, by 
Figure 6.1.2: Photograph of control plaque with Diametrics multi-parameter sensor in place. 
Sensor measures tissue pH, pCO2, and pO2 values continuously in the nine plaques in the 
validation study. 
Sensor tip 
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collecting a spectrum through the media at the same applied pressure (without the plaque) 
and comparing the reflected signals. The probe was cleaned thoroughly with isopropyl 
alcohol and stored at the end of the day. 
 
6.2.1. FT-NIR Spectrometer 
 
Spectra from 28 plaques (plaques K1-14 and K17-30) were collected using a Nicolet 
Nexus 670 Fourier transform near infrared-based spectrometer (75 Watt tungsten-halogen 
lamp / quartz beamsplitter) employing a room temperature InGaAs detector and a fiber 
optic probe module. The spectral range scanned was 667 to 2436 nm (15000-4097 cm-1), 
and 128 interferogram scans at a spectral resolution of 32 cm-1 were averaged. Single-
beam spectra were automatically computed with the triangular apodization and Fourier-
transformation routines available on the spectrometer software. A reference spectrum was 
collected using a 50% reflectance standard (Labsphere, NH) prior to each tissue 
spectrum. The software automatically calculates the absorbance spectrum for each tissue 
measurement. 
 
The reference detector voltage was checked for stability after the spectrometer was 
allowed to warm up for ~ 1 hour (±4.6 volts). The signal off of the 50% reflectance 
standard was set to provide a center burst interferogram voltage of 0.50/-0.45 V. The gain 
was set to 8 for all spectral measurements. This procedure allowed the signal from the 
fiber optic probe to have the best possible signal-to-noise ratio given the known fiber 
optic-to-FT spectrometer losses. The resulting spectral resolution was approximately 2.5 
nm and the acquisition time was ~42 seconds. These spectra were used for both lactate 
and tissue pH optical determinations.  
Figure 6.2.1: Optical probe used for all spectra collection. A) Photograph, 3 mm OD probe on reflectance 
standard. The probe contains all multimode, 200-micron diameter core, ultra-low OH fibers bundled in a 1.5 m 
total length bifurcated cable. B) Probe-tissue interface schematic. The center, source input fibers (seven shown in 
orange) are arranged hexagonally at the probe-tissue interface and bundled in one leg attached to the source. The 
receiving fibers (twelve shown in yellow) are in a ring at the probe-tissue interface, separated from the center 
seven fibers by a 50-micron thin walled plastic tube, and bundled in another leg attached to the receiving 
spectrometer’s detector interface. A 1 mm quartz window (refractive index, n=1.44, not shown) was mounted on 
the face of the probe. Diffuse light interaction with plaque depicted. 
tissue 
interface
A) B) 
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6.2.2. PDA Spectrometer  
 
Optical reflectance spectra (400 – 1100 nm) from 16 plaques (plaques K15-30) were 
taken using a Control Development (South Bend, IN) 512 element photo-diode array 
(PDA) spectrometer with a room temperature Si detector, and converted to absorbance 
using a dark current-corrected reference single-beam spectrum collected as described 
below.  The spectral resolution of the spectrometer was 0.5 nm. The source was a 
separate unmodulated, ~7.5 Watt tungsten-halogen lamp (Ocean Optics, FL). Two 
plaques (plaque K15 and 16) were used solely for determining the optimal integration 
time and sample averaging.   
 
After the 50% reflectance standard was measured on the FT spectrometer, the source and 
receiver fiber optic connectors were removed from the Nicolet FT spectrometer and 
placed on the Ocean Optics source and Control Development spectrometer respectively.  
The probe height was maintained and a reference spectrum taken prior to each tissue 
spectrum. The maximum reference signal at 727 nm was checked (after the spectrometer 
and source were allowed to warm up for ~1 hr) to be within ±5% of 45,000 A/D counts 
(minus the dark current signal, measured prior to each reference signal).  The integration 
time was set to be 3.6 seconds, and sample averaging to 15, resulting in an acquisition 
time of 54 seconds. These settings allowed the tissue spectra to be collected at the 
maximum signal-to-noise ratio possible with the PDA spectrometer in a reasonable time.  
 
The visible tissue spectra were offset to the peak value at 970 nm on the FT-NIR spectra 
and spliced together to form spectra for the full range (400–2400 nm). After a 
preliminary data analysis, the spectrometer’s stability was checked by analyzing the 
reference spectra intensities at 970 and 2250 nm for each day and over multiple days.  
 
6.3. Reference Measurements 
 
Thirty (K1-30) fresh human carotid endarterectomized plaques were collected over a 
period of 8 months at the UMass Memorial Healthcare University Campus (IRB approval 
Docket#10041).  Plaques were taken from the operating room and immediately placed in 
an oxygenated media bath preparation as described in Section 6.1. All standard biological 
hazard precautions were followed as if handling blood.  
 
First, the plaque was fixed to the ceramic grid in the bath. Plaque features and gross 
pathology were documented by drawing, descriptive text, and photography (see Figure 
6.3.1 for a representative plaque). A random area was chosen for the optical probe to be 
placed and registered on the drawing by grid mapping. After the optical spectra were 
collected as described in Section 6.3, the optical probe was adjusted back to zero position 
(no pressure applied), allowing the area directly under the probe to be visualized. Next, a 
T-type needle thermistor probe (Omega Engineering, CT) was placed directly under the 
optical probe and the tissue temperature recorded.  The tissue micro-pH electrode was 
then inserted in the same area under the probe and as close to the needle thermistor at a 
depth of ~0.75 to 1 mm and recorded. Lastly, a 4-mm diameter biopsy device was placed 
close to the optical probe area and allowed to cut into the plaque at the junction.  The 
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optical probe was pulled away at the same time the tissue biopsy was cutting the area just 
under the optical probe.  Extreme care was taken to make sure the area biopsied was the 
same as the registered location on the grid, and cut through the entire thickness of the 
plaque.  The thickness of the biopsy was measured.  A small sliver was cut and placed in 
formalin for histology processing.  Approximately 9/10 of the biopsy was then finally 
snap frozen in liquid nitrogen and stored in a cryovial.  Each biopsy was labeled with the 
map location.  The apparatus for the specific reference measurements of tissue pH and 
tissue lactate are summarized below.  
 
The reference measurements, biopsy thickness, and observed gross pathology were 
entered into a Microsoft Excel spreadsheet.  Correlations were drawn for tissue pH versus 
temperature, pH versus lactate, lactate versus temperature, and pH or lactate versus gross 
pathology.   The total time the plaque was in the media from start to finish was 
documented. Experimental notes were maintained and kept in a logbook for future 
reference. No reference data was collected for K15 and K16 due to needed adjustments in 
the visible spectrometer data collection. 
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Figure 6.3.1: Top) Photograph, bottom) drawing, and descriptive text of a representative plaque 
(K13). Ceramic plate grid holes are represented in drawing. Plaque is fixed to grid with stainless 
steel wires. Co-registration of gross pathology, optical spectra, and reference measurements were 
collected as described in the text. A thrombotic region can be seen in the upper right side of the 
tissue (grid position A3). 
A 
B 
C 
1 2 3 
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6.3.3. Tissue pH 
 
Micro-pH electrodes in a sharp, beveled 21-gauge needle (~750 µm diameter, MI-407 
Microelectrodes Inc., NH) were used to make the reference tissue pH measurements. The 
reference junction electrode was placed in the media bath and both electrodes are 
connected to a Thermo Orion 720A pH meter. The electrodes were calibrated prior to 
each experiment using five NIST-traceable buffers (Fisher Scientific, 4.00, 6.00, 7.00, 
7.40, and 10.00 at 25°C).  The calibration slope was recorded.  The pH meter readout was 
automatically temperature corrected to the in-vitro media temperature. The tissue pH 
measurements were performed and recorded at the same grid location the optical spectra 
as described in Section 6.2. After each tissue measurement, the electrodes were rinsed in 
warm Tergazyme solution and distilled water, then checked for drift in a 4.00 buffer at 
37°C. This was done to avoid protein buildup and electrode drift from location to 
location. Two electrodes were calibrated for each experiment such that if one exhibited 
drift problems, the other could be used until the end of the experiment. These values were 
used for the optical calibration of tissue pH. 
 
6.3.4. Tissue Lactate  
 
Biopsy samples were immediately collected after the tissue pH and temperature 
measurements.  A ~4 mm diameter biopsy of the area directly under the optical probe 
was collected as described in the general procedures. Each biopsy piece was immediately 
frozen in liquid nitrogen and placed in a cryovial for storage. All samples were stored in 
liquid nitrogen tanks until ready to extract (no more than 6 weeks).   
 
Tissue weights were obtained prior to assay using a Sartorius analytical balance. A 
standard Sigma Blood Lactate Kit UV-340A (Sigma Diagnostics, MO) was adapted to 
tissue extracts and microplate assay.  Tissue extracts were prepared by homogenization 
according to Lowry and Bergmeyer [87, 88] and neutralized to pH 7-8 by addition of 
KHCO3. For each sample, 25 ul of this neutralized perchloric acid (PCA) extract was 
combined with 200 ul of assay reagent in a microtiter plate, and incubated for 30 minutes 
at 25°C. The absorbance at 340 nm was read and recorded on a Dynatech Lab MRX 
Microplate Reader after incubation. Calibration curves were generated for each batch run 
by plotting blank-corrected absorbance vs. concentration (mg/ml) of freshly prepared 
standards.  A percent recovery factor (see below) is calculated and multiplied to the 
dilution-corrected values obtained from the curve. Finally, to obtain a weight basis, the 
concentration was divided by the weight of each sample to obtain units of micromoles 
lactate per gram of tissue. These values are used for the optical calibration. 
 
Percent Recovery Procedure (adapted from Bergmeyer et al [88] 
 
In the homogenization and assay process, some tissue is inevitably lost.  This loss 
represents a loss of information that may degrade the optical determination of lactate, due 
to inaccuracies in the reference measurement.  Therefore, for each batch assay, a percent 
62 
recovery procedure was performed to make an estimate of precisely how much lactate 
was lost and correct the data accordingly. 
 
One sample was randomly taken and split in half during homogenization step.  A known 
amount of lactate standard (50 ul of 0.4 mg/ml or 0.02 mg lactate) was added to the 
second aliquot of the sample. The dilution factors were calculated for both the undoped 
and doped test tubes. Both test tubes were processed as normal through rest of the 
procedure. To calculate the percent recovery, first the concentration of both samples was 
determined from the calibration curve. The percent recovery factor is then calculated by 
assuming what is in the un-doped homogenate is in the second tube plus the value Y as 
above. That is, if X represents the concentration of lactate in the original homogenate, 
then X+Y should be the concentration of the doped sample (volume dilution factors 
accounted). The ratio of the doped sample concentration from the calibration curve and 
the expected X+Y concentration is the percent of lactate that can be feasibly recovered. 
This correction is applied to all other samples.  A sample calculation is presented in 
Figure 6.3.2. 
 
6.4. Calibration Model Development 
 
Galactic Grams/32 software  (Galactic Industries Corp., NH) was used to visualize and 
where necessary, compute additional pre-processing of the optical spectra. The PLS/IQ 
module was used to perform partial least-squares (PLS) multivariate calibrations for both 
the optical determination of tissue pH and lactate. For the lactate determination, only the 
near-infrared spectral data was required.  The theoretical peaks at ~2250 and 2295 nm 
should be apparent in a valid PLS model. For the tissue pH determination, no a priori 
information was assumed. Models were created using the full spectral region collected 
(400-2400 nm) and a wavelength selection approach, based on choosing only those 
Figure 6.3.2: Sample Calculation for tissue lactate recovery and final calculations to provide reference lactate 
concentrations for optical calibration. 
SAMPLE CALCULATION: 
 
Calibration Slope=7.5 Abs. Units/mg/ml lactate   MW of lactate = 90 grams/mole 
Calibration Intercept=0.015 Abs. Units 
Blank-corrected Absorbance of sample 1 = 0.52    
 
Lactate concentration = (0.52-0.015) ÷ 7.5 = 0.0673 mg/ml lactate or 748 nanomoles/ml 
 
To account for volume added to tissue homogenate in step 1, multiply by supernatant volume correction factor 
(ex. (200 ul PCA + 20 ul KHCO3)/200 ul PCA). Also account for % Recovery.  
 
To get weight basis, divide concentration by weight of tissue per ml of PCA. For example, if the tissue weighted 
15 mg, the above lactate concentration would be reported as: 
 
In this example let % recovery = 85% and amount KHCO3 (neutralization base) added was 20 ul: 
 
748 nanomoles/ml * 1.1 ÷ 0.85 ÷ (15 mg / 0.2 ml)= 12.9 nanomoles/mg tissue or 12.9 umoles /gram tissue. 
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wavelength regions that are most highly correlated to the reference values. Preliminary 
data analysis was performed on the first ~20 points to assess data quality. Historically, for 
optical tissue pH calibrations, twenty points were adequate to generate a reasonable 
multivariate calibration model. 
 
For the entire calibration data set (lactate 82 points, tissue pH 48 points), additional pre-
processing methods were tested.  Two standard pre-processing methods available in the 
software -- Baseline Correction and Multiplicative Signal Correction -- were tested as to 
their ability to improve the optical determinations over and above standard PLS.  An 
automatic, linear baseline correction was applied to test if spectral drift could be removed 
by simply calculating a least-squares regression line in the selected spectral range and 
then subtracting the line from all the spectra [89, 90].   Multiplicative Signal Correction 
(MSC) was applied to test if the variance in the spectral data could be removed by 
correcting for light scattering. MSC assumes that the wavelength dependency of 
scattering is different and unrelated to that of the reference data [89, 91]. The mean 
spectrum is used as the “ideal” spectrum and a linear regression for all the spectra is 
calculated. The generated slope is subtracted and the offset is ratioed on each spectrum to 
give MSC corrected spectra.  
 
In addition to these standard pre-processing methods, cluster analysis and orthogonal 
signal correction (OSC) were used to evaluate sources of error in either the spectral 
measurement or reference measurements. Cluster analysis techniques were used to 
investigate whether if, by finding groups of spectra that are closer together or 
homogeneous (and therefore have reduced variability compared to the entire spectral data 
set), improvement in the PLS modeling could be made in an unsupervised fashion  (i.e., 
without information from the reference measurements). Groups of spectra identified by 
cluster analysis were reviewed to see if other patterns--such as groupings corresponding 
to gross pathology, experimental conditions, or time--could be deduced for each cluster. 
The OSC method was used to investigate whether there exists a spectral correction made 
by removing components orthogonal to the reference measurements, that could allow the 
reference variation to be modeled independently and thereby improve the PLS models.  
Cluster analysis and orthogonal signal correction were applied to the spectral data 
separately and PLS models were repeated using the either newly formed cluster matrices 
or OSC-corrected spectral matrix. 
 
6.4.1. Partial least-squares 
 
Partial least-squares (PLS) calibration is an empirical, factor analysis based multivariate 
method that decomposes the measured absorbance matrix into two smaller components 
called loading vectors and scores. Both spectral and the reference values are used in the 
decomposition. Loading vectors represent linear combinations of the original calibration 
spectra that explain most of the variance in the set. The score is the weight of each 
loading vector component needed to reconstruct a calibration spectrum. The first loading 
vector and score matrix usually contains most of the variance and successive factors are 
calculated from the residual matrices.  The variance in the data should be related to the 
desired reference measurement for a good calibration fit; however, other chemical 
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compositions, and experimental conditions may contribute to the model. Spurious 
correlations, if any, must be identified and removed.  
 
Mean centering was used for pre-processing in all model development. The average 
spectrum is calculated from all the calibration spectra and then subtracted from all the 
calibration spectra.  Mean centering tends to reduce the model complexity [71]. Loading 
vectors and scores were calculated for the maximum number of factors and a leave-one-
point-out cross validation algorithm was used to assess the model for each factor. Cross-
validation predicts the nth reference value from the nth spectrum, based on an n-1 PLS 
model. This was performed successively for each spectrum until all spectra were 
predicted based on a PLS model of the n-1 points for all factors. The optimal number of 
factors for each calibration was determined from the Predicted Residual Sum of Squares 
(PRESS) for each factor, and using a F-test (alpha level of 0.25) to identify the smallest 
number of factors required for the model [71]. If there is no minimum PRESS after one 
factor, no model can be created with the data. Outlier detection was performed according 
to Haaland (spectra or reference values that have an F-ratio value ≥ 3) [71]. Outliers were 
further investigated for any adverse experimental conditions as well as their histological 
classification in relation to the calibration method employed.  
 
Correlation plots of the measured reference variable versus the optically determined 
value were evaluated. The coefficient of multiple determination (or R2) and the estimated 
accuracy (standard error of cross-validation (SECV)) were calculated for standard PLS 
only (preliminary data sets) and for two standard pre-processing methods -- Baseline 
Correction and Multiplicative Scatter Correction (MSC) -- in analysis of the entire data 
set.  
 
Where no models could be generated because no minimum in PRESS could be achieved 
(Model? =N), factor 1 R2 and SECV were calculated but reported in italicized 
parentheses for comparison. Where there is a minimum PRESS for a factor greater than 
1, but is not statistically significant from factor 1 based on an F-test (Model? =N†), the 
minimum factor results are reported and additional outlier detection was performed. 
Where there is a minimum PRESS for a factor greater than 1 and it is statistically 
significant from factor 1 result (Model? =Y) that factor was reported and additional 
outlier detection was performed.  
 
6.4.2. Cluster Analysis 
 
Cluster analysis is one of several unsupervised pattern recognition techniques. It can be 
used to study the homogeneity of a large set of complex data. It has been used in several 
research fields as a pre-processing step to other multivariate statistical methods, based on 
the assumption of homogeneity. [92]  
 
In order to investigate independently and mathematically whether the entire data set of 
optical spectra were divisible by pathology, time, or a parameter other than the desired 
reference tissue pH or lactate values, the spectra were evaluated with general hierarchical 
clustering techniques available in Matlab (Version 6.1.0.450 Release 12.1, Mathworks, 
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MA).  The Euclidean and Minkowski distance metrics were each tested to find 
similarities (or dissimilarity) between every combination of pairs of spectra (for n spectra 
there are n-1 pairs or objects) in the data set. The objects were then clustered by the 
shortest, average, or centroid proximity metrics.  The best clustering solution was 
evaluated by using the cophenetic correlation coefficient routine available in the 
software. The closer the cophenetic correlation coefficient is to 1, the better the clustering 
solution. It indicates that the clustering of groups of objects is strongly correlated with the 
distances between the objects. Only the clustering algorithms that gave the highest 
cophenetic correlation coefficient for the data set was further analyzed. Natural groupings 
in the hierarchical tree were assessed by both comparing the length of each link in a 
cluster tree with the lengths of neighboring links below it in the tree and by cutting off 
the hierarchical tree at arbitrary points to create a desired number of clusters. The 
groupings were further investigated for relationships to the plaque experiments. Cross-
validated PLS models were developed for each of the groupings. The efficacy of the 
cluster analysis subsequent groupings was determined by the resulting PLS models R2 
and SECV.   
 
6.4.3. Orthogonal Signal Correction 
 
An important pre-processing method that is increasingly used is orthogonal signal 
correction (OSC) [93, 94]. While other pre-processing methods such as baseline 
correction, derivatives, multiplicative signal correction, and other mathematical filters 
may inadvertently remove information from the spectra regarding the measured reference 
variable, OSC attempts to define a spectral variance matrix that is approximately 
orthogonal (set of parameters or variables that can be treated independently) to the 
reference values.  OSC was used only for the entire data set for the lactate determination 
(82 points) because 1) a defined wavelength region could be described that needed 
correction and 2) no additional convolution regarding data from two different 
spectrometers (as in the tissue pH calibration) needed to be described. 
 
The algorithm described by Wold [95] was coded into Matlab. The original spectral 
matrix was corrected by subtracting the orthogonal matrix generated, and PLS models 
were run by using n-1 OSC pre-processed spectra for calibration, applying the n-1 OSC 
correction factor to the nth unprocessed spectrum, and then predicting the reference value 
using the n-1 PLS model from the nth processed spectrum. One component and two-
component orthogonal matrices subtraction were tested.  If models could be created, 
standard PLS outlier detection was followed. The efficacy of the orthogonal signal 
correction was determined by the resulting PLS models R2 and SECV.   
 
 
66 
7. RESULTS 
 
In this section, the results of all the experiments are described. First, the validation of the 
living status of the freshly excised tissue is presented (Section 7.1). Next, all the spectral 
and reference data from the large scale in-vitro study on ~30 plaques are shown (Sections 
7.2 and 7.3). Out of the 126 data points that were collected, only 82 points could be used 
for the lactate determination, because of adverse experimental conditions as described in 
Section 7.3 (see tabulation of Reference Measurements Data in Table 7.3.1).  Due to 
circumstances beyond control, full spectral data from 400-2400 nm could only be 
collected for 57 out of the 126 points. Experimental conditions also ruled out several 
points for the tissue pH determination; 48 out of the 57 full-spectra data were used in the 
end. Lastly, the calibration model development results are presented in Section 7.4.  
Preliminary PLS calibration model results are shown for the first ~20 points for each 
optical calibration. Additional points that were added to the initial calibration model data 
were modeled in the aggregate and compared to the preliminary results. 
 
7.1. Laboratory Setup and Validation 
 
The average and standard deviation of each parameter in the nine validation plaques (2 
controls, 7 media test plaques) is shown in Table 7.1.1. The tissue pH and pCO2 for the 
test plaques are within the physiological range of respiring tissues; the control plaques 
tissue pH and pCO2 are lower and may not represent viable tissue. Tissue temperatures of 
the control plaques are also lower. Tissue pO2 is higher in the test plaques, indicating 
oxygen is being delivered and utilized (evidenced by slightly rising pCO2 values). 
However, the thickness of the plaque affected the readings. Figure 7.1.2 shows the 
changes in measured parameters (top: pH and pCO2, center: pH and temperature, bottom: 
pH and pO2) over a three and half hour time period for a representative plaque placed in 
the media. The sensor itself takes ~ 30 minutes to equilibrate in the tissue (time of sensor 
placement shown in top plot). The top plot shows the media pH and pCO2 values as 
discrete points measured by the blood-gas analyzer (m pH and m pCO2). Media pH was 
always higher than tissue pH (~7.45 versus ~7.15 in data shown). Media pCO2 values 
were also consistently lower than tissue pCO2 values. Physiological changes in tissue 
pCO2 (slight rise over time) were observed in all plaques. The media pO2 values were 
consistently around 400 ± 40 mmHg, while the plaque tissue pO2 depended more on the 
thickness of the tissue from experiment to experiment. After the sensor stabilization 
period, the tissue pH and temperature measurements (center plot) remain stable for the 
entire time the plaques are in the media. The bottom plot shows the media pH and pO2 
values as discrete points (m pH and m pO2). Figure 7.1.3 shows box-whisker plots for the 
pH and temperature changes over time for the plaques in media versus the controls (i.e. 
∆, or delta, pH or ∆ temperature per hour, indicative of the stability over time for that 
particular parameter). The change in pH and temperature per hour is significantly greater 
in the plaques placed only in the warmed, humidified air (mean, controls 0.25 pH units/hr 
and 1.5°C/hr, n=2) than the plaques place in media (mean, test plaques, 0.03 pH units/hr 
and 0.4°C/hr, n=7).   
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Table 7.1.1: Average and standard deviation of all continuous measurements in validation of the 
laboratory setup.  
Parameters Control (no media) Media 
pH  6.75±0.15 
6.77±0.16 
6.93±0.03 
7.16±0.01 
7.05±0.02 
7.04±0.01 
7.04±0.02 
7.01±0.05 (thick plaque) 
7.29±0.01 
Temperature (°C) 32.2 ±0.9 
32.7±0.6 
33.6±0.5 
35.4±0.3 
33.7±0.5 
35.8±0.4 
35.2±0.3 
36.8±0.4 (thick plaque)  
36.9±0.3 
PO2 (mmHg) 108±15 
39±15 
313±17 
438±18 
228±40 
129±62 
248±156 
6±13 (thick plaque) 
266±160 
PCO2 (mmHg) 8±4 
12±6 
50±2 
47±6 
77±4 
81±11 
83±4 
70±10 (thick plaque) 
66±4 
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Figure 7.1.2: Changes in parameters over ~3.5 hrs of a representative plaque. (m = media values). 
Red line = tissue pH, right axis; Blue line = tissue PCO2; Green line = tissue temperature; Purple line 
=tissue PO2. 
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Figure 7.1.3: Box-whisker plots for ∆pH / hour and ∆temperature / hour (respectively) for the control (n=2) 
and test plaques placed in media bath (n=7). The change in pH and temperature over time is greater in the 
controls than the test plaques. 
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7.2. Spectra Collection 
7.2.1. Lactate Spectra 
Spectra collected for the optical determination of lactate are shown in Figure 7.2.0.  The 
mean spectrum is shown in Figure 7.2.1 for clarity.  Peak assignments are listed in Table 
7.2.1. 
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Figure 7.2.1: Optical spectra for lactate determination. 667-2400 nm. 82 pts. 
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Figure 7.2.1: Mean of spectra shown in Figure 7.2.0. 667-2400 nm. Water bands at ~1450 and ~1940 nm 
dominate the spectral features. Peak assignments are given in Table 7.2.1.
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Table 7.2.1: Peak assignments for mean spectrum  shown in Figure 7.2.1. 667-2400 nm. 
Peak Wavelength (nm) Chemical Species References 
982 Water  [96], [97]  
1196 Water [98], [97] 
1449 Water [99] 
1730 (weak, broad) Cholesterol, lipids, alkyl CH groups, proteins [99], [34] 
1780 (weak, broad) Cholesterol, lipids, alkyl CH groups, proteins [99], [34], [35] 
1943 Water, (lipids) [97] ([34]) 
2168 (weak) Non-specific proteins [99] 
2250, 2295 Lactic acid [72] 
2318 (weak, broad, shoulder) C-H combinations from lipids [35], [34] 
 
 
7.2.2. Tissue pH spectra 
Spectra collected for the optical determination of tissue pH are shown in Figure 7.2.2.  
The mean spectrum is shown in Figure 7.2.3. for clarity.  Peak assignments are listed in 
Table 7.2.2.  
 
Between 500-600 nm, the spectral features are varied. Not all the spectra exhibit 
hemoglobin bands, and in some spectra, the signal is fairly flat and featureless. There is 
an anomaly observed at 633 nm in all spectra. This was investigated and found to be 
unrelated to the tissue characteristics.  The top most spectrum was taken from an area of 
plaque that contained a large amount of blood.  Below ~515 nm of this spectrum, strong 
hemoglobin absorption occurs (~10x or an order of magnitude higher than the amount at 
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Figure 7.2.2: Optical spectra for tissue pH determination. 400-1075 nm. 48 points. Hemoglobin 
bands dominate between 500 - 600 nm.  However, a few spectra are featureless in this region.  
Peak assignments are listed in Table 7.2.2. 
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575 nm). Very little light, if any, is reflected back to the probe interface. The detector 
noise is apparent at extremely high hemoglobin or blood content.   
 
 
 
Table 7.2.2: Peak assignments for visible spectra shown in Figure 7.2.2. 
Peak Wavelength (nm) Chemical Species References 
417 OxyHb  [100] 
540 OxyHb,OxyMb [100, 101] 
574 OxyHb [100] 
633 Optical Anomaly Removed before models built 
970 Water  [96] 
 
Twelve spectra for lactate and six spectra for pH out of 126 points collected (see 
Reference Measurements Section 7.3) were not used either because they were spectrally 
flat between 2000-2400 nm, or showed evidence of reflectance off of the ceramic plate 
underneath the plaque, i.e. the plaque was too thin or optically transparent for the entire 
wavelength region from 667-2400 nm. Other factors unrelated to spectra collection 
reduced the number of points available for calibration. Eighty-two and forty-eight spectra 
were used for the optical determination of tissue lactate and tissue pH respectively. 
Figures 7.2.4 and 7.2.5 show the spectra broken down by the observed gross pathology. 
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Figure 7.2.3: Mean of spectra shown in Figure 7.2.2. Peak assignments are listed in Table 7.2.2. 
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Figure 7.2.4: 82 spectra for lactate determination broken down by gross pathology, a) 22 thrombotic, 
b) 19 calcified, and: c) 41 yellow/fatty. 
c)
a) b) 
74 
 
 
 
 
Spectrometer variation was analyzed by tabulating the intensities of the reference 
spectrum collected each day at 970 nm and 2250 nm.  The percent change in the intensity 
of each day, and the average and standard deviation for several representative experiment 
days are shown in Table 7.2.3. After the initial preliminary sets of optical data were 
collected and optical calibrations generated to test data quality, the percent change of the 
intensity of the reference within each day was less than 3%.  The intensities at 970 nm 
and ~2250 nm stayed stable over time. 
 
Table 7.2.3: Spectrometer stability over time. Representative days over an 8 month period of data 
collection. 
  970 nm  2248.7 nm 
Date % change each day Average STD % change each day Average STD 
1/10/2002 2.7% 0.13321 0.00151 2.5% 0.21283 0.00204
2/13/2002 2.0% 0.13962 0.00119 1.8% 0.21699 0.00197
4/9/2002 0.5% 0.13416 0.00034 2.1% 0.21279 0.00204
5/8/2002 2.8% 0.13562 0.00128 0.9% 0.21065 0.00077
6/27/2002 0.5% 0.13186 0.00036 1.2% 0.21180 0.00129
7/19/2002 1.3% 0.12763 0.00076 1.9% 0.21319 0.00180
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Figure 7.2.5: 48 spectra for pH determination broken down by gross pathology, a) 11 thrombotic, 
b) 14 calcified, and c) 23 yellow/fatty 
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7.3. Reference Measurements 
 
Table 7.3.1 shows all the reference measurement data, with the points not usable for 
optical calibration identified. The average experiment time was 2 hours and 54 minutes. 
The average and standard deviation of all the pH readings (n=86), the lactate readings 
(n=82), and tissue temperature (n=86) was 7.24 and 0.24 pH units, 3.2 and 2.7 
micromoles lactate/gram tissue, and 34.3 and 1.4 °C, respectively. Figure 7.3.1 show 
histograms of the distribution of the lactate and tissue pH values respectively used for 
calibration for all points and broken down by observed gross pathology.  The actual 82 
tissue lactate points used for optical calibration broken down by gross pathology: 19 
calcified, 22 thrombotic, and 41 yellow/fatty. The actual 48 tissue pH points (7.33 ± 0.21 
mean ± standard deviation) used for optical calibration broken down by gross pathology: 
14 calcified, 11 thrombotic, and 23 yellow/fatty. It was shown in an earlier section 
(Laboratory Setup and Validation Results, Section 7.1) that the time of the experiment, if 
kept under a total of 4 hours (from the OR to last point collection), that the plaque 
remains viable and values do not change significantly with the continuously oxygenated 
media preparation. A temperature change of no more than 0.5°C per hour is acceptable, 
down to the lowest temperature in the validation set of 32°C. Points with tissue 
temperature greater than or equal to 32°C were used.  
 
Further analysis of the measured variables was made to elucidate spurious correlations 
before developing calibration models. Table 7.3.2 shows the correlation coefficients 
calculated between the measured variables used for optical calibration.  No correlation 
was observed. Figure 7.3.2 shows the same reference measurements plotted against each 
other and temperature (A) Tissue lactate vs. temperature B) Tissue pH vs. temperature, 
C) Tissue pH vs. lactate).  
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Figure 7.3.1: Histogram for reference lactate (top, total n=82) and tissue pH (bottom, 
total n=48) measurements broken down by gross pathology. 
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Table 7.3.1: Reference Measurements Data. Points not usable for optical calibration were identified. 
Table Legend: Gross Pathology: c- calcified, y – yellow/fatty, t – thrombus 
Used for Model: Y – yes 667-2400 nm for lactate, y – for pH 667-2400 nm only, 
Y- both visible and NIR for pH, * - low temperature, # - high off of lactate assay 
calibration curve, m – lost sample, or no electrodes for pH, s – spectral 
reflection of plate or lactate region flat and featureless 
Experiment ID / Total 
Duration 
Point# pH Temp Gross 
Pathology 
LA Used for 
Lactate 
Model? 
Used for pH 
Model? 
1 7.23 33.0 c 5.9 Y y 
2 7.75 32.9 c 0.9 Y y 
3 7.87 33.0 c 1.2 Y y 
4 7.49 32.2 y 1.1 Y y 
5 7.47 32.6 y 0.6 Y y 
6 7.28 32.9 t 0.4 Y y 
7 7.38 33.0 c 0.3 Y y 
K1 
3 hrs 26 min 
8 7.88 33.0 t 2.3 Y y 
9 7.37 32.2 y 9.2 Y y 
10 7.24 31.5 y 10.8 * * 
11 7.34 31.4 y 4.5 * * 
12 7.44 31.1 t 1.1 * * 
13 7.44 31.1 t 2.5 * * 
K2 
2 hrs 23 min 
14 7.13 31.1 y 2.7 * * 
15 7.16 30.7 y 1.9 * * 
16 7.40 31.4 y 2 * * 
17 7.27 30.7 y 3.7 * * 
K3 
2 hrs 10 min 
18 7.35 31.2 y 5.7 * * 
19 7.54 33.3 y 10 Y y 
20 7.30 32.6 y 10.1 Y y 
21 7.18 31.8 c high # * 
22 7.12 31.2 y 6.5 * * 
K4 
2 hrs 13 min 
23 7.27 30.9 t 1.9 * * 
24 7.15 31.5 t 3.9 * * 
25 7.01 30.9 y 2.4 * * 
K5 
1 hr 53 min 
26 7.25 30.6 c -- m * 
27 7.46 31.2 t 3.9 * * 
28 7.40 30.2 c 4.8 * * 
29 7.46 30.0 c 1.4 * * 
K6 
1 hr 25 min 
30 7.34 29.2 c high # * 
31 7.36 30.5 y 2.2 * * 
32 7.37 30.0 y 2.2 * * 
33 7.44 29.1 y 1.6 * * 
34 7.37 28.6 y 2.6 * * 
35 7.21 28.6 c 4.4 * * 
K7 
2 hrs 5 min 
36 7.24 28.5 c 0.5 * * 
37 6.92 33.4 y 1.5 Y y 
38 7.16 32.7 t 2.1 Y y 
39 7.26 32.2 y 1.4 Y y 
K8 
1 hr 46 min 
40 7.09 32.0 y 3.4 Y y 
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Experiment ID / Total 
Duration 
Point# pH Temp Gross LA Used for 
Lactate 
Model? 
Used for pH 
Model? 
41 6.89 36.6 y 1.6 Y y 
42 6.80 36.4 y 4.6 Y y 
43 6.65 36.0 y 1.9 Y y 
44 6.64 35.7 y 0.9 Y y 
K9 
2 hrs 18 min 
45 7.10 35.4 y 1.7 Y y 
46 7.44 34.2 y 2.2 s s 
47 7.34 33.4 y 2 Y y 
K10 
1 hr 56 min 
48 7.49 32.9 c 1 s s 
49 7.37 36.7 y 1.4 s s 
50 7.18 35.7 y 1.1 Y y 
51 7.09 35.5 c 1.9 Y y 
52 7.08 35.5 t 1.8 Y y 
K11 
2 hrs 29 min 
53 6.90 37.3 c 2.5 Y y 
54 7.51 37.8 y high # y 
55 7.28 36.7 y 4.7 s s 
56 7.27 37.5 t 1.2 Y y 
K12 
1 hr 36 min 
57 7.40 37.1 c high # y 
58 7.30 33.6 y 3.6 Y y 
59 7.28 34.2 t 1.9 s s 
60 7.22 32.9 y 1.9 Y y 
61 7.10 32.3 c 1.3 s s 
62 7.30 33.0 t 1.1 Y y 
K13 
2 hrs 37 min 
63 7.26 33.5 t 0.3 Y y 
64 7.05 35.2 t 5.3 Y y 
65 7.13 35.2 y 2.3 Y y 
66 7.33 34.5 c high # y 
67 7.37 33.6 t 1.2 Y y 
68 7.14 34.2 c high # y 
K14 
2 hrs 32 min 
69 7.23 33.6 y 7.2 Y y 
70 7.46 33.3 t 10 Y Y 
71 7.45 33.6 t 6.3 Y Y 
72 7.44 33.4 t 6.3 Y Y 
K17 
2 hrs 11 min 
73 7.27 32.0 t 0.9 Y Y 
74 7.48 35.7 y 7.7 Y Y 
75 7.50 34.3 c 4.9 Y Y 
76 7.55 35.0 y 7.1 Y Y 
K18 
3 hrs 0 min 
77 7.41 33.4 c 2.5 Y Y 
78 7.04 34.1 c 6.3 Y Y 
79 7.08 33.3 c 7.4 Y Y 
80 7.03 34.3 y 4.1 Y Y 
81 6.74 34.2 y 4.0 Y Y 
K19 
4 hrs 0 min 
82 7.39 35.0 y 5.4 Y Y 
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Experiment ID / Total 
Duration 
Point# pH Temp Gross LA Used for 
Lactate 
Model? 
Used for pH 
Model? 
83 7.07 36.1 c 1.7 Y Y 
84 6.99 34.6 c 1.5 Y Y 
85 7.32 34.5 t 0.3 Y Y 
86 7.33 34.5 t 3.6 Y Y 
K20 
3 hrs 49 min 
87 7.11 34.5 y 1.4 Y Y 
88 7.21 35.1 c 1.5 Y Y 
89 7.30 33.6 c 2.5 Y Y 
K21 
2 hr 52 min 
90 7.55 33.8 c 10.6 s Y 
91 7.38 35.1 t 3.7 s Y 
92 6.97 34.3 y 2.8 Y Y 
93 7.10 33.4 c 4.6 Y Y 
K22 
1 hr 50 min 
94 7.22 32.7 y 5.4 Y Y 
95 7.22 36.8 t 3.2 Y Y 
96 7.15 35.4 y 2.7 Y Y 
97 7.29 35.5 t 1.2 Y Y 
98 7.40 35.4 y 1.1 Y Y 
99 7.33 35.5 t 1.6 Y Y 
K23 
4 hrs 0 min 
100 7.45 33.9 y 0.1 Y Y 
101 7.48 36.3 c 0.9 Y Y 
102 7.51 34.1 y 0.7 Y Y 
K24 
2 hrs 29 min 
103 7.72 33.6 c -- m Y 
104 7.32 34.2 t 1.3 Y Y 
105 7.46 33.2 c 4.9 s Y 
106 7.47 32.7 y -- m Y 
107 7.51 32.5 c 0.6 Y Y 
K25 
3 hrs 14 min 
108 7.34 32.0 y 0.5 s Y 
109 7.26 31.6 t 1.6 * * K26 
3 hrs 32 min 110 -- 32.4 t 1.3 Y m 
111 7.23 32.7 y 8.5 Y Y K27 
3hrs 43 min 112 -- 32.9 c 8.0 Y m 
113 -- 35.2 y 5.9 Y m 
114 -- 34.9 c 3.2 Y m 
K28 
4 hrs 0 min 
115 -- 35.7 y 1.5 Y m 
116 -- 36.5 y 4.6 Y m 
117 -- 35.5 y 1.6 Y m 
118 -- 36.2 t 1.2 Y m 
119 7.49 35.8 y 1.5 Y Y 
120 7.66 35.1 y 1.5 s Y 
K29 
3 hrs 58 min 
121 7.45 35.5 y 1.9 s Y 
122 7.53 34.4 Y 3.2 Y Y 
123 7.60 34.1 Y 1.4 Y Y 
124 6.89 34.2 Y 9.0 Y Y 
125 7.48 35.8 Y 1.1 Y Y 
K30 
3 hrs 59 min 
126 7.25 34.6 Y 0.9 Y Y 
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Figure 7.3.2: Correlation plots of the reference measurements from ~24 plaques. A) Tissue lactate vs. 
temperature B) Tissue pH vs. temperature, C) Tissue pH vs. lactate. Correlations are negligible 
(Table 7.3.2). 
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Table 7.3.2: Correlation coefficients between measured (reference) variables. No spurious 
correlations apparent. 
Variables Correlation Coefficient between data 
Tissue Lactate – Tissue Temperature 0.03 (n=82) 
Tissue pH – Tissue Temperature 0.00004 (n=48) 
Tissue Lactate – Tissue pH 0.0008 (n=48) 
0.001 (n=74 inclusive) 
 
7.4. Calibration Model Development 
 
Preliminary data analysis was carried out on the first 21 points when they were available 
for both the tissue lactate (Sample #’s 1-9, 19, 20, 37-45, and 47 in Table 7.3.1.) and the 
first 20 points for tissue pH using full spectral range data, 400-2400 nm (Sample #’s #70-
90 in Table 7.3.1). The preliminary analysis was done to provide an initial assessment of 
data quality. The entire data set (82 points for lactate and 48 points for tissue pH) as 
tabulated in Table 7.3.1 were analyzed at the end of experimentation and compared to the 
preliminary data results.  
 
7.4.1. Lactate Determination 
 
Preliminary data analysis on 21 points from the first six plaques (K1, K2, K4, K8, K9, 
and K10) showed that a calibration model could be built using the 2030-2330 nm region 
only. Table 7.4.1 summarizes these results before and after outlier detection was 
performed. The data description, whether a model could be generated based on PRESS 
(see Section 6.4), the number of factors required, the correlation to the reference and 
estimated accuracy (R2 and standard error of cross-validation or SECV), and the number 
of points removed are shown. The range of the reference tissue lactate (LA) concentration 
was 0.1 – 10.1 micromoles LA per gram of tissue.   The raw spectra are shown in Figure 
7.4.1.a. The R2 of the determination was 0.83 and the standard error of cross-validation 
(SECV) was 1.4 micromoles LA per gram of tissue (correlation plot, Figure 7.4.1.b.). The 
number of factors used was six, with the percent variance captured by each factor 
summarized in Table 7.4.2. Figure 7.4.2 show the corresponding loading vectors for a) 
factors 1-3, and b) factors 4-6.  The fourth and sixth loading vectors contain positive 
correlation peaks at ~2250 and 2295 nm. This preliminary calibration model has 
acceptable accuracy using 17 points. 
 
Table 7.4.1:  Preliminary model results for lactate determination, 2030-2330 nm. 
Data / Pre-Processing Model? Factors R2 SECV % removed 
n=21 
First 6 plaques, mean-centered Y 6 0.45 2.4 0 
First 6 plaques, mean-centered, 
after statistical outlier detection 
Y 6 0.83 1.4 21% 
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Table 7.4.2: Preliminary data analysis: percent variance explained by six factor model. 
Spectral Variance Reference Lactate Variance Factor # 
% variance captured Total %  % variance captured Total % 
1 99.7 99.7 43.1 43.1 
2 0.036 99.997 19.8 62.9 
3 0.001965 99.999 6.0 68.9 
4 0.0004 100 12.8 81.8 
5 0.00015 100 12.6 94.4 
6 7.37x10-5 100 4.4 98.8 
 
Figure 7.4.1: Preliminary model results: spectra and correlation plot.  a) Seventeen spectra from 
the first six plaques collected.  b) Actual versus predicted lactate values. Solid line is unity line. 
R2=0.75, SECV=1.4 micromoles/gram tissue, 6-factor model. 
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Figure 7.4.2: Preliminary model results: loadings. Six factors. Top: a) Loadings for factors 1-3, blue 
factor 1, green factor  2, red factor 3.Bottom b) Factors 4-6. Blue factor 4, green factor 5, red factor 6. 
Note peaks at ~2250 and 2295 nm. 
b) 
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Table 7.4.2 summarizes the calibration model results for the entire 82 data point set for 
lactate determination.  Tests were separated into four groups based on wavelength region 
and pre-processing methods. For each test, the description, wavelength region, whether a 
model could be generated based on PRESS, number of factors required, the correlation to 
the reference and estimated accuracy (R2 and standard error of cross-validation or 
SECV), and the number of points removed (from the entire set, n=82) are shown. Where 
no models could be generated because no minimum in PRESS could be achieved 
(Model? =N, see Methods, Section 6.4), results from the factor 1 model are reported in 
italicized parentheses only for comparison. Where there is a minimum PRESS for a factor 
greater than 1, but the results are not statistically different, based on an F-test (Model? 
=N†), the results from the minimum PRESS factor are reported as well as any results 
after additional outlier removal. Where there is a minimum PRESS for a factor greater 
than 1 and it is statistically different (Model? =Y), the results for the minimum PRESS 
factor are reported as well as the results after additional outlier removal. 
 
Table 7.4.3: Summary of Calibration Model Development Results for 82 lactate points.  Preliminary 
data calibration models shown as test 2d and e for comparison. 
Test 
Group 
Data / Pre-Processing Region Model? Factors R2 SECV % 
removed  
n=82 
1a All 82 points, mean-centered 1100-
2400 
N† 5  0.10 2.4 0 
1b All 82 points, mean-centered 
(outliers removed from 1a) 
1100-
2400 
N† 2 0.004 1.8 18% 
1c Baseline Correction 1100-
2400 
N     
1d Multiplicative Signal Correction 1100-
2400 
N     
        
2a All 82 points, mean-centered 2030-
2330 
N (1) (0.008) (1.9) 0 
2b Baseline Correction 2030-
2330 
N    0 
2c Multiplicative Signal Correction 2030-
2330 
N    0 
2d First 6 plaques, mean-centered  2030-
2330 
Y 6 0.45 2.4 75% 
2e First 6 plaques, mean-centered 
(outliers removed from 2d) 
2030-
2330 
Y 6 0.83 1.4 79% 
        
3 Cluster Analysis  2030-
2330 
     
3a Group A – 45 points  Y 3 0.21 2.9 45% 
3b Group B – 31 points  N (1) (0.13) (3.9) 62% 
3c Group C – 6 points  Y 2 0.12 2.3 93% 
        
4a OSC – one components removed 2030-
2330 
N (1)  (0.03) (2.8) 0 
4b OSC – two components removed 2030-
2330 
N (1) (0.02) (6.3) 0 
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Group 1 showed using the full spectral range 1100-2400 nm, that no models could be 
adequately generated that included all the 82 data points (test 1a). Even after statistical 
outlier removal, no improvement in model could be made (test 1b). Baseline correction 
(test 1c), Multiplicative Signal Correction (test 1d), and second-derivative (test 1e) 
standard preprocessing methods did not help.  
 
Group 2 showed using the 2030-2330 nm range, that no models could be adequately 
generated using all 82 data points (test 2a). Because there was no minimum PRESS in 
test 2a (Model? =N), meaningful outlier detection is not possible. Baseline correction 
(test 2b) and Multiplicative Signal Correction (test 2c) standard pre-processing methods 
did not help. Significant model degradation using the entire data set occurred compared 
to the preliminary model results using 21 points (results from Table 7.4.1 are shown in 
Table 7.4.2 as tests 2d and 2e for comparison to entire data set). 
 
Group 3 showed using the 2030-2330 nm range and Cluster Analysis, variation in the 
spectral data affected the calibration. From the eighty-two spectra, three clusters were 
determined using Minkowski’s distance metric with p=3 for n-1 objects and the centroid 
proximity metric to find groupings.  The clustering solution (or dendrogram) produced is 
shown in Figure 7.4.3 with the spectra in each cluster plotted on the left. Forty-five 
spectra were in Group A, thirty-one in Group B, and six in Group C. Spectra from the 
first six plaques (twenty one points) were all in cluster A. A 3-factor PLS model could be 
generated with the Group A cluster; however, the accuracy is degraded compared to tests 
2d and 2e.  
 
Group 4 showed using the 2030-2330 nm and Orthogonal Signal Correction, variation in 
the reference data affected the calibration.  No models could be created with the entire 
eighty-two points after either one or two orthogonal components (spectral components 
whose variation can be treated mathematically independent from the reference data) were 
removed. 
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Figure 7.4.3: Clustering solution for 82 spectra for the optical determination of lactate. Cluster A – 
45 spectra, B – 31 spectra, and C – 6 spectra.  Cluster A contained the first 21 calibration spectra 
collected, i.e., chronologically those calibration points used from plaques K1, K2, K4, K8, K9 and 
K10 found in Table 7.3.1 were all in Cluster A.  
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7.4.2. Tissue pH Determination  
 
Preliminary data analysis on 20 points from the first five plaques (K17 to K21 inclusive) 
showed that a calibration model could be built using a wavelength selection approach for 
tissue pH. The three regions that were identified were: Region 1: 400-615 nm, Region 2: 
924-1889 nm, and Region 3: 2043-2341 nm. Table 7.4.4 summarizes these results before 
and after outlier detection was performed. The data description, whether a model could 
be generated based on PRESS (see Section 6.4), the number of factors required, the 
correlation to the reference and estimated accuracy (R2 and standard error of cross-
validation or SECV), and the number of points removed are shown. The range of the 
reference tissue pH was 6.99 to 7.55. Wavelength selection and additional statistical 
outlier removal produced a 3-factor model with R2=0.75, SECV=0.09.  Figure 7.4.4 
shows the a) spectra, and b) correlation plot. The percent variance captured by each factor 
is summarized in Table 7.4.5. Figure 7.4.5 shows the three loading vectors in each 
wavelength region. Region 3 only marginally improved the model performance (NS). 
This preliminary calibration model has acceptable accuracy using 17 points. 
Table 7.4.4:  Preliminary model results for tissue pH determination. Three regions: R1=400-615 nm, 
R2=924-1889 nm, and R3=2043-2341 nm. 
Data / Pre-Processing Model? Factors R2 SECV % removed 
n=20 
First 5 plaques, mean-centered Y 3 0.27 0.18 0 
First 5 plaques, mean-centered, 
after statistical outlier detection 
Y 3 0.75 0.09 15% 
 
 
 
Table 7.4.5: Percent variance captured by PLS tissue pH model shown in Figure 7.4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectral Variance Reference Tissue pH Variance Factor # 
% variance captured Total % % variance captured Total % 
1 48.9 48.9% 57.8 57.8 
2 45.1 94% 7.3 65.1 
3 4.0 98% 19.2 84.3 
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Figure 7.4.4: Preliminary model results from tissue pH calibration, spectra and correlation plot. 
Top: 17 spectra and the 3 spectral regions used for model.  Bottom: Actual electrode pH versus 
NIR predicted pH. Solid line is unity line. R2=0.75 and SECV=0.09 pH units. 
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Figure 7.4.5: Preliminary model results: tissue pH loading vectors. Blue Factor 1, Green Factor 2, Red 
Factor 3. Hemoglobin bands at ~540 ,575 and 1650 nm show up in factor 2 loadings and factor 1 loadings for 
region 1 and 2 respectively. Region 3 only marginally improves model accuracy and prediction. 
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Table 7.4.6 summarizes the calibration model results for tissue pH determination for  
three different test groups. For each test, the description, wavelength region, whether 
model could be generated based on PRESS (see Methods, Section 6.4), number of factors 
required, the accuracy (R2), precision (standard error of cross-validation or SECV), and 
the number of points removed (from the entire set, n=48) are shown. Where no models 
could be generated because no minimum in PRESS could be achieved (Model? =N), 
factor 1 results are reported in italicized parentheses for comparison. Where there is a 
minimum PRESS for a factor greater than 1, but is not statistically significant from factor 
1 based on an F-test (Model? =N†), the minimum factor results are reported as well as the 
results after additional outlier removal. Where there is a minimum PRESS for a factor 
greater than 1 and it is statistically significant from factor 1 result (Model? =Y), that 
factor is reported as well as the results after additional outlier removal. 
 
Group 1 showed using three regions identified by wavelength selection in the preliminary 
data analysis, that a weak model could be built (test 1a). The regions identified were 400-
615 nm, 924-1889 nm, and 2043-2341 nm. However the accuracy is still not acceptable 
with 30 points after outlier removal (test 1c) when compared to the preliminary results 
(shown in Table 7.4.6 as test 1d and 1e).  
 
Group 2 showed using the full wavelength region 400-2400 nm, that a weak model could 
be built (test 2a). However, no models could be created with greater than one factor, even 
after significant outlier removal, which is indicative of not being able to properly model 
tissue pH variance  (tests 2b-2d).  Multiplicative Signal Correction (test 2e) and Baseline 
Correction did not help (2f-2i).  
 
Group 3 showed using the 400-1100 nm range and Cluster Analysis, variation in the 
spectral data affected the calibration. From the forty-eight spectra, two clusters were 
determined using the Euclidean distance metric for n-1 objects and the Shortest Distance 
proximity metric to find groupings. The dendrogram produced is shown in Figure 7.4.6 
with the spectra in each cluster plotted on the left. Thirty-nine spectra were in Group A 
and nine in Group B. Even after outlier removal, neither cluster A or B provided 
improved results. The spectra in Group B were identified as arising for plaque 
measurements having the same gross pathology characteristics, i.e. all were from 
thrombotic regions of plaque.  
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Table 7.4.6: Summary of Calibration Model Development Results for tissue pH.  
 *R1: 400-615 nm, R2: 924-1889 nm, R3: 2043-2341 nm; # R1: 431-615; R2: 1354-2029 nm; † minimum 
PRESS achieved but results from factor 1 not statistically different from the results from the minimum 
PRESS factor based on F-test 
Test 
ID 
Data / Pre-Processing Region Model? Factors R2 SECV % Removed 
n=48 
1a All points, mean-centered 3 Regions* N† 1 0.14 0.19 0 
1b All points, mean-centered 3 Regions* Y 1 0.23 0.16 17% 
1c All points, mean-centered 3 Regions* Y 2 0.52 0.12 38% 
1d First 5 plaques, mean-centered  3 Regions* Y 3 0.27 0.18 58% 
1e First 5 plaques, mean-centered (outliers 
removed from 1d) 
3 Regions* Y 3 0.75 0.09 65% 
        
2a All points, mean-centered 400-2400 N† 1 0.13 0.19 0 
2b All points, mean-centered “ Y 1 0.20 0.15 11% 
2c All points, mean-centered “ Y 1 0.34 0.13 25% 
2d All points, mean-centered “ Y 1 0.44 0.11 42% 
2e Multiplicative Signal Correction 400-2400 N     
2f Baseline Correction 2 Regions# N† 1 0.13 0.19 0 
2g Baseline Correction “ Y 1 0.22 0.15 19% 
2h Baseline Correction “ Y 1 0.22 0.14 25% 
2i Baseline Correction “ Y 1 0.36 0.13 33% 
        
4 Cluster Analysis 400-1100      
5a Group A – 39 points  N† 1  0.14 .21 19% 
5b Group A – 7 outliers removed  Y 1 0.29 0.16 33% 
5c Group A – more outliers removed  Y 1 0.42 0.14 58% 
5d Group B, 9 points  N 1 0.25 0.13 81% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
400 500 600 700 800 900 1000 1100
0
0.5
1
1.5
2
2.5
400 500 600 700 800 900 1000 1100
0
0.2
0.4
0.6
0.8
1
A 
B 
Figure 7.4.6: Clustering solution for optical determination of tissue pH.  Two clusters: A contains 39 
spectra, B contains 9 spectra. The underlying pathology in cluster B was identified as all thrombotic 
points. 
93 
8. DISCUSSION 
 
In this section, a discussion of the results and interpretation is presented. First, the 
validation of the living status of the freshly excised tissue is discussed and similar studies 
reviewed to demonstrate importance of maintenance of metabolic status (Section 8.1). 
Next, the spectral data collection is discussed to highlight the pathological variability and 
challenges. The reference data collection is reviewed along with prior studies to 
demonstrate the challenges of matching reference tissue volume to optical volume and 
how it might affect the accuracy. Lastly, the calibration model development results are 
presented in Section 7.4.  Preliminary PLS calibration model results showed that for the 
first ~17 points for each optical calibration, adequate models could be generated. 
However, when additional points were added, the initial calibration model results were 
degraded. The sources of variability that were investigated that might contribute to model 
degradation are reviewed.   
 
8.1. Laboratory Setup and Validation 
 
The physiological monitoring of plaques in a controlled environment using oxygenated, 
physiological media demonstrated that over time, the plaque tissue could be maintained 
at relatively constant metabolism over 4 hours. The oxygenated media environment 
allowed the plaques to remain in near in-vivo status for the duration of the data collection. 
The liquid media pH, pCO2, and pO2 values, were stable and different from the plaque 
tissue measurements. The measured plaque metabolic parameters were not significantly 
dependent on the media values. The placement of the sensor may have played a role in 
the starting value of the tissue pH, pCO2 or pO2 reading. The thickest plaque (~3 mm) 
where the sensor was placed had a pO2 value of 6 mmHg, although its pH, pO2 and 
temperature were within the range of the other test plaques. This may indicate that thicker 
plaques will not have enough oxygen delivered deep into the tissue and may have less 
stability over 4 hours. The other six test plaques and two control plaques were closer in 
thickness (~1.5 mm).  
 
Prior studies [36] of tissue pH in atherosclerotic plaques studied different buffering 
systems on preserving plaques ex-vivo. No significant difference was seen between the 
coefficients of variation of pH between treating the plaques after surgical removal with 
Dulbecco’s Modified Eagles’ Medium (DMEM), normal saline or phosphate buffer after 
30 minutes. However, no continuous oxygenation to the plaque tissue was made and no 
separate determination of oxygenation or tissue viability was provided.  The 
measurement of physiological parameters with the Diametrics sensor described here is 
the first study that demonstrates that plaques produce CO2, and enough oxygen is 
delivered to the inner layers of the plaque to preserve the living cells.  
 
pH heterogeneity in human carotid plaques has been reported using fluorescence ratio 
imaging microscopy  (dual emission, pH sensitive BCECF dye) and pH sensitive SNARF 
fluorescence microscopy (single emission) and microelectrodes [36] with pH ranging 
from 6.8 to 8.3 pH units (microelectrodes, mean ± SD 7.55 ± 0.32). In the validation 
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study reported here, the lower average pH for the controls (6.75 ± 0.15 and 6.77±0.16) 
and the rate of change in tissue pH (0.25 pH units/hr in the controls) demonstrated that 
physiological tissue pH can not be maintained for more than ~30 minutes without 
adequate nutrient supplement. The average pH in the control plaques is similar to other 
reports of low tissue pH in atherosclerotic plaques. The average pH of the seven plaques 
placed in the media was consistently higher and more stable than the control plaques. 
Due to the Diametric sensor’s fragility, no measurements could be made in a calcified 
region of plaque over time. Areas of highly calcified plaques were reported in the 
literature with significantly higher pH values, up to 8.3 pH units. In addition, the plaques 
placed in the media had a smaller range in pH (mean, 6.93 to 7.29) and less heterogeneity 
was observed. The magnitude of pH heterogeneity, reported in the fluorescence 
microscopy studies that included both calcified and non-calcified areas, was not 
observed. 
 
Based on the stability of the physiological parameters, the oxygenated media bath 
preparation established a method to keep the plaque tissue viable for up to four hours. 
Areas of plaques that were heavily calcified or too thin to place the fragile sensor were 
not included in the validation. While the stability of calcified areas was not measured 
directly and could be a limitation it is assumed that these calcified areas will have the 
same metabolic properties as other areas of the plaque, if the thickness is not too great 
(>1.5 mm).  
 
8.2. Spectra Collection 
 
Eighty-two spectra for lactate determination and forty-eight spectra for tissue pH 
determination were collected. Several spectra had to be eliminated out of the 126 total 
points collected based on adverse reflection of the ceramic grid under the plaque, or 
featureless (flat) signal between 2000-2500 nm.  Although these flat spectra were 
typically highly calcified plaque, the low signal-to-noise from the known detector 
response cannot be ruled out.  
 
Figures 7.2.4 and 7.2.5 showed the optical spectra collected (lactate and tissue pH 
spectra, respectively) broken down by the observed gross pathology. These figures are 
demonstrative of how gross pathology is a subjective and highly imperfect 
caterogorization scheme.  For several points, a mix of calcified and thrombotic, or 
thrombotic and yellow, regions was apparent. Heterogeneity in a 3 mm diameter area is 
typical, and exacerbates the ability to discern the type of plaque with the naked eye. 
Microscopic heterogeneity as evidenced by histology may be a better indicator of what 
“type” of plaque the point was and to which category its spectra belong.  
 
The optical spectra of the atherosclerotic plaques were collected in a near-physiological 
environment. These optical spectra will represent metabolically active tissue, in contrast 
to static morphological measurements reported elsewhere on plaques frozen then thawed 
prior to spectroscopic measurements [62, 102]. 
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8.3. Reference Measurements 
 
The reference lactate values measured in the carotid plaques were not uniformly 
distributed across the physiologically relevant concentration range (2-20 
micromoles/gram tissue); the average and median was skewed to the low concentrations 
(average 3.2, median 1.9 micromoles LA/gram tissue). The micro-enzymatic assay was 
sensitive to ±0.1 micromoles LA/gram tissue based on the intercept of the calibration 
curve. The calibrated measurement range was from 0 to 11 micromoles/gram tissue. 
However, the intra-serial precision was 0.5 micromoles LA/gram tissue, based on three 
replicate measurements on the same microtiter plate.  This error limits the accuracy that 
can be achieved with the optical determination of lactate.  
 
Other researchers [103] using tissue lactate as an indicator of anaerobic metabolism 
demonstrated that in cancer tissue, lactate values were predictive of increased risk of 
metastases, with a median tumor lactate concentration of 7.1 micromoles/gram tissue. 
Tumors that subsequently metastasized were 12.9 micromoles/gram tissue versus 4.8 
micromoles/gram for patients disease-free after two years.  Tissue lactate measured in 
normal and atherosclerotic rabbit aortas [77] were shown to be 2.9 and 5.5 
micromoles/gram tissue, respectively. The highest lactate concentrations were seen deep 
in the plaque (>500 microns). The lactate values measured in this study are within the 
lower range of the reported literature values. The skewed median of the micro-enzymatic 
measurements may represent either 1) a lesser degree of anaerobic metabolism in this 
media preparation than tumors and atherosclerotic rabbit aortas incubated with 
oxygenated media in approximately a similar manner as described here, or 2) a dilution 
effect due to the large amount of tissue the biopsy covered. The bioluminescence method 
used in the other tissue lactate studies provided depth resolution of the lactate 
concentration per gram of tissue. It may be a better reference method to use for the 
optical calibration in the future. 
 
The reference pH values were consistent with the values observed during method 
validation. The electrodes have a reported measurement error of 0.03 pH units. The range 
of all the tissue pH reference measurements used for the optical calibration was from 6.74 
to 7.72.  An acceptable error in pH units based on significant digits would be ± 0.05 pH 
units, given the range of values that are reported for prior plaque tissue measurements 
(see Section 8.1 discussion).  The combined error of ±0.08 pH units was used as an 
acceptance criterion for the estimated error (or SECV) for the optical determination of 
tissue pH. However, the volume of tissue measured optically may be too big compared to 
the electrode measurement (2 mm working optical diameter versus a ~750 micron 
working diameter of electrode). This difference in volume may affect the calibration 
accuracy and prediction. 
 
Correlation analysis demonstrated that the measured tissue temperature is uncorrelated to 
lactate or pH reference measurements This is an important finding because the partial 
least-squares method employed here could inadvertently model some other variable if it 
is related to the desired calibration variable of either tissue pH or lactate.  Spurious 
correlation to temperature can be ruled out in assessing the calibration models 
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interpretability. The fact that optical calibration models could be created with real 
temperature variation is another indicator that the spectra collected in this in-vitro setting 
is impervious to the temperature. In addition, it was demonstrated that tissue pH and 
lactate reference measurements were not correlated. The sampling volume difference 
between the tissue lactate biopsy and the micro-electrode pH measurement alone could 
cause the lack of correlation between these known, physiologically-related 
measurements.  
 
8.4. Calibration Model Development 
8.4.1. Lactate Determination 
 
The calibration model development for lactate determination showed that an acceptable 
model could be made with only a subset of points (17 out of 82 or 20% of the data in 6 
plaques, i.e., plaques K1, K2, K4, K8, K9, K10). This model had loading vectors that 
demonstrated real chemical species were contributing to the determination. The 
cumulative percent variation captured in the lactate model demonstrated that by the 
fourth and sixth loading vector, variation in the spectra could be in part due to the 
theoretical lactate peaks at ~2250 and ~2295 nm. However, the contribution of the lactate 
peaks is weak.  Figure 7.4.2, shows that the first three loading vectors for lactate 
determination are demonstrative of over 99% of the spectral variance. These large 
changes could be due to dominating effects of water (loading vector 2) or protein 
concentrations (loading vector 3).  In contrast, by loading vector 3, only ~69% of the 
variability in the reference lactate concentration was captured. There is still considerable 
variance in the reference data left to be explained, even though the spectral variation is 
well captured. This variability could account for the limited accuracy of the preliminary 
data model.   
 
In the entire data set, this knowledge that the water and protein variability may affect 
model accuracy was implemented using additional pre-processing techniques to reduce 
the variability. Since large non-specific proteins may contribute to scattering in the near 
infrared (1100-2400 nm), it was hoped that Multiplicative Signal Correction (MSC) could 
provide some reduction in the contribution of scattering components in the full 82-point 
spectral data set and also reduce model complexity (number of factors required). MSC 
corrects for scattering by associating the mean spectrum as the “ideal spectrum” and 
correcting all spectra with linear regression (slope and offset from the ideal). However, 
no models could be created when MSC was applied either on the full wavelength region 
or on the 2030-2330 nm data. Automatic baseline correction, intended to remove spectral 
drift and/or the baseline water shifts, did not help the lactate determination using the full 
82-point calibration data in either wavelength region selected. 
 
Other pre-processing techniques that could help elucidate the lack of decent calibration 
models using the entire data set were used. Cluster analysis methods were employed to 
assess the spectral (in)homogeneity and find any correlation to other measured 
experimental variation(s), as the full data set is split up but conserved. Orthogonal signal 
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correction was used to assess the independence of the variability in the reference 
measurement.  
 
The clustering algorithm produced three clusters with the 82 spectra in an unsupervised 
fashion. Cluster A, containing 45 spectra (or 55% of the data), showed that the order the 
spectra were collected was important and could attribute to deterioration in the model for 
the full set of data over time. All the points that produced the acceptable lactate model 
(test 2e in Table 7.4.1) were in cluster A.  If there was no chronological dependence, then 
it should have been possible to generate an acceptable model with any other six plaques 
or seventeen points randomly chosen. This was performed on 3 different sets of 17 
randomly chosen points. However, no models could be created in this manner. The 
Cluster A PLS results were deteriorated (test 3a) compared to the first twenty-one points 
model (test 2d), indicating that even within a relatively homogeneous cluster of spectra, 
significant variability still exists. Clusters B and C were not adequate to produce any PLS 
models. No correlation to other experimental variation was observed in this clustering 
solution.  
 
It is important to note that the cophenetic coefficient, a metric that can be used to 
determine the validity of the clustering solution (the closer to 1 the better), was 0.76, the 
highest among all the other possible combinations of distance metrics for this data set. A 
low cophenetic coefficient is indicative of inconsistency among objects and groupings. It 
can be inferred that the variability in spectral data is high, as inconsistency in the cluster 
formation was observed. Natural groupings could not be determined based solely on the 
length of each link in the cluster tree with the lengths of neighboring links below it in the 
tree. Instead, three clusters were determined by cutting off the hierarchical tree at an 
arbitrary point. A better clustering algorithm could possibly provide a clustering solution 
that would group the spectra differently and in such a way that new PLS models could be 
generated. 
 
Orthogonal Signal Correction demonstrated that variability in the lactate reference 
measurement could be important. OSC assumes that the reference data is accurate and 
noise-free. By removing spectral components that are orthogonal to the reference values, 
it is assumed that no information correlated to the reference values should be lost. 
However, the OSC results showed no significant model improvement compared to the 
original 82 point PLS model. The lack of precision in the reference measurement at low 
concentrations may contribute to the poor accuracy in the optical determination and the 
inability of OSC to improve the model results using the full 82 point calibration data. 
 
Further investigation of why only the first six plaques (plaques K1, 2, 4, 8, 9, and 10) 
could create an acceptable model was made. First, chronological logs on the spectrometer 
were reviewed to see if data was corrupted after experiment K10. Nothing was found. 
Any equipment changes in the laboratory setup were reviewed. It was noted that a new 
incubator and heating pad was used starting with experiment K9. Although many points 
were removed because of low temperatures in K3, and in K5 to K7, the temperatures 
from the points used in the acceptable model versus the rest (i.e. the points from K11-
K30 marked Y in column “Used for Lactate Model?” in Table 7.3.1) were not 
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significantly different. In addition, the temperature ranges were within the validated 
range for living plaques (Section 7.1). Any difference in the in-vitro temperature was 
ruled out.  
 
Secondly, the time to collect optical spectra for each point was reviewed.  Spectrometer 
variation between collecting the backgrounds can potentially occur during the 10-15 
minutes it takes to make a full set of measurements for one location in the plaque. The 
time between spectrometer reference/background and tissue spectra collection on the FT-
NIR spectrometer and the experiment durations were longer after K14 because additional 
optical data was being collected with the visible spectrometer. If the time between 
spectrometer reference collection and tissue spectra collection was significantly different, 
then adding the points from plaques K11-K14 only to the acceptable model should not 
lead to model degradation. This was not the case. By adding the K11-K14 points to the 
first six plaques calibration data, no models could be created. The experiment durations 
were all within the validated range for living plaques and therefore the differences in the 
experiment durations was ruled out. Spectrometer reference variability as shown in Table 
7.2.3 may contribute to the variability seen in the spectra. An average 1.7% change at 
1150 nm was seen over the experiment collection period after the preliminary data set 
was collected.  
 
Next, calibration curves for lactate assay processing, and the reference lactate 
measurements % recovery studies were investigated. The slope and intercept values for 
the calibration curves for each assay batch processed were comparable and therefore 
should not significantly impact the reported lactate value. There was, however, 
considerable variability in the percent recovery values determined between the batches of 
lactate assays.  Plaques K1 and K2 were in one batch, K4 was in its own batch, and 
plaques K8-K10 were in yet another batch. For the rest of the plaques, K11-14, K17-22, 
and K23-30 were separate batched lactate assays. If the batch a plaque point belonged to 
was significant, then it is should be that only plaques with similar percent recovery values 
model.  To test this, each batch group was rotated in and out of the calibration set. The 
large individual batches did not model. Groups of batches with similar percent recovery 
did not model. However, with all the other variations apparent, the significance of the 
batch grouping cannot be ruled out. The reported assay error and the range of lactate 
values (see discussion in Section 8.3) also make this assessment problematic.  
 
Approximately 5 or 6 points per factor are required to demonstrate the model is not 
overfit [26]. The seventeen points that created an acceptable lactate calibration model 
based on R2 and SECV was an overfit model. The many sources of variation within each 
plaque, between plaques, and variation in spectrometer over time may have confounded 
the ability to make a model as more points were added to the preliminary model results. 
The narrow range of lactate values in the entire data set and spreading of the data at low 
concentrations also limits the accuracy.  Increasing the number of calibration samples 
over a wider lactate concentration range should create a more evenly distributed range of 
lactate values and may be able to account for plaque-to-plaque variation.  Better reference 
methods such as HPLC or bioluminescence [104] could help discriminate the low 
concentrations and improve the predictions. Spectrometer variation might be reduced 
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with a cooled detecting element or by modeling this variability separately. The significant 
added variability in the data was not adequately modeled and resulted in serious 
degradation from the preliminary model results.  
 
8.4.2. Tissue pH Determination 
 
The preliminary model results showed that tissue pH determination is feasible. This 
model had loading vectors that resembled hemoglobin and water absorption. The 
cumulative percent variation captured by the three loading vectors in the tissue pH model, 
in each wavelength region contributing to the model, showed positive correlation peaks at 
the wavelengths where oxyhemoglobin absorb in both the visible (Figure 7.4.5 top plot, 
factors 2 and 3) and near-infrared (Figure 7.4.5. center plot factor 1). Alam et al [105] 
demonstrated in whole blood experiments, that the 1650 nm peak is a pH-inducible shift 
in the histidine residue of hemoglobin molecule, further corroborating the validity of the 
tissue pH model in atherosclerotic plaques. The other dominant feature in the loading 
vectors is water at 1450 nm (Figure 7.4.5. center plot, factor 3). This may be related to 
hydrogen bonding effects from pH-induced changes in water. A three-factor model is 
acceptable for the seventeen points used for the tissue pH determination. Most of the 
spectral variation is captured by the third factor (98%), however, only 84% of the 
variation in the reference tissue pH was explained.  This unmodeled variability could 
account for the limited accuracy of the model.  Additional factors could be used, 
however, this both increases model complexity and unwanted noise-correlation.  
 
No models could be created using Multiplicative Signal Correction or automatic baseline 
correction after outlier removal using the full 48 points and additional wavelength 
selection.  It was hoped that MSC could provide a reduction in the contribution of 
scattering components that was apparent in observing all the spectra together. However, 
no models could be created. The automatic baseline correction, also intended to remove 
this shift, did not help. These methods may have reduced model complexity (only models 
with one factor were generated), but the correlation due to noise overshadows any 
possibility of modeling the tissue pH. 
 
Cluster analysis methods were then employed for the full 48 tissue pH calibration data to 
assess the spectral (in)homogeneity and find any correlation to other measured 
experimental variation(s). Again, the full data set is split up but conserved. The clustering 
algorithm produced two clusters in an unsupervised fashion. Cluster A, containing 39 
points, still contained considerable spectral variability and could not produce models with 
more than one factor, even after outlier removal. Cluster B, containing 9 points, 
demonstrated that pathology was the major source of spectral variability. Spectra 
collected from points that were identified as grossly thrombotic during the experiments 
were in a unique cluster (Group B, Figure 7.4.6). However, the acceptable model used 
points in both clusters. The clustering solution was not able to separate based on any time 
dependence, unlike in the lactate spectra clustering. The variability due to pathology was 
overwhelming.  
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The cophenetic coefficient for this solution was 0.9025, the highest among all other 
combinations of distance metrics. Two clusters were determined by detecting natural 
groupings based on the length of each link in the cluster tree with the lengths of 
neighboring links below it in the tree. The solution is better than the lactate spectra 
clustering in terms of inconsistency (i.e. the clusters formed in the tissue pH clustering 
solution were more appropriate). Additional pre-processing on Cluster A may reduce 
spectral variability. Only nine points were available in Group B, so a good model could 
not be developed.  More points that exhibit thrombus pathological characteristics would 
be required if the model is to be improved. The apparent mismatch in the size of the 
optical probe tissue volume and the tissue pH reference measurement may be a more 
important factor in the entire data set, as variability in pathology under the fiber optic 
probe is seen. This might be resolved by creating a smaller fiber optic probe that is closer 
to ~1 mm in diameter as the micro-electrodes used.  
 
Further investigation was made on why only the first five plaques measured for the 
optical determination of tissue pH (i.e. plaques K17 to 21 inclusive) could create an 
acceptable model. Unlike in the lactate investigation, the time between reference and 
tissue spectra collection did not change after K21. No adverse chronological logs were 
found. No changes in the laboratory setup were made at this stage. Spectrometer 
reference variability as shown in Table 7.2.3 may contribute to the variability seen in the 
spectra. An average 1.6% change at 970 nm on the FT-NIR spectrometer (affecting 
spectral Region 2) was seen over the experiment collection period after the preliminary 
data set was collected. 
 
In a previous work describing optical tissue pH calibration and real tissue pH 
heterogeneity in-vivo in the myocardium [28], similar challenges of matching the optical 
volume and reference measurement volume were outlined.  However, when ischemic 
changes occur in the intact myocardium, the direction of pH change is homogenous and 
may be more optically predictable compared to the atherosclerotic plaque. Improvement 
of the optical depth resolution that was required in the myocardium was on the order of 3-
5 mm. The spatial distribution of tissue pH in the atherosclerotic plaque is more 
heterogeneous, on the order of microns. In addition, due to the histological variability of 
necrotic and living tissue on the order of microns, the direction of pH change due to 
ischemic, hypoxic, or anaerobic conditions in the in-vitro situation may not be as 
optically predictable. The averaging effect of the optical probe volume in this research 
may be a large contribution to the limited accuracy of the optical calibration. 
 
8.5. Medical Interpretation and Significance of Results 
 
While no actual method of detecting vulnerable plaque was undertaken during this 
research, it has been shown that the two metabolic parameters, namely tissue pH and 
lactate concentration, can be feasibly determined with optical spectroscopy in the 
atherosclerotic plaque within the stated limitations.  Due to the lack of agreement as to 
what is the definition of vulnerable plaque, the possibility of using plaque tissue pH 
and/or lactate measurements (or even other metabolic indicators, optical or otherwise) 
would be up to the clinician’s discretion.  Future Receiver-Operator-Curves for tissue pH 
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and lactate could be defined, with the addition of other independent patient information 
and diagnostic tests (PET, SPECT, calcium score, etc.) such that the clinician can 
determine a vulnerability score. 
 
Of the two metabolic parameters proposed to be optically determined, the tissue lactate 
may be considered more feasible in the long run. The spectral data range for lactate is 
shorter than the ranges needed for tissue pH determinations. Tissue lactate is more 
homogenous [77], and high concentrations would provide a signal of anaerobic 
metabolism or dead tissue, while differences in the spatial distribution of tissue pH is 
more heterogeneous, and may not be as accurately predicted if a large optical probe is 
used. 
 
The ultimate optical probe for the determination of the atherosclerotic plaque’s metabolic 
status would embody a catheter that 1) can be inserted safely into the coronary arteries 
and 2) make measurements anywhere on the vessel wall, whether by 360° or 180° turning 
of the optical catheter. It has been noted in this study that the optical volume and 
reference measurements were not adequately matched. Separate optical probes or source-
receiver separations may need to be incorporated into one probe and a more complex 
fiber-optic catheter based optical spectroscopy system would be envisioned to detect 
metabolic status or vulnerability in atherosclerotic plaque.   A realistic coronary artery 
measurement in-vivo may require saline flush or temporary or intermittent stoppage of 
the blood due to the strong absorbance of hemoglobin and water, and the additional red 
blood cells that act as scattering components. Brezinski et al [106] have shown through 
optical matching that the OCT measurements of the vessel wall can be made without 
contacting the wall directly and through the matched blood.  Zuluaga et al have devised a 
near-infrared spectroscopic method and correction to determine whether a particular 
optical configuration can measure a wavelength calibration standard under varying depths 
of blood [107]. With proper signal conditioning, a system could be developed to take 
optical spectra through a blood flow field to make metabolic determinations of 
atherosclerotic plaque. 
 
The significance of the results presented is that optical determinations of the metabolic 
status of living atherosclerotic plaques are feasible. However, several limitations apply. 
For tissue pH, the underlying pathology and mismatched volume of measurements were 
identified as the major limiting factors. Highly calcified plaques could not be validated 
over time and obtaining accurate reference pH measurements were difficult. Plaques 
exhibiting both grossly thrombotic areas and mildly yellow fatty plaques with thrombosis 
were used to create an acceptable model. More calibration data would needed to 
definitively determine from where unmodeled sources of variation arise. In addition, the 
optical probe size was much larger than the reference pH electrode size, which could lead 
to an averaged or an erroneous optical measurement. For lactate, the reference 
measurement precision and unmodeled tissue characteristics apparent in the loading 
vectors in the calibration were the major limiting factors. In both determinations, sources 
of variation that were rejected were the tissue temperature and the duration of one day’s 
plaque experiment (max. 4 hours). However, plaque-to-plaque variability and spectral 
variation could not be ruled out or deconvoluted in either optical determination. 
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9. CONCLUSION 
 
The overall goal of this research was to show the feasibility of using optical spectroscopy 
to accurately determine metabolic derangements (namely, tissue pH and lactate 
concentration) in living human atherosclerotic lesions. This goal was accomplished in 
light of several limitations discovered in the process. Methodology was established for 
using an optical, spectroscopic probe in-vitro and maintaining atherosclerotic plaque in 
the living state for an extended period of time. Preliminary data demonstrated that optical 
determinations for tissue pH and lactate could be made. By comparing the material 
presented in Chapters 5-8 of this dissertation with the specific aims of this research listed 
in Chapter 2, the following conclusions can be made:  
 
1) A reflectance-based optical fiber probe that uses visible to near-infrared light 
optimally to interrogate a small volume of tissue was developed for in-vitro use. 
The probe design was aided by the generation of diffuse reflectance profiles using 
Monte Carlo simulations of light propagation and literature values of normal and 
atherosclerotic wall optical properties. Probes with different optical 
configurations and source-receiver separations were characterized by signal-to-
noise ratio and analyzed over several wavelength regions. It was determined from 
the simulations that with a 50 micron source-receiver separation, the target 
volume of 1 mm3 tissue could be met. The final optimized probe was built to 
optimally collect visible to near-infrared light using a 50 micron source-receiver 
separation and an optical window on both FT-NIR and dispersive spectrometers.  
 
2) Using the optimized optical probe the depth penetration was estimated using thin 
tissue slices.  The depth penetration at key wavelengths was estimated by 
successively stacking thin sections of non-diseased tissue on to the end of optical 
probe and collecting the reflectance spectra. The results compared well with the 
theoretical simulations and provided depth penetration data on wavelength 
regions specific to lactate peak locations.  The requirement that the optical probe 
interrogates 1 mm3 tissue was met based on the depth penetration tests. The 
optical probe fully satisfies the specifications set out in Specific Aim 1 and 2. 
 
3) Major interferents to the optical spectra and reference measurements were 
identified. It was shown that by maintaining the plaque in an oxygenated, nutrient 
environment, tissue pH and temperature was stable up to 4 hours. By establishing 
this methodology, it can be concluded that the plaque is living and measured 
optical spectra will represent metabolically active tissue, in contrast to static 
morphological measurements reported elsewhere. In-vitro tissue temperature was 
shown not to adversely affect the optical determinations. Pathological variation 
was identified as a confounder and shown to be detrimental in creating acceptable 
calibration models using all the data for tissue pH. The duration of one day’s 
(max. 4 hr) experiment was determined not to adversely affect the optical 
determinations.  
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4) Using optimized fiber optic probe matched to system instrumentation, ~50-100 
data points were collected while maintaining the plaque’s physiological state in-
vitro, and analyzed as a large calibration set of human carotid endarterectomy 
specimens. Multivariate calibration techniques were used with additional pre-
processing methods in attempt to augment the calibration set’s ability to optically 
determine tissue pH and tissue lactate. The optically-predicted values from the 
empirical model to the reference measurements were compared using calibration 
metrics of correlation coefficient (R2), standard error of cross-validation (SECV) 
and the minimum number of factors needed for model accuracy. Preliminary data 
with the first 5-6 plaques in both the lactate and tissue pH calibrations 
(approximately the first 20-21 points in each set, not the same samples) showed 
that adequate results could be obtained with additional outlier removal.  The 
initial seventeen point, six-factor lactate calibration results met the correlation 
(coefficient of multiple determination) specification of R2 ≥0.75. The estimated 
accuracy did not meet the specification for an SECV of 1.0 micromoles 
lactate/gram tissue. Further improvement in the SECV could not be achieved. In 
addition, the lactate model result was an overfit of the data.  Adding more points 
degraded the model R2 and SECV. Unmodeled spectral variability, inadequate 
reference measurement spatial resolution and precision, and remaining mismatch 
between optical volume versus biopsy volume contributed to the model 
degradation. The initial seventeen point, three-factor tissue pH calibration also 
met the correlation (coefficient of multiple determination) specification of R2 
≥0.75 but not the estimated accuracy at 0.08 pH units. Adding more points 
degraded the model R2 and SECV. The number of factors indicated a good fit of 
the data. A smaller optical probe may be required for the tissue pH determination, 
as well as more points that identify as thrombotic in gross pathology.  
 
The general specification requirements (Table 2.2.1.) is reproduced here with the added 
information of acceptability of the data clearly marked: 
 
Specification Tissue pH Tissue Lactate Concentration 
[Micromoles lactate/gram 
tissue] 
in-vitro 
Temperature 
(°C) 
in-vitro Experimental 
Stability  Met? 
< 0.03 change/hr 
YES 
- <0.4°C change/hr 
YES 
Optical Calibration 
Range Met? 
6.80 – 7.60 
PROVISIONALLY,
6.99 – 7.55 
2 – 20 
PROVISIONALLY  
[0.1 – 10.1] 
32.0 – 38.0 
YES 
Optical Calibration 
Met? Coefficient of 
Multiple Determination 
(R2) / Estimated 
Accuracy (SECV) 
≥0.75 YES, 
provisionally 
0.08 pH units NO 
 
≥0.75 YES, provisionally 
1.0 µmoles/ gram tissue NO 
- 
Maximum # of Factors 
in Optical Calibration 
Model [26] 
5 to 6 independent  
samples per factor 
YES 
5 to 6 independent  samples 
per factor 
NO, overfit  
- 
 
In Chapter 3, Hypotheses and Research Methods, three hypotheses were outlined that 
described the focus of this work. Scientific methods were used in the course of the 
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research and hypothesis testing: statistical analysis of data, mathematical modeling, 
experimentation, induction and deduction. The validity of these hypotheses are evaluated 
here based on the scientific method: 
 
 
1) A small fiber optic prototype (< 3 mm optical working diameter) will make 
optical measurements in-vitro for the assessment of metabolically active plaque in 
a defined region of tissue (< 1mm3 volume).  Both theoretical and practical 
considerations are allowed for in the design and implementation.  
 
This hypothesis is accepted. The fiber optic probe design process achieved its 
target of being <3 mm optical working diameter and maximum tissue volume 
interrogation of 1 mm3.  
 
2) The in-vitro experimental factors, identified a priori as the tissue temperature, 
experiment time, and the gross constituent information of the plaque (i.e. gross 
pathology), can be assessed to their importance in affecting the optical calibration.  
It is hypothesized that the acceptance criteria for in-vitro experimental stability as 
defined in Section 2.2 can be met. 
 
This hypothesis is accepted. The in-vitro temperature, experiment time, and the 
gross plaque constituent information, were measured. The effect on the optical 
calibration was deduced to be minimal for temperature and experiment time. The 
stability of the atherosclerotic tissue and the media preparation was met up to 4 
hours. The gross pathology affected the optical calibration of the tissue pH 
models.  
 
3) Mathematical models can be developed which relate the corresponding optical 
spectra to the individual metabolic parameters (pH and lactate), measured with 
accepted reference methods, in the presence of inherent pathological variability.  
By collecting the optical spectra in a controlled, stable in-vitro environment and 
by using partial least-squares (PLS) multivariate calibration, accurate 
determinations can be achieved for the individual metabolic parameters of plaque 
tissue pH and plaque lactate concentration. The correlation coefficient of the 
determination and standard error of cross-validation will be used to determine 
calibration performance. The number of factors will be used to determine the 
appropriateness (e.g., overfit/underfit) of the optical calibration. 
 
This hypothesis is accepted on the basis of preliminary data that demonstrated 
limited models could be created. The coefficient of multiple determination (the 
acceptance criterion was stated in Section 2.2. as R2≥0.75) was achieved for a 
seventeen point, six-factor model for lactate. However, the estimated accuracy 
and maximum number of factors requirement were not met.  The coefficient of 
multiple determination was achieved for a seventeen point, three-factor model for 
tissue pH. However, the estimated accuracy was not met (0.08 pH units specified 
versus 0.09 pH units achieved). The maximum number of factors requirement was 
met in the tissue pH calibration. The accuracy of the optical tissue pH 
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measurement at an R2 of 0.75 in the seventeen point model and could not be 
improved by separation of the points by the observed pathological variability. No 
models could be created with all the 82 data points for lactate or the 48 data points 
for tissue pH, in the presence of observed pathological variations.   
 
The overall hypothesis that reflectance-mode optical spectroscopy, using visible to near 
infrared light energy, can be used in-vitro to develop calibration equations that provide an 
optical determination of the atherosclerotic tissue pH and lactate concentration is 
accepted with limitations.   The optical volumes needed for lactate and tissue pH are 
considerably different. For each optical determination, 1) the probe size and depth 
penetration, or optical volume, has to be better matched with the reference volume, 2) the 
area and volume of the reference measurement has to be small enough such that 
pathology and optical spectra are nearly homogeneous, 3) accurate, spatially resolved 
reference measurements need to be made that uniformly spans the physiological range, 
and 4) all sources of spectral variation must be modeled in order for the correlation and 
estimated accuracy to be improved to levels acceptable for future in-vivo development of 
this technique.  
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10. FUTURE WORK 
 
The limited feasibility of the lactate and tissue pH optical calibrations shown here in 
living, atherosclerotic carotid plaques indicates that significant in-vitro model 
development is still required. The clustering algorithms for both lactate and pH tested 
were simple algorithms in the family of unsupervised techniques and may not have 
provided the most appropriate solution for the calibration data. Other algorithms within 
this family may provide better solutions and ultimately better multivariate calibration 
results.   Supervised pattern recognition techniques such as Artificial Neural Networks or 
fuzzy clustering could be implemented to assess the spectral differences and reference 
measurement variation together in a non-linear multivariate calibration methodology.  
Improved accuracy of the lactate reference measurement would help eliminate a large 
source of controllable error in the optical calibration. More data collection is prescribed, 
in an in-vitro tissue model where the protein and water content variability can be 
adequately described or reduced.  Long-term spectrometer variation also must be reduced 
or compensated. This may be achieved by either using more expensive stable 
spectrometers with cooled detectors (preferred), or additional characterization of the 
spectrometers to model this drift. A bench simulation or in-vitro tissue model that has 
reduced variability in scattering components should be used to address the concern that 
unmodeled scattering variation due to protein or water content overwhelms the lactate 
signal in the 2030-2330 nm region. This should be performed as well for the tissue pH in 
the visible region to address unmodeled spectral variation seen and to definitively 
determine if pathology is the root cause of the variation.. All of the sources of variability 
identified here need to be carefully studied in order to even consider the next step in 
improving the accuracy and prediction of the optical method for in-vivo use, described 
below for future work. 
 
The Watanabe rabbit model has been used by several investigators to study 
atherosclerosis progression because it is able to develop classic early lesions similar to 
humans. However, this animal model is unable to produce lesions of higher complexity. 
The purpose of testing an optical method in the Watanabe rabbit in-vivo would be two-
fold: 1) to validate whether the mathematical techniques generated on the in-vitro tissue 
model extend to the in-vivo rabbit model with acceptable error, and 2) to provide an 
initial assessment of the efficacy of placement and overall design strategies of the 
catheter.  
 
To perform the experiment in a live animal, typical catheterization procedures would be 
used to optically measure the rabbit aorta. The catheter will be advanced using a stepper 
motor so the exact placement of the catheter where spectra are taken can be made. If 
needed, the rabbit's chest will be opened at the same time so the surgeon can identify the 
catheter's location by hand. Alternatively, a radio-opaque marker can be placed on the 
catheter tip and the animal x-rayed to find the catheter's exact location.  Histology and 
lactate analysis of the aorta could be performed in the marked locations using the 
procedures previously described. The reference measurements would be compared to the 
output of the spectroscopic measurements processed in the mathematical modeling. 
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Rigorous acceptance criteria should be used to accept or reject the feasibility of 
performing the optical determinations in-vivo. 
 
In summary, only after the optical calibrations are improved to meet or exceed the 
acceptance criteria on the bench or in-vitro, testing on animals in-vivo should be 
considered. Calibration transfer methods would be required to account for any changes in 
catheter design.  The final catheter design may have mechanisms such as radio-opaque 
markers, an inflatable balloon, and saline flush ports so the optical field can be cleared. 
The efficacy of building an adult sized optical catheter and conducting human clinical 
trials for vulnerable plaque detection based on metabolic status could conceivably 
continue from any additional data collected in-vitro that can demonstrate significantly 
improved accuracy than those described here or in-vivo in an acceptable animal model 
calibration.  
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